

400

PIPERIDINYL]PHENYL}-2-

METHYLPROPANAMIDE:

Prepared by Procedure Q1 and Scheme AC using 3,5-dimethyl-4-isoxazolesulfonyl chloride and N-(3-{1-[(3S)-3-amino-3-phenylpropyl]-4-piperidinyl}phenyl)-2-

5 methylpropanamide: ^1H NMR (400 MHz, CDCl_3) δ 7.53 (s, 2H), 7.3-7.1 (m, 5H), 7.05 (t, 2H, $J = 6.5$ Hz), 6.81 (d, 1H, $J = 7.1$ Hz), 4.65 (dd, 1H, $J = 6.3, 2.2$ Hz), 3.11 (t, 2H, $J = 7.2$ Hz), 2.4 (m, 4H), 2.2 (s, 3H), 2.05 (m, 2H), 2.01 (s, 3H), 2.0-1.8 (m, 7H), 1.21 (d, 6H, $J = 7.1$ Hz); ESMS m/e : 539.5 ($M + H$) $^+$.

10

Example 603

METHYL 3-{[(3-{4-[3-(ISOBUTYRYLAMINO)PHENYL]-1-PIPERIDINYL}PROPYL)AMINO]SULFONYL}-2-

15 THIOPHENECARBOXYLATE: Prepared Procedure Q1 and Scheme AC using methyl 3-(chlorosulfonyl)-2-thiophenecarboxylate and N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}-2-methylpropanamide: Anal. Calcd for $\text{C}_{24}\text{H}_{33}\text{N}_3\text{O}_5\text{S}\cdot\text{HCl}$: C, 6.00; H, 5.30; N, 7.72. Found: C, 52.9; H, 6.04; N, 7.59; ESMS m/e : 508.2 ($M + H$) $^+$.

20

Example 604

2-METHYL-N-{3-[1-((3S)-3-{[(4-PHENOXYANILINO)CARBONYL]AMINO}-3-PHENYLPROPYL)-4-

25 PIPERIDINYL]PHENYL}PROPANAMIDE: Prepared by Procedure P and Scheme AB using 1-isocyanato-4-phenoxybenzene and N-(3-{1-[(3S)-3-amino-3-phenylpropyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e : 591.3 ($M + H$) $^+$.

30

Example 605

N-[3-(1-{(3S)-3-[(ANILINOCARBONYL)AMINO]-3-PHENYLPROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:

401

Prepared by Procedure P and Scheme AB using isocyanatobenzene and N-(3-{1-[(3S)-3-amino-3-phenylpropyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e: 499.2 (M + H)⁺.

5

Example 606

N-{3-[1-((3S)-3-{[(TERT-BUTYLAMINO) CARBOTHIOYL] AMINO}-3-PHENYLPROPYL)-4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE:

Prepared by Procedure P and Scheme AB using 2-isothiocyanto-2-methylpropane and N-(3-{1-[(3S)-3-amino-3-phenylpropyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e: 495.1 (M + H)⁺.

10

Example 607

15 N-{3-[1-((3S)-3-{[(2-FLUOROANILINO) CARBONYL] AMINO}-3-PHENYLPROPYL)-4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE:

Prepared by Procedure P and Scheme AB using 1-fluoro-2-isocyanatobenzene and N-(3-{1-[(3S)-3-amino-3-phenylpropyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e: 517.0 (M + H)⁺.

20

Example 608

2-METHYL-N-[3-(1-{(3S)-3-PHENYL-3-[(2-TOLUIDINOCARBOTHIOYL) AMINO] PROPYL}-4-

25 PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure P and Scheme AB using 1-isothiocyanto-2-methylbenzene and N-(3-{1-[(3S)-3-amino-3-phenylpropyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e: 529.1 (M + H)⁺.

30

Example 609

N-{3-[1-((3S)-3-{[(BENZYLAMINO) CARBONYL] AMINO}-3-PHENYLPROPYL)-4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE:

402

phenylpropyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ^1H NMR (400 MHz, CDCl_3) δ 8.44 (s, 1H), 7.67 (d, 1H, $J = 7.9$ Hz), 7.31-7.13 (m, 13H), 6.38 (s, 1H), 6.80 (d, 1H, $J = 7.9$ Hz), 5.54 (m, 1H), 4.81 (m, 1H), 4.41 (dd, 1H, $J = 14.8, 6.2$ Hz), 4.29 (dd, 1H, $J = 14.9, 5.4$ Hz), 2.99 (d, 1H, $J = 11.2$ Hz), 2.87 (d, 1H, $J = 11.2$ Hz), 2.67 (q, 1H, $J = 6.2$ Hz), 2.3 (m, 3H), 2.0-1.5 (m, 7H), 1.23 (d, 6H, $J = 6.7$ Hz); ESMS m/e : 513.2 ($M + H$) $^+$.

10

Example 610

2-METHYL-N-{3-[1-((3S)-3-{[(2-

NITROANILINO) CARBONYL] AMINO}-3-PHENYLPROPYL)-4-

PIPERIDINYL] PHENYL} PROPANAMIDE: Prepared by Procedure P and Scheme AB using 1-isocyanato-2-nitrobenzene and N-(3-{1-[(3S)-3-amino-3-phenylpropyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e : 543.6 ($M + H$) $^+$.

15

20 **Example 611**

N-{3-[1-((3S)-3-{[(3,4-DICHLOROANILINO) CARBONYL] AMINO}-3-PHENYLPROPYL)-4-PIPERIDINYL] PHENYL}-2-

METHYLPROPANAMIDE: Prepared by Procedure P and Scheme AB using 1,2-dichloro-4-isocyanatobenzene and N-(3-{1-[(3S)-3-amino-3-phenylpropyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e : 567.1 ($M + H$) $^+$.

25

Example 612

2-METHYL-N-(3-{1-[(3S)-3-({[2-

(METHYLSULFANYL) ANILINO] CARBONYL] AMINO)-3-PHENYLPROPYL]-4-PIPERIDINYL} PHENYL) PROPANAMIDE: Prepared by Procedure P and Scheme AB using 1-isocyanato-2-(methylsulfanyl)benzene and N-(3-{1-[(3S)-3-amino-3-

30

403

phenylpropyl]-4- piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e : 545.0 ($M + H$)⁺.

Example 613

5 ***N*-{3-[1-(3-{[(4-FLUOROANILINO) CARBONYL] AMINO} PROPYL)-4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE:** Prepared by Procedure P and Scheme AB using 1-fluoro-4-isocyanatobenzene and *N*-{3-[1-(3-aminopropyl)-4-piperidinyl}phenyl]-2-methylpropanamide: ¹H NMR (400
10 MHz, CDCl₃) δ 7.45 (q, 2H, $J = 4.7$ Hz), 7.23 (m, 4H), 7.05 (t, 4H, $J = 7.8$ Hz), 6.75 (m, 1H), 4.05 (m, 1H), 3.19 (s, 1H), 2.71 (m, 1H), 2.53 (m, 1H), 2.25 (m, 3H), 1.8 (m, 9H), 1.25 (d, 6H, $J = 6.4$ Hz); ESMS m/e : 441.1 ($M + H$)⁺.

15

Example 614

***N*-{3-[1-(3-{[(3,4-DICHLOROANILINO) CARBONYL] AMINO} PROPYL)-4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE:** Prepared by
20 Procedure P and Scheme AB using 1,2-dichloro-4-isocyanatobenzene and *N*-{3-[1-(3-aminopropyl)-4-piperidinyl}phenyl]-2-methylpropanamide: ESMS m/e : 493.2 ($M + H$)⁺.

25

Example 615

2-METHYL-*N*-[3-(1-{3-[(2-TOLUIDINOCARBOTHIOYL) AMINO] PROPYL}-4-PIPERIDINYL) PHENYL]PROPANAMIDE: Prepared by Procedure P
and Scheme AB using 1-isothiocyanato-2-methylbenzene and
30 *N*-{3-[1-(3-aminopropyl)-4-piperidinyl}phenyl]-2-methylpropanamide: ESMS m/e : 453.2 ($M + H$)⁺.

Example 616

N-{3-[1-(3-{[(BENZYLAMINO) CARBONYL] AMINO} PROPYL)-4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure P and Scheme AB using (isocyanatomethyl)benzene and N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 437.2 (M + H)⁺.

Example 617

N-{3-[1-(3-{[(4-ETHOXYANILINO) CARBONYL] AMINO} PROPYL)-4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure P and Scheme AB using 1-ethoxy-4-isocyanatobenzene and N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 467.2 (M + H)⁺.

Example 618

N-[3-(1-{3-[(ANILINOCARBONYL) AMINO] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure P and Scheme AB using isocyanatobenzene and N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 422.9 (M + H)⁺.

Example 619

2-METHYL-N-(3-{1-[3-({[2-(METHYLSULFANYL) ANILINO] CARBONYL} AMINO) PROPYL]-4-PIPERIDINYL} PHENYL) PROPANAMIDE: Prepared by Procedure P and Scheme AB using 1-isocyanato-2-(methylsulfanyl)benzene and N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 469.1 (M + H)⁺.

Example 620

N-{3-[1-(3-{[(TERT-BUTYLAMINO) CARBOTHIOYL] AMINO} PROPYL) - 4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure P and Scheme AB using 2-isothiocyanato-2-methylpropane and N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 419.0 (M + H)⁺.

Example 621

2-METHYL-N-{3-[1-(3-{[(4-PHENOXYANILINO) CARBONYL] AMINO} PROPYL) - 4-PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure P and Scheme AB using 1-isocyanato-4-phenoxybenzene and N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 515.5 (M + H)⁺.

Example 622

N-(3-{4-[3-(ACETYLAMINO) PHENYL]-1-PIPERIDINYL} PROPYL) - 4-(2,4-DIFLUOROPHENYL) - 2-METHYL-6-OXO-1,4,5,6-TETRAHYDRO-3-PYRIDINECARBOXAMIDE: Prepared by Procedure AC and Scheme AM using N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}acetamide and 4-(2,4-difluorophenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxylic acid: ESMS m/e: 525.2 (M + H)⁺.

Example 623

N-(3-{4-[3-(ACETYLAMINO) PHENYL]-1-PIPERIDINYL} PROPYL) - 4-(3,4-DIFLUOROPHENYL) - 2-METHYL-6-OXO-1,4,5,6-TETRAHYDRO-3-PYRIDINECARBOXAMIDE: Prepared by Procedure AC and Scheme AM using N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}acetamide and 4-(3,4-difluorophenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxylic acid: ESMS m/e: 525.2 (M + H)⁺.

Example 624

***N*-(6-{4-[3-(ISOBUTYRYLAMINO) PHENYL]-1-PIPERIDINYL}HEXYL)-1-(4-NITROPHENYL)-5-**

5 **(TRIFLUOROMETHYL)-1H-PYRAZOLE-4-CARBOXAMIDE:** Prepared by Procedure Q1 (THF) and Scheme AT using *N*-{3-[1-(6-aminohexyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 1-(4-nitrophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carbonyl chloride: ESMS *m/e*: 629.2 (M + H)⁺.

10

Example 625

***N*-[3-(1-{6-[(DIPHENYLACETYL) AMINO]HEXYL}-4-**

15 **PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:** Prepared by Procedure Q1 (THF) and Scheme AT using *N*-{3-[1-(6-aminohexyl)-4-piperidinyl]phenyl}-2-methylpropanamide and diphenylacetyl chloride: ESMS *m/e*: 540.3 (M + H)⁺.

Example 626

5-(3,5-DICHLOROPHENOXY)-*N*-(6-{4-[3-

20 **(ISOBUTYRYLAMINO) PHENYL]-1-PIPERIDINYL}HEXYL)-2-FURAMIDE:**

Prepared by Procedure Q1 (THF) and Scheme AT using *N*-{3-[1-(6-aminohexyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 5-(3,5-dichlorophenoxy)-2-furoyl chloride: ESMS *m/e*: 600.2 (M + H)⁺.

25

Example 627

***N*-(6-{4-[3-(ISOBUTYRYLAMINO) PHENYL]-1-**

30 **PIPERIDINYL}HEXYL)-2-PHENOXYNICOTINAMIDE:** Prepared by Procedure Q1 (THF) and Scheme AT using *N*-{3-[1-(6-aminohexyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 2-phenoxy nicotinoyl chloride: ESMS *m/e*: 543.3 (M + H)⁺.

Example 628

N-(6-{4-[3-(ISOBUTYRYLAMINO) PHENYL]-1-

PIPERIDINYL}HEXYL)-2-NAPHTHAMIDE: Prepared by Procedure

5 Q1 (THF) and Scheme AT using N-{3-[1-(6-aminohexyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 2-naphthoyl chloride: ESMS *m/e*: 500.3 (M + H)⁺.

Example 629

10 **1-BENZYL-3-TERT-BUTYL-N-(6-{4-[3-**

(ISOBUTYRYLAMINO) PHENYL]-1-PIPERIDINYL}HEXYL)-1H-

PYRAZOLE-5-CARBOXAMIDE: Prepared by Procedure Q1 (THF)

and Scheme AT using N-{3-[1-(6-aminohexyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 1-benzyl-3-

15 **tert-butyl-1H-pyrazole-5-carbonyl chloride:** ESMS *m/e*: 586.3 (M + H)⁺.

Example 630

3-CHLORO-N-(6-{4-[3-(ISOBUTYRYLAMINO) PHENYL]-1-

20 **PIPERIDINYL}HEXYL)-4-(ISOPROPYLSULFONYL)-2-**

THIOPHENECARBOXAMIDE: Prepared by Procedure Q1 (THF) and

Scheme AT using N-{3-[1-(6-aminohexyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 3-chloro-4-(isopropylsulfonyl)-2-thiophenecarbonyl chloride: ESMS

25 *m/e*: 596.2 (M + H)⁺.

Example 631

N-[3-(1-{6-[(ANILINOCARBONYL) AMINO]HEXYL}-4-

PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by

30 Procedure Q1 (THF) and Scheme AT using N-{3-[1-(6-aminohexyl)-4-piperidinyl]phenyl}-2-methylpropanamide and phenyl isocyanate : ESMS *m/e*: 465.2 (M + H)⁺.

Example 632

N-{3-[1-(6-{[(2,4-DICHLOROANILINO) CARBONYL] AMINO}HEXYL)-4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure Q1 (THF) and Scheme AT using N-{3-[1-(6-aminohexyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 2,4-dichlorophenyl isocyanate: ESMS m/e: 533.2 (M + H)⁺.

Example 633

N-(6-{4-[3-(ISOBUTYRYLAMINO) PHENYL]-1-PIPERIDINYL}HEXYL)-1-PHENYL-5-PROPYL-1H-PYRAZOLE-4-CARBOXAMIDE: Prepared by Procedure Q1 (THF) and Scheme AT using N-{3-[1-(6-aminohexyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 1-phenyl-5-propyl-1H-pyrazole-4-carbonyl chloride: ESMS m/e: 558.3 (M + H)⁺.

Example 634

2-METHYL-N-{3-[1-(6-{[(1-NAPHTHYLAMINO) CARBONYL] AMINO}HEXYL)-4-PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure Q1 (THF) and Scheme AT using N-{3-[1-(6-aminohexyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 1-naphthyl isocyanate: ESMS m/e: 515.3 (M + H)⁺.

Example 635

N-{3-[1-(6-{[(1,1'-BIPHENYL)-4-YLAMINO) CARBONYL] AMINO}HEXYL)-4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure Q1 (THF) and Scheme AT using N-{3-[1-(6-aminohexyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 4-biphenyl isocyanate: ESMS m/e: 541.3 (M + H)⁺.

Example 636

409

2-METHYL-N-{3-[1-(6-{[(2-NAPHTHYLAMINO) CARBONYL] AMINO}HEXYL)-4-

5 PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure Q1 (THF) and Scheme AT using N-{3-[1-(6-aminohexyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 2-naphthyl isocyanate: ESMS m/e : 515.3 (M + H)⁺.

Example 637

10 N-{3-[1-(3-{[(3,4-DIMETHOXYPHENYL) SULFONYL] AMINO}PROPYL)-4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure Q1 (THF) and Scheme AT using N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 3,4-dimethoxybenzenesulfonyl chloride: ESMS m/e :
15 504.2 (M + H)⁺.

Example 638

N-(3-{4-[3-(ISOBUTYRYLAMINO) PHENYL]-1-PIPERIDINYL}PROPYL)-5-METHYL-3-PHENYL-4-
20 ISOXAZOLECARBOXAMIDE: Prepared by Procedure Q1 (THF) and Scheme AT using N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 5-methyl-3-phenyl-4-isoxazolecarbonyl chloride: ESMS m/e : 489.3 (M + H)⁺.

25

Example 639

N-{3-[1-(3-{[(4-FLUOROPHENYL) ACETYL] AMINO}PROPYL)-4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by
30 Procedure Q1 (THF) and Scheme AT using N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}-2-methylpropanamide and (4-fluorophenyl)acetyl chloride: ESMS m/e : 440.3 (M + H)⁺.

410

Example 640

N-{3-[1-(3-{[(4-CHLORO-3-NITROPHENYL) SULFONYL] AMINO} PROPYL) -4-

PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by

5 Procedure Q1 (THF) and Scheme AT using N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 4-chloro-3-nitrobenzenesulfonyl chloride: ESMS m/e: 523.1 (M + H)⁺.

10 **Example 641**

2-(4-CHLOROPHENOXY) -N-(3-{4-[3-(ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL} PROPYL) NICOTINAMIDE: Prepared by Procedure Q1 (THF) and Scheme AT using N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 2-(4-chlorophenoxy)nicotinoyl chloride: ESMS m/e: 535.2 (M + H)⁺.

Example 642

5-(3,5-DICHLOROPHENOXY) -N-(3-{4-[3-(ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL} PROPYL) -2-FURAMIDE:

20 Prepared by Procedure Q1 (THF) and Scheme AT using N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 5-(3,5-dichlorophenoxy)-2-furoyl chloride: ESMS m/e: 558.2 (M + H)⁺.

Example 643

N-{3-[1-(3-{[(2-FLUOROPHENYL) SULFONYL] AMINO} PROPYL) -4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by

30 Procedure Q1 (THF) and Scheme AT using N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 2-fluorobenzenesulfonyl chloride: ESMS m/e: 462.2 (M + H)⁺.

Example 644

**N-{3-[1-(3-{[(3,5-DIMETHYL-4-
ISOXAZOLYL) SULFONYL] AMINO} PROPYL) -4-PIPERIDINYL] PHENYL}-
2-METHYLPROPANAMIDE:** Prepared by Procedure Q1 (THF) and
Scheme AT using N-{3-[1-(3-aminopropyl)-4-
piperidinyl]phenyl}-2-methylpropanamide and 3,5-
dimethyl-4-isoxazolesulfonyl chloride: ESMS m/e: 463.2
(M + H)⁺.

Example 644

**N-{3-[1-(3-{[(4-TERT-BUTYLPHENYL) SULFONYL] AMINO} PROPYL) -
4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE:** Prepared by
Procedure Q1 (THF) and Scheme AT using N-{3-[1-(3-
aminopropyl)-4-piperidinyl]phenyl}-2-methylpropanamide
and 4-tert-butylbenzenesulfonyl chloride: ESMS m/e:
500.3 (M + H)⁺.

Example 646

**N-{3-[1-(6-AMINOHEXYL) -4-PIPERIDINYL] PHENYL}-2-
METHYLPROPANAMIDE:** Prepared by Procedure AE and Scheme Y
using N-(3-{1-[6-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-
yl)hexyl]-4-piperidinyl}phenyl)-2-methylpropanamide and
hydrazine hydrate: ESMS m/e: 346.2 (M + H)⁺.

Example 647

**N-{3-[1-(2-{[(1,1'-BIPHENYL] -4-
YLAMINO) CARBONYL] AMINO} ETHYL) -4-PIPERIDINYL] PHENYL}-2-
METHYLPROPANAMIDE:** Prepared by Procedure Q1 (THF) and
Scheme AT using N-{3-[1-(2-aminoethyl)-4-
piperidinyl]phenyl}-2-methylpropanamide and 4-biphenyl
isocyanate: ESMS m/e: 485.2 (M + H)⁺.

412

Example 648

5- (3,5-DICHLOROPHENOXY) -N-(2-{4-[3-(ISOBUTYRYLAMINO) PHENYL]-1-PIPERIDINYL}ETHYL)-3-FURAMIDE:

- 5 Prepared by Procedure Q1 (THF) and Scheme AT using N-{3-[1-(2-aminoethyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 5-(3,5-dichlorophenoxy)-3-furoyl chloride: ESMS m/e: 544.1 (M + H)⁺.

10 **Example 649**

N-[3-(1-{2-[(DIPHENYLACETYL) AMINO] ETHYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:

- Prepared by Procedure Q1 (THF) and Scheme AT using N-{3-[1-(2-aminoethyl)-4-piperidinyl]phenyl}-2-methylpropanamide and diphenylacetyl chloride: ESMS m/e: 484.2 (M + H)⁺.
- 15

Example 650

N-(2-{4-[3-(ISOBUTYRYLAMINO) PHENYL]-1-PIPERIDINYL}ETHYL)-2-NAPHTHAMIDE: Prepared by Procedure Q1 (THF) and Scheme AT using N-{3-[1-(2-aminoethyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 2-naphthoyl chloride: ESMS m/e: 444. 2 (M + H)⁺.

20

Example 651

- 25 3-(2,6-DICHLOROPHENYL)-N-(4-{4-[3-(ISOBUTYRYLAMINO) PHENYL]-1-PIPERIDINYL}BUTYL)-5-METHYL-4-ISOXAZOLECARBOXAMIDE:
- Prepared by Procedure Q1 (THF) and Scheme AT using N-{3-[1-(4-aminobutyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolecarbonyl chloride: ESMS m/e: 571.2 (M + H)⁺.
- 30

Example 652

413

3-(2,6-DICHLOROPHENYL)-N- (5-{4-[3-(ISOBUTYRYLAMINO)PHENYL]-1-PIPERIDINYL}PENTYL)-5-METHYL-4-ISOXAZOLECARBOXAMIDE:

Prepared by Procedure Q1 (THF) and Scheme AT using N-{3-[1-(5-aminopentyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolecarbonyl chloride. ESMS m/e: 585.2.(M + H)⁺.

Example 653

10 N-[3-(1-{4-[(DIPHENYLACETYL)AMINO]BUTYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure Q2(THF/DCM, 1:3)) and Scheme AT using N-{3-[1-(4-aminobutyl)-4-piperidinyl]phenyl}-2-methylpropanamide and diphenylacetyl chloride: ESMS m/e: 15 512.0 (M + H)⁺.

Example 654

N-[3-(1-{5-[(DIPHENYLACETYL)AMINO]PENTYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by 20 Procedure Q2(THF/DCM, 1:3)) and Scheme AT using N-{3-[1-(5-aminopentyl)-4-piperidinyl]phenyl}-2-methylpropanamide and diphenylacetyl chloride: ESMS m/e: 526.0 (M + H)⁺.

25 Example 655

3,5-DICHLORO-N-(4-{4-[3-(ISOBUTYRYLAMINO)PHENYL]-1-PIPERIDINYL}BUTYL)BENZAMIDE: Prepared by Procedure Q2 (THF/DCM, 1:3) and Scheme AT using N-{3-[1-(4-aminobutyl)-4-piperidinyl]phenyl}-2-methylpropanamide 30 and 3,5-dichlorobenzoyl chloride: ESMS m/e: 490.0 (M + H)⁺.

Example 656

414

5- (3,5-DICHLOROPHENOXY) -N- (4-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL} BUTYL) -2-

FURAMIDE:

Prepared by Procedure Q2 (THF/DCM, 1:3) and Scheme AT
5 using N-{3-[1-(4-aminobutyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 5-(3,5-dichlorophenoxy)-2-furoyl chloride: ESMS m/e: 572.0 (M + H)⁺.

Example 657

10 3-CHLORO-N-(4-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL} BUTYL) BENZAMIDE: Prepared by Procedure Q2 (THF/DCM, 1:3) and Scheme AT using N-{3-[1-(4-aminobutyl)-4-piperidinyl]phenyl}-2-methylpropanamide and 3-chlorobenzoyl chloride: ESMS m/e: 456.0 (M + H)⁺.

15

Example 658

3,4-DIFLUORO-N-(4-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL} BUTYL) BENZAMIDE: Prepared by Procedure Q2 (THF/DCM, 1:3) and Scheme AT using N-{3-[1-(4-aminobutyl)-4-piperidinyl]phenyl}-2-methylpropanamide
20 and 3,4-difluorobenzoyl chloride: ESMS m/e: 458.0 (M + H)⁺.

Example 659

25 N-{3-[1-(4-{[(3,5-DICHLOROANILINO) CARBONYL] AMINO} BUTYL) -4-PIPERIDINYL] PHENYL} -2-METHYLPROPANAMIDE: Prepared by Procedure Q2 (THF/DCM, 1:3) and Scheme AT using N-(3-{1-[4-(formylamino)butyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 3,5-dichlorophenyl isocyanate:
30 ESMS m/e: 505.0 (M + H)⁺.

Example 660

415

N-{3-[1-(4-{[(1,1'-BIPHENYL]-4-YLAMINO) CARBONYL}AMINO}BUTYL)-4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure Q2 (THF/DCM, 1:3) and Scheme AT using **N-{3-[1-(4-aminobutyl)-4-piperidinyl]phenyl}-2-methylpropanamide** and **4-biphenyl isocyanate**: ESMS m/e : 513.0 (M + H)⁺.

Example 661

2-METHYL-N-(3-{1-[5-(4-NITROPHENYL)-5-OXOPENTYL]-4-PIPERIDINYL}PHENYL)PROPANAMIDE: Prepared by Procedure K and Scheme B1 (K₂CO₃) using **5-chloro-1-(4-nitrophenyl)-1-pentanone** and **2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide**: ESMS m/e : 452.2 (M + H)⁺.

Example 662

N-(3-{1-[5-(4-FLUOROPHENYL)-5-OXOPENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme B1 (K₂CO₃) using **5-chloro-1-(4-fluorophenyl)-1-pentanone** and **2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide**: ESMS m/e : 425.2 (M + H)⁺.

Example 663

2-METHYL-N-[3-(1-{5-EXO-5-[2-(TRIFLUOROMETHYL) PHENYL] PENTYL]-4-PIPERIDINYL}PHENYL)PROPANAMIDE: Prepared by Procedure K and Scheme B1 (K₂CO₃) using **5-chloro-1-[2-(trifluoromethyl)phenyl]-1-pentanone** and **2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide**: ESMS m/e : 475.2 (M + H)⁺.

30

Example 664

N-(3-{1-[5-(3-BROMOPHENYL)-5-OXOPENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by

416

Procedure K and Scheme B1 (K_2CO_3) using 1-(3-bromophenyl)-5-chloro-1-pentanone and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e : 485.1 ($M + H$)⁺.

5 **Example 665**

2-METHYL-N-(3-{1-[5-(3-NITROPHENYL)-5-OXOPENTYL]-4-PIPERIDINYL}PHENYL)PROPANAMIDE: Prepared by Procedure K and Scheme B1 (K_2CO_3) using 5-chloro-1-(3-nitrophenyl)-1-pentanone and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e : 452.2 ($M + H$)⁺.

10

Example 666

N-(3-{1-[5-(3-CHLOROPHENYL)-5-OXOPENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme B1 (K_2CO_3) using 1-(3-chlorophenyl)-5-chloro-1-pentanone and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e : 441.1 ($M + H$)⁺.

15

Example 667

N-(3-{1-[5-(4-BROMOPHENYL)-5-OXOPENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme B1 (K_2CO_3) using 1-(4-bromophenyl)-5-chloro-1-pentanone and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e : 485.1 ($M + H$)⁺.

20

25

Example 668

N-(3-{1-[5-(2-IODOPHENYL)-5-OXOPENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme B1 (K_2CO_3) using 1-(2-iodophenyl)-5-chloro-1-pentanone and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e : 533.0 ($M + H$)⁺.

30

Example 669

417

N-(3-{1-[5-(3-FLUOROPHENYL)-5-
OXOPENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:

Prepared by Procedure K and Scheme B1 (K₂CO₃) using 1-(3-fluorophenyl)-5-chloro-1-pentanone and 2-methyl-*N*-[3-(4-piperidinyl)phenyl]propanamide: ESMS *m/e*: 425.2 (M + H)⁺.

Example 670

2-METHYL-*N*-[3-(1-{5-OXO-5-[3-(TRIFLUOROMETHYL)PHENYL]PENTYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE: Prepared by Procedure K and Scheme B1 (K₂CO₃) using 1-[3-(trifluoromethyl)phenyl]-5-chloro-1-pentanone and 2-methyl-*N*-[3-(4-piperidinyl)phenyl]propanamide: ESMS *m/e*: 475.2 (M + H)⁺.

Example 671

N-(3-{1-[5-(2-FLUOROPHENYL)-5-OXOPENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme B1 (K₂CO₃) using 1-(2-fluorophenyl)-5-chloro-1-pentanone and 2-methyl-*N*-[3-(4-piperidinyl)phenyl]propanamide: ESMS *m/e*: 425.2 (M + H)⁺.

Example 672

N-(3-{1-[5-(3-IODOPHENYL)-5-OXOPENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme B1 (K₂CO₃) using 1-(3-iodophenyl)-5-chloro-1-pentanone and 2-methyl-*N*-[3-(4-piperidinyl)phenyl]propanamide: ESMS *m/e*: 533.0 (M + H)⁺.

Example 673

N-(3-{1-[5-(2-CHLOROPHENYL)-5-OXOPENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by

418

Procedure K and Scheme B1 (K_2CO_3) using 1-(2-chlorophenyl)-5-chloro-1-pentanone and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e : 441.1 ($M + H$)⁺.

5 **Example 674**

2-METHYL-N-[3-(1-{5-OXO-5-[4-(TRIFLUOROMETHYL)PHENYL]PENTYL}-4-

PIPERIDINYL)PHENYL]PROPANAMIDE: Prepared by Procedure K and Scheme B1 (K_2CO_3) using 1-[4-(trifluoromethyl)phenyl]-5-chloro-1-pentanone and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e : 475.2 ($M + H$)⁺.

15 **Example 675**

N-(3-{1-[5-(4-CHLOROPHENYL)-5-OXOPENTYL]-4-

PIPERIDINYL)PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme B1 (K_2CO_3) using 1-(4-chlorophenyl)-5-chloro-1-pentanone and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e : 441.1 ($M + H$)⁺.

20

Example 676

N-(3-{1-[5-(4-IODOPHENYL)-5-OXOPENTYL]-4-

PIPERIDINYL)PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme B1 (K_2CO_3) using 1-(4-iodophenyl)-5-chloro-1-pentanone and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e : 533 ($M + H$)⁺.

25

Example 677

N-(3-{1-[5-(2-BROMOPHENYL)-5-OXOPENTYL]-4-

PIPERIDINYL)PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme B1 (K_2CO_3) using 1-(2-bromophenyl)-5-chloro-1-pentanone and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e : 485.1 ($M + H$)⁺.

30

Example 678

2-(4-CHLOROPHENOXY)-N-(4-{4-[3-(ISOBUTYRYLAMINO) PHENYL]-
1-PIPERIDINYL}BUTYL)NICOTINAMIDE: Prepared by Procedure
5 Q2 (THF/DCM, 1:3) and Scheme AT using N-{3-[1-(4-
aminobutyl)-4-piperidinyl]phenyl}-2-methylpropanamide
and 2-(4-chlorophenoxy)nicotinoyl chloride: ESMS m/e:
549.0 (M + H)⁺.

Example 679

10 N-(4-{4-[3-(ISOBUTYRYLAMINO) PHENYL]-1-
PIPERIDINYL}BUTYL)-3,4-DIMETHOXYBENZAMIDE: Prepared by
Procedure Q2 (THF/DCM, 1:3) and Scheme AT using N-{3-
[1-(4-aminobutyl)-4-piperidinyl]phenyl}-2-
15 methylpropanamide and 3,4-dimethoxybenzoyl chloride:
ESMS m/e: 482.0 (M + H)⁺.

Example 680

3-(2-CHLOROPHENYL)-N-(4-{4-[3-(ISOBUTYRYLAMINO) PHENYL]-
20 1-PIPERIDINYL}BUTYL)-5-METHYL-4-ISOXAZOLECARBOXAMIDE:
Prepared by Procedure Q2 (THF/DCM, 1:3) and Scheme AT
using N-{3-[1-(4-aminobutyl)-4-piperidinyl]phenyl}-2-
methylpropanamide and 3-(2-chlorophenyl)-5-methyl-4-
isoxazolecarbonyl chloride: ESMS m/e: 537.0 (M + H)⁺.

25

Example 681

3-(2-CHLOROPHENYL)-N-(5-{4-[3-(ISOBUTYRYLAMINO) PHENYL]-
1-PIPERIDINYL}PENTYL)-5-METHYL-4-ISOXAZOLECARBOXAMIDE:
Prepared by Procedure Q2 (THF/DCM, 1:3) and Scheme AT
30 using N-{3-[1-(5-aminopentyl)-4-piperidinyl]phenyl}-2-
methylpropanamide and 3-(2-chlorophenyl)-5-methyl-4-
isoxazolecarbonyl chloride: ESMS m/e: 551.0 (M + H)⁺.

420

Example 682

2-METHYL-N-{3-[1-(3-{1-METHYL-2-[4-(TRIFLUOROMETHYL) PHENYL]-1H-INDOL-3-YL}PROPYL)-4-PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure E
5 and Scheme M using 2-methyl-N-[3-(1-{5-oxo-5-[4-(trifluoromethyl)phenyl]pentyl}-4-piperidinyl)phenyl]propanamide and 1-methyl-1-phenylhydrazine: ESMS m/e : 562.2 (M + H)⁺.

10 **Example 683**

2-METHYL-N-{3-[1-(3-{1-METHYL-2-[4-(TRIFLUOROMETHYL) PHENYL]-1H-INDOL-3-YL}PROPYL)-4-PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure E
and Scheme M using 2-methyl-N-[3-(1-{5-oxo-5-[4-(trifluoromethyl)phenyl]pentyl}-4-
15 piperidinyl)phenyl]propanamide and 4-(trifluoromethoxy)phenylhydrazine hydrochloride: ESMS
 m/e : 632.2 (M + H)⁺.

20 **Example 684**

2-METHYL-N-{3-[1-(3-{2-[4-(TRIFLUOROMETHYL) PHENYL]-1H-INDOL-3-YL}PROPYL)-4-PIPERIDINYL] PHENYL}PROPANAMIDE:
Prepared by Procedure E and Scheme M using 2-methyl-N-[3-(1-{5-oxo-5-[4-(trifluoromethyl)phenyl]pentyl}-4-
25 piperidinyl)phenyl]propanamide and phenylhydrazine: ESMS
 m/e : 548.2 (M + H)⁺.

Example 685

2-METHYL-N-{3-[1-(3-{1-PHENYL-2-[4-(TRIFLUOROMETHYL) PHENYL]-1H-INDOL-3-YL}PROPYL)-4-PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure E
30 and Scheme M using 2-methyl-N-[3-(1-{5-oxo-5-[4-(trifluoromethyl)phenyl]pentyl}-4-

piperidinyl)phenyl]propanamide and 1,1-diphenylhydrazine hydrochloride: ESMS m/e : 624.2 ($M + H$)⁺.

Example 686

5 2-METHYL-N-{3-[1-(3-{2-[4-(TRIFLUOROMETHYL) PHENYL]-1H-BENZO[G]INDOL-3-YL}PROPYL)-4-

PIPERIDINYL]PHENYL}PROPANAMIDE: Prepared by Procedure E and Scheme M using 2-methyl-N-[3-(1-{5-oxo-5-[4-(trifluoromethyl)phenyl]pentyl}-4-

10 piperidinyl)phenyl]propanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e : 598.2 ($M + H$)⁺.

Example 687

2-METHYL-N-{3-[1-(3-{7-METHYL-2-[4-(TRIFLUOROMETHYL) PHENYL]-1H-INDOL-3-YL}PROPYL)-4-

15 PIPERIDINYL]PHENYL}PROPANAMIDE: Prepared by Procedure E and Scheme M using 2-methyl-N-[3-(1-{5-oxo-5-[4-(trifluoromethyl)phenyl]pentyl}-4-

20 piperidinyl)phenyl]propanamide and 1-(2-methylphenyl)hydrazine hydrochloride: ESMS m/e : 562.2 ($M + H$)⁺.

Example 688

2-METHYL-N-{3-[1-(3-{5-METHYL-2-[4-(TRIFLUOROMETHYL) PHENYL]-1H-INDOL-3-YL}PROPYL)-4-

25 PIPERIDINYL]PHENYL}PROPANAMIDE: Prepared by Procedure E and Scheme M using 2-methyl-N-[3-(1-{5-oxo-5-[4-(trifluoromethyl)phenyl]pentyl}-4-

30 piperidinyl)phenyl]propanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e : 562.2 ($M + H$)⁺.

Example 689

422

N-{3-[1-(3-{5-METHOXY-2-(TRIFLUOROMETHYL) PHENYL]-1H-INDOL-3-YL}PROPYL)-4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using 2-methyl-N-[3-(1-{5-oxo-5-[4-(trifluoromethyl)phenyl]pentyl}-4-piperidinyl)phenyl]propanamide and 4-methoxyphenylhydrazine hydrochloride: ESMS m/e : 578.2 ($M + H$)⁺.

10 **Example 690**

N-[3-(1-{3-[2-(3-FLUOROPHENYL)-7-METHYL-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using **N**-(3-{1-[5-(3-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-(2-methylphenyl)hydrazine hydrochloride: ESMS m/e : 512.2 ($M + H$)⁺.

Example 691

N-[3-(1-{3-[2-(4-CHLOROPHENYL)-1-METHYL-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using **N**-(3-{1-[5-(4-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-methyl-1-phenylhydrazine: ESMS m/e : 528.2 ($M + H$)⁺.

25

Example 692

N-[3-(1-{3-[2-(4-FLUOROPHENYL)-5-METHOXY-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using **N**-(3-{1-[5-(4-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-methoxyphenylhydrazine hydrochloride: ESMS m/e : 528.2 ($M + H$)⁺.

30

423

Example 693

N-[3-(1-{3-[2-(2-FLUOROPHENYL)-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and phenylhydrazine: ESMS m/e : 498.2 (M + H)⁺.

Example 694

N-[3-(1-{3-[2-(3-FLUOROPHENYL)-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N-(3-{1-[5-(3-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-(trifluoromethoxy)phenylhydrazine hydrochloride: ESMS m/e : 582.2 (M + H)⁺.

Example 695

N-[3-(1-{3-[2-(2-FLUOROPHENYL)-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-(trifluoromethoxy)phenylhydrazine hydrochloride: ESMS m/e : 582.2 (M + H)⁺.

Example 696

N-[3-(1-{3-[2-(4-FLUOROPHENYL)-1-PHENYL-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N-(3-{1-[5-(4-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1,1-diphenylhydrazine hydrochloride: ESMS m/e : 548.2 (M + H)⁺.

Example 697

N-[3-(1-{3-[2-(2-FLUOROPHENYL)-1H-BENZO[G]INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-naphthylhydrazine hydrochloride:
ESMS m/e: 547.7 (M + H)⁺.

Example 698

N-[3-(1-{3-[2-(2-FLUOROPHENYL)-5-METHYL-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e: 512.2 (M + H)⁺.

Example 699

N-[3-(1-{3-[2-(3-FLUOROPHENYL)-1H-BENZO[G]INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(3-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e: 548.2 (M + H)⁺.

Example 700

N-[3-(1-{3-[2-(4-FLUOROPHENYL)-1-METHYL-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(4-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-methyl-1-phenylhydrazine: ESMS m/e: 512.2 (M + H)⁺.

Example 701

425

N-[3-(1-{3-[2-(3-FLUOROPHENYL)-5-METHOXY-1*H*-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(3-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-methoxyphenylhydrazine hydrochloride: ESMS *m/e*: 528.2 (*M* + *H*)⁺.

Example 702

N-[3-(1-{3-[2-(3-FLUOROPHENYL)-1-PHENYL-1*H*-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(3-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1,1-diphenylhydrazine hydrochloride: ESMS *m/e*: 574.2 (*M* + *H*)⁺.

Example 703

N-[3-(1-{3-[2-(4-CHLOROPHENYL)-5-(TRIFLUOROMETHOXY)-1*H*-INDOL-3-YL] PROPYL}-4-

PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(4-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-(trifluoromethoxy)phenylhydrazine hydrochloride: ESMS *m/e*: 598.2 (*M* + *H*)⁺.

Example 704

N-[3-(1-{3-[2-(3-FLUOROPHENYL)-1*H*-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(3-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and phenylhydrazine: ESMS *m/e*: 498.2 (*M* + *H*)⁺.

Example 705

***N*-[3-(1-{3-[2-(3-FLUOROPHENYL)-1-METHYL-1*H*-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**

5 Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(3-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-methyl-1-phenylhydrazine: ESMS *m/e*: 512.2 (*M* + *H*)⁺.

10 **Example 706**

***N*-[3-(1-{3-[2-(3-FLUOROPHENYL)-5-METHYL-1*H*-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(3-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS *m/e*: 512.2 (*M* + *H*)⁺.

15

Example 707

***N*-[3-(1-{3-[2-(4-CHLOROPHENYL)-1*H*-BENZO[G]INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**

20 Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(4-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS *m/e*: 564.2 (*M* + *H*)⁺.

25

Example 708

***N*-[3-(1-{3-[2-(4-CHLOROPHENYL)-1*H*-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:** Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(4-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-phenylhydrazine hydrochloride: ESMS *m/e*: 514.2 (*M* + *H*)⁺.

30

Example 709

***N*-[3-(1-{3-[2-(2-FLUOROPHENYL)-1-METHYL-1*H*-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(2-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-methyl-1-phenylhydrazine: ESMS m/e : 512.2 ($M + H$)⁺.

Example 710

***N*-[3-(1-{3-[2-(2-FLUOROPHENYL)-7-METHYL-1*H*-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(2-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-(2-methylphenyl)hydrazine hydrochloride: ESMS m/e : 512.2 ($M + H$)⁺.

Example 711

***N*-[3-(1-{3-[2-(2-FLUOROPHENYL)-1-PHENYL-1*H*-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(2-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1,1-diphenylhydrazine hydrochloride: ESMS m/e : 574.2 ($M + H$)⁺.

Example 712

***N*-[3-(1-{3-[2-(2-FLUOROPHENYL)-5-METHOXY-1*H*-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(2-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-methoxyphenylhydrazine hydrochloride: ESMS m/e : 528.2 ($M + H$)⁺.

Example 713

428

N-[3-(1-{3-[2-(4-CHLOROPHENYL)-5-METHOXY-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(4-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-methoxyphenylhydrazine hydrochloride: ESMS m/e : 544.2 (M + H)⁺.

Example 714

N-[3-(1-{3-[2-(4-FLUOROPHENYL)-1H-BENZO[G]INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(4-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e : 548.2 (M + H)⁺.

Example 715

N-[3-(1-{3-[2-(4-FLUOROPHENYL)-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-

METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(4-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-(trifluoromethoxy)phenylhydrazine hydrochloride: ESMS m/e : 582.9 (M + H)⁺.

Example 716

N-[3-(1-{3-[2-(4-FLUOROPHENYL)-7-METHYL-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(4-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-(2-methylphenyl)hydrazine hydrochloride: ESMS m/e : 512.2 (M + H)⁺.

Example 717

N-[3-(1-{3-[2-(4-FLUOROPHENYL)-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by
5 Procedure E and Scheme M using N-(3-{1-[5-(4-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and phenylhydrazine: ESMS m/e: 498.2 (M + H)⁺.

10 **Example 718**

N-[3-(1-{3-[2-(4-FLUOROPHENYL)-5-METHYL-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N-(3-{1-[5-(4-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-
15 methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e: 512.2 (M + H)⁺.

Example 719

N-[3-(1-{3-[2-(4-CHLOROPHENYL)-7-METHYL-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:
20 Prepared by Procedure E and Scheme M using N-(3-{1-[5-(4-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-(2-methylphenyl)hydrazine hydrochloride: ESMS m/e: 528.2 (M + H)⁺.

25

Example 720

N-[3-(1-{3-[2-(4-CHLOROPHENYL)-5-METHYL-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N-(3-{1-[5-(4-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-
30 methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e: 528.2 (M + H)⁺.

Example 721

N-[3-(1-{3-[2-(4-CHLOROPHENYL)-1-PHENYL-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(4-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1,1-diphenylhydrazine hydrochloride: ESMS m/e : 590.2 (M + H)⁺.

Example 722

10 **N-[3-(1-{3-[2-(3-CHLOROPHENYL)-7-METHYL-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(3-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-(2-methylphenyl)hydrazine hydrochloride: ESMS m/e : 528.1 (M + H)⁺.

Example 723

20 **N-[3-(1-{3-[2-(3-CHLOROPHENYL)-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(3-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-(trifluoromethoxy)phenylhydrazine hydrochloride: ESMS m/e : 598.2 (M + H)⁺.

Example 724

30 **N-[3-(1-{3-[2-(3-CHLOROPHENYL)-1-METHYL-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(3-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-methyl-1-phenylhydrazine: ESMS m/e : 528.2 (M + H)⁺.

Example 725

***N*-[3-(1-{3-[2-(3-CHLOROPHENYL)-1-PHENYL-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:**

- 5 Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(3-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1,1-diphenylhydrazine hydrochloride: ESMS *m/e*: 590.3 (*M* + *H*)⁺.

10 **Example 726**

***N*-[3-(1-{3-[2-(3-CHLOROPHENYL)-5-METHOXY-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:**

- Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(3-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-methoxyphenylhydrazine hydrochloride: ESMS *m/e*: 544.3 (*M* + *H*)⁺.
- 15

Example 727

***N*-[3-(1-{3-[2-(3-CHLOROPHENYL)-5-METHYL-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:**

- 20 Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(3-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS *m/e*: 528.2 (*M* + *H*)⁺.

25

Example 728

***N*-[3-(1-{3-[2-(3-CHLOROPHENYL)-1H-BENZO[G]INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:**

- Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(3-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS *m/e*: 564.2 (*M* + *H*)⁺.
- 30

Example 729

N-[3-(1-{3-[2-(3-CHLOROPHENYL)-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(3-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and phenylhydrazine: ESMS *m/e*: 514.2 (M + H)⁺.

Example 730

N-[3-(1-{3-[2-(2-CHLOROPHENYL)-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and phenylhydrazine: ESMS *m/e*: 514.2 (M + H)⁺.

Example 731

N-[3-(1-{3-[2-(2-CHLOROPHENYL)-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-

METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-(trifluoromethoxy)phenylhydrazine hydrochloride: ESMS *m/e*: 598.2 (M + H)⁺.

Example 732

N-[3-(1-{3-[2-(2-CHLOROPHENYL)-1H-BENZO[G]INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS *m/e*: 564.2 (M + H)⁺.

433

Example 733

***N*-[3-(1-{3-[2-(2-CHLOROPHENYL)-7-METHYL-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(2-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-(2-methylphenyl)hydrazine hydrochloride: ESMS *m/e*: 528.2 (*M* + *H*)⁺.

Example 734

***N*-[3-(1-{3-[2-(2-CHLOROPHENYL)-1-PHENYL-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(2-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1,1-diphenylhydrazine hydrochloride: ESMS *m/e*: 590.2 (*M* + *H*)⁺.

Example 735

***N*-[3-(1-{3-[2-(2-CHLOROPHENYL)-1-METHYL-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(2-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-methyl-1-phenylhydrazine: ESMS *m/e*: 528.2 (*M* + *H*)⁺.

Example 736

***N*-[3-(1-{3-[2-(2-CHLOROPHENYL)-5-METHYL-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(2-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS *m/e*: 528.2 (*M* + *H*)⁺.

Example 737

434

N-[3-(1-{3-[2-(3-**IODOPHENYL**)-1*H*-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(3-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and phenylhydrazine: ESMS *m/e*: 606.2 (M + H)⁺.

Example 738

N-[3-(1-{3-[2-(3-**IODOPHENYL**)-1-METHYL-1*H*-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(3-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-methyl-1-phenylhydrazine: ESMS *m/e*: 620.2 (M + H)⁺.

15

Example 739

N-[3-(1-{3-[2-(3-**IODOPHENYL**)-1-PHENYL-1*H*-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(3-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1,1-diphenylhydrazine hydrochloride: ESMS *m/e*: 682.2 (M + H)⁺.

20

Example 740

N-[3-(1-{3-[2-(3-**IODOPHENYL**)-1*H*-BENZO[G]INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(3-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS *m/e*: 656.2 (M + H)⁺.

30

Example 741

435

**N-[3-(1-{3-[2-(3-
(TRIFLUOROMETHOXY)-1H-INDOL-3-YL] PROPYL}-4-
PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using N-(3-{1-[5-
5 (3-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-
methylpropanamide and 4-
(trifluoromethoxy)phenylhydrazine hydrochloride: ESMS
m/e: 690.2 (M + H)⁺.

10 **Example 742**

**N-[3-(1-{3-[2-(3-iodophenyl)-5-METHYL-1H-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using N-(3-{1-[5-
(3-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-
15 methylpropanamide and 4-methylphenylhydrazine
hydrochloride: ESMS m/e: 620.2 (M + H)⁺.

Example 743

**N-[3-(1-{3-[2-(3-iodophenyl)-7-METHYL-1H-INDOL-3-
20 YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using N-(3-{1-[5-
(3-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-
methylpropanamide and 1-(2-methylphenyl)hydrazine
hydrochloride: ESMS m/e: 620.2 (M + H)⁺.

25

Example 744

**N-[3-(1-{3-[2-(4-iodophenyl)-5-(TRIFLUOROMETHOXY)-1H-
INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-
METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using N-(3-{1-[5-
30 (4-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-
methylpropanamide and 4-

436

(trifluoromethoxy)phenylhydrazine hydrochloride: ESMS
m/e: 690.1 (M + H)⁺.

Example 745

5 N-[3-(1-{3-[2-(4-iodophenyl)-5-methyl-1H-indol-3-
YL]propyl}-4-piperidinyl)phenyl]-2-methylpropanamide:
Prepared by Procedure E and Scheme M using N-(3-{1-[5-
(4-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-
methylpropanamide and 4-methylphenylhydrazine
10 hydrochloride: ESMS m/e: 620.1 (M + H)⁺.

Example 746

N-[3-(1-{3-[2-(4-iodophenyl)-7-methyl-1H-indol-3-
YL]propyl}-4-piperidinyl)phenyl]-2-methylpropanamide:
15 Prepared by Procedure E and Scheme M using N-(3-{1-[5-
(4-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-
methylpropanamide and 1-(2-methylphenyl)hydrazine
hydrochloride: ESMS m/e: 620.1 (M + H)⁺.

Example 747

20 N-[3-(1-{3-[2-(4-iodophenyl)-1-phenyl-1H-indol-3-
YL]propyl}-4-piperidinyl)phenyl]-2-methylpropanamide:
Prepared by Procedure E and Scheme M using N-(3-{1-[5-
(4-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-
25 methylpropanamide and 1,1-diphenylhydrazine
hydrochloride: ESMS m/e: 682.1 (M + H)⁺.

Example 748

30 N-[3-(1-{3-[2-(4-iodophenyl)-1-methyl-1H-indol-3-
YL]propyl}-4-piperidinyl)phenyl]-2-methylpropanamide:
Prepared by Procedure E and Scheme M using N-(3-{1-[5-
(4-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-

437

methylpropanamide and 1-methyl-1-phenylhydrazine:
ESMS m/e : 620.1 (M + H)⁺.

Example 749

5 **N-[3-(1-{3-[2-(4-iodophenyl)-1H-benzo[G]indol-3-yl]propyl}-4-piperidinyl)phenyl]-2-methylpropanamide:**
Prepared by Procedure E and Scheme M using N-(3-{1-[5-(4-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-naphthylhydrazine hydrochloride:
10 ESMS m/e : 656.1 (M + H)⁺.

Example 750

N-[3-(1-{3-[2-(4-iodophenyl)-1H-indol-3-yl]propyl}-4-piperidinyl)phenyl]-2-methylpropanamide:
15 Prepared by Procedure E and Scheme M using N-(3-{1-[5-(4-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and phenylhydrazine: ESMS m/e : 606.1 (M + H)⁺.

Example 751

N-[3-(1-{3-[2-(3-bromophenyl)-5-(trifluoromethoxy)-1H-indol-3-yl]propyl}-4-piperidinyl)phenyl]-2-methylpropanamide: Prepared by Procedure E and Scheme M using N-(3-{1-[5-(3-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-(trifluoromethoxy)phenylhydrazine hydrochloride: ESMS
25 m/e : 642.0 (M + H)⁺.

Example 752

30 **N-[3-(1-{3-[2-(4-bromophenyl)-1H-benzo[G]indol-3-yl]propyl}-4-piperidinyl)phenyl]-2-methylpropanamide:**
Prepared by Procedure E and Scheme M using N-(3-{1-[5-(4-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-

438

methylpropanamide and 1-naphthylhydrazine
hydrochloride: ESMS m/e : 608.0 (M + H)⁺.

Example 753

5 ***N*-[3-(1-{3-[2-(4-BROMOPHENYL)-7-METHYL-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**
Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(4-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-(2-methylphenyl)hydrazine
10 hydrochloride: ESMS m/e : 572 (M + H)⁺.

Example 754

***N*-[3-(1-{3-[2-(4-BROMOPHENYL)-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**
15 **Prepared by Procedure E and Scheme M using** *N*-(3-{1-[5-(4-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-(trifluoromethoxy)phenylhydrazine hydrochloride: ESMS
 m/e : 642 (M + H)⁺.

20

Example 755

***N*-[3-(1-{3-[2-(3-BROMOPHENYL)-1H-BENZO[G]INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**
Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(3-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-naphthylhydrazine hydrochloride:
25 ESMS m/e : 608.0 (M + H)⁺.

Example 756

30 ***N*-[3-(1-{3-[2-(4-BROMOPHENYL)-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:** Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(4-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-

439

methylpropanamide and phenylhydrazine: ESMS m/e :
558.1 (M + H)⁺.

Example 757

5 ***N*-[3-(1-{3-[2-(3-BROMOPHENYL)-1-PHENYL-1H-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(3-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1,1-diphenylhydrazine
10 hydrochloride: ESMS m/e : 634.0 (M + H)⁺.

Example 758

***N*-[3-(1-{3-[2-(3-BROMOPHENYL)-1-METHYL-1H-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**

15 Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(3-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-methyl-1-phenylhydrazine: ESMS
 m/e : 572.0 (M + H)⁺.

20 **Example 759**

***N*-[3-(1-{3-[2-(4-BROMOPHENYL)-1-METHYL-1H-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(4-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-methyl-1-phenylhydrazine: ESMS
25 m/e : 572.0 (M + H)⁺.

Example 760

30 ***N*-[3-(1-{3-[2-(4-BROMOPHENYL)-1-PHENYL-1H-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using *N*-(3-{1-[5-(4-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-

440

methylpropanamide and 1,1-diphenylhydrazine
hydrochloride: ESMS m/e : 634.0 ($M + H$)⁺.

Example 761

5 N-[3-(1-{3-[2-(4-BROMOPHENYL)-5-METHOXY-1H-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N-(3-{1-[5-
(4-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-
methylpropanamide and 4-methoxyphenylhydrazine
10 hydrochloride: ESMS m/e : 588.1 ($M + H$)⁺.

Example 762

N-[3-(1-{3-[2-(3-BROMOPHENYL)-7-METHYL-1H-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:
15 Prepared by Procedure E and Scheme M using N-(3-{1-[5-
(3-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-
methylpropanamide and 1-(2-methylphenyl)hydrazine
hydrochloride: ESMS m/e : 572 ($M + H$)⁺.

Example 763

20 N-[3-(1-{3-[2-(3-BROMOPHENYL)-5-METHYL-1H-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N-(3-{1-[5-
(3-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-
25 methylpropanamide and 4-methylphenylhydrazine
hydrochloride: ESMS m/e : 572 ($M + H$)⁺.

Example 764

30 N-[3-(1-{3-[2-(4-BROMOPHENYL)-5-METHYL-1H-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N-(3-{1-[5-
(4-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-

441
methylpropanamide and 4-methylphenylhydrazine
hydrochloride: ESMS m/e : 572.0 ($M + H$)⁺.

Example 765

5 N-[3-(1-{3-[2-(3-BROMOPHENYL)-5-METHOXY-1H-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N-(3-{1-[5-
(3-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-
methylpropanamide and 4-methoxyphenylhydrazine
10 hydrochloride: ESMS m/e : 588.0 ($M + H$)⁺.

Example 766

2-METHYL-N-[3-(1-{3-[2-(3-NITROPHENYL)-1H-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE:
15 Prepared by Procedure E and Scheme M using 2-methyl-N-
(3-{1-[5-(3-nitrophenyl)-5-oxopentyl]-4-
piperidinyl}phenyl)propanamide and phenylhydrazine: ESMS
 m/e : 525.2 ($M + H$)⁺.

Example 767

2-METHYL-N-[3-(1-{3-[2-(3-NITROPHENYL)-1H-BENZO[G]INDOL-
3-YL] PROPYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE:
Prepared by Procedure E and Scheme M using 2-methyl-N-
(3-{1-[5-(3-nitrophenyl)-5-oxopentyl]-4-
25 piperidinyl}phenyl)propanamide and 1-naphthylhydrazine
hydrochloride: ESMS m/e : 575.1 ($M + H$)⁺.

Example 768

2-METHYL-N-[3-(1-{3-[2-(3-NITROPHENYL)-5-
30 (TRIFLUOROMETHOXY)-1H-INDOL-3-YL] PROPYL}-4-
PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure E
and Scheme M using 2-methyl-N-(3-{1-[5-(3-nitrophenyl)-
5-oxopentyl]-4-piperidinyl}phenyl)propanamide and 4-

442

(trifluoromethoxy)phenylhydrazine hydrochloride: ESMS
m/e: 609.1 (M + H)⁺.

Example 769

5 2-METHYL-N-[3-(1-{3-[5-METHYL-2-(3-NITROPHENYL)-1H-
INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE:

Prepared by Procedure E and Scheme M using 2-methyl-N-
(3-{1-[5-(3-nitrophenyl)-5-oxopentyl]-4-
piperidinyl}phenyl)propanamide and 4-
10 methylphenylhydrazine hydrochloride: ESMS m/e: 539.2 (M
+ H)⁺.

Example 770

15 N-[3-(1-{3-[5-METHOXY-2-(3-NITROPHENYL)-1H-INDOL-3-
YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using 2-methyl-N-
(3-{1-[5-(3-nitrophenyl)-5-oxopentyl]-4-
piperidinyl}phenyl)propanamide and 4-
20 methoxyphenylhydrazine hydrochloride: ESMS m/e: 555.2 (M
+ H)⁺.

Example 771

2-METHYL-N-[3-(1-{3-[2-(3-NITROPHENYL)-1-PHENYL-1H-
INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE:

25 Prepared by Procedure E and Scheme M using 2-methyl-N-
(3-{1-[5-(3-nitrophenyl)-5-oxopentyl]-4-
piperidinyl}phenyl)propanamide and 1,1-diphenylhydrazine
hydrochloride: ESMS m/e: 601.1 (M + H)⁺.

30 **Example 772**

2-METHYL-N-[3-(1-{3-[1-METHYL-2-(3-NITROPHENYL)-1H-
INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE:

Prepared by Procedure E and Scheme M using 2-methyl-N-

443

(3-{1-[5-(3-nitrophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)propanamide and 1-methyl-1-phenylhydrazine: ESMS m/e : 539.2 (M + H)⁺.

5 **Example 773**

2-METHYL-N-[3-(1-{3-[7-METHYL-2-(3-NITROPHENYL)-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE:

Prepared by Procedure E and Scheme M using 2-methyl-N-(3-{1-[5-(3-nitrophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)propanamide and 1-(2-methylphenyl)hydrazine hydrochloride: ESMS m/e : 539.2 (M + H)⁺.

10

Example 774

15 **N-[3-(1-{3-[5-METHOXY-2-(4-NITROPHENYL)-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:**

Prepared by Procedure E and Scheme M using 2-methyl-N-(3-{1-[5-(4-nitrophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)propanamide and 4-methoxyphenylhydrazine hydrochloride: ESMS m/e : 555.6 (M + H)⁺.

20

Example 775

N-[3-(1-{3-[2-(2-BROMOPHENYL)-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and phenylhydrazine: ESMS m/e : 557.9 (M + H)⁺.

25

30

Example 776

2-METHYL-N-[3-(1-{3-[5-METHYL-2-(4-NITROPHENYL)-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE:

444

Prepared by Procedure E and Scheme M using 2-methyl-N-(3-{1-[5-(4-nitrophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)propanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e : 539.1 (M + H)⁺.

Example 777

2-METHYL-N-[3-(1-{3-[2-(4-NITROPHENYL)-1H-BENZO[G]INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE: Prepared by Procedure E and Scheme M using 2-methyl-N-(3-{1-[5-(4-nitrophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)propanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e : 574.7 (M + H)⁺.

Example 778

2-METHYL-N-(3-{1-[(5E)-5-(4-NITROPHENYL)-5-(PHENYLHYDRAZONO)PENTYL]-4-PIPERIDINYL}PHENYL)PROPANAMIDE: Prepared by Procedure E and Scheme AX using 2-methyl-N-(3-{1-[5-(4-nitrophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)propanamide and phenylhydrazine: ESMS m/e : 542.4 (M + H)⁺.

Example 779

2-METHYL-N-[3-(1-{3-[7-METHYL-2-(4-NITROPHENYL)-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE: Prepared by Procedure E and Scheme M using 2-methyl-N-(3-{1-[5-(4-nitrophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)propanamide and 1-(2-methylphenyl)hydrazine hydrochloride: ESMS m/e : 538.8 (M + H)⁺.

Example 780

445

2-METHYL-N-{3-[1-((5E)-5-(4-NITROPHENYL)-5-{[4-(TRIFLUOROMETHOXY) PHENYL] HYDRAZONO}PENTYL)-4-

PIPERIDINYL] PHENYL} PROPANAMIDE: Prepared by Procedure E and Scheme M using 2-methyl-N-(3-{1-[5-(4-nitrophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)propanamide and 4-(trifluoromethoxy)phenylhydrazine hydrochloride: ESMS m/e : 626.2 (M + H)⁺.

Example 781

10 N-[3-(1-{3-[2-(2-BROMOPHENYL)-1H-BENZO[G]INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e : 608.0 (M + H)⁺.

Example 782

20 N-[3-(1-{3-[2-(2-BROMOPHENYL)-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-(trifluoromethoxy)phenylhydrazine hydrochloride: ESMS m/e : 641.9 (M + H)⁺.

25

Example 783

30 N-[3-(1-{3-[2-(2-BROMOPHENYL)-7-METHYL-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-(2-methylphenyl)hydrazine hydrochloride: ESMS m/e : 572.0 (M + H)⁺.

446

Example 784

N-[3-(1-{3-[2-(2-BROMOPHENYL)-1-PHENYL-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1,1-diphenylhydrazine hydrochloride: ESMS m/e: 634 (M + H)⁺.

Example 785

10 N-[3-(1-{3-[2-(2-BROMOPHENYL)-5-METHYL-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e: 572.0 (M + H)⁺.

Example 786

20 N-[3-(1-{3-[2-(2-IODOPHENYL)-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-(trifluoromethoxy)phenylhydrazine hydrochloride: ESMS m/e: 690.0 (M + H)⁺.

Example 787

30 N-[3-(1-{3-[2-(2-IODOPHENYL)-5-METHYL-1H-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e: 620.2 (M + H)⁺.

Example 788

2-METHYL-N-[3-(1-{3-[1-METHYL-2-(4-NITROPHENYL)-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE:

5 Prepared by Procedure E and Scheme M using 2-methyl-N-(3-{1-[5-(4-nitrophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)propanamide and 1-methyl-1-phenylhydrazine: ESMS m/e : 539.6 (M + H)⁺.

10 **Example 789**

2-METHYL-N-[3-(1-{3-[2-(4-NITROPHENYL)-1-PHENYL-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE:

Prepared by Procedure E and Scheme M using 2-methyl-N-(3-{1-[5-(4-nitrophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)propanamide and 1,1-diphenylhydrazine hydrochloride: ESMS m/e : 601.6 (M + H)⁺.

15

Example 790

N-[3-(1-{3-[2-(2-IODOPHENYL)-1H-INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and phenylhydrazine: ESMS m/e : 606.1 (M + H)⁺.

20

25

Example 791

N-[3-(1-{3-[2-(2-IODOPHENYL)-1H-BENZO[G]INDOL-3-YL]PROPYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e : 656.1 (M + H)⁺.

30

Example 792

N-[3-(1-{3-[2-(2-iodophenyl)-1-phenyl-1H-indol-3-yl]propyl}-4-piperidinyl)phenyl]-2-methylpropanamide:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1,1-diphenylhydrazine hydrochloride: ESMS *m/e*: 682.1 (M + H)⁺.

Example 793

N-[3-(1-{3-[2-(2-iodophenyl)-7-methyl-1H-indol-3-yl]propyl}-4-piperidinyl)phenyl]-2-methylpropanamide:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-iodophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-(2-methylphenyl)hydrazine hydrochloride: ESMS *m/e*: 619.6 (M + H)⁺.

Example 794

N-[3-(1-{3-[2-(2-bromophenyl)-1-methyl-1H-indol-3-yl]propyl}-4-piperidinyl)phenyl]-2-methylpropanamide:

Prepared by Procedure E and Scheme M using N-(3-{1-[5-(2-bromophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide and 1-methyl-1-phenylhydrazine: ESMS *m/e*: 572 (M + H)⁺.

Example 795

4-(3,4-difluorophenyl)-N-(3-{4-[3-(isobutyrylamino)phenyl]-1-piperidinyl}propyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide:

Prepared by Procedure AC and Scheme AM using 4-(3,4-difluorophenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxylic acid and N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS *m/e*: 553.0 (M + H)⁺.

Example 796**4-(2,4-DIFL****UOROPHENYL)-N-(3-{4-[3-(ISOBUTYRYLAMINO)PHENYL]-1-****PIPERIDINYL}PROPYL)-2-METHYL-6-OXO-1,4,5,6-TETRAHYDRO-3-**

5 **PYRIDINECARBOXAMIDE:** Prepared by Procedure AC and
Scheme AM using 4-(2,4-difluorophenyl)-2-methyl-6-oxo-
1,4,5,6-tetrahydro-3-pyridinecarboxylic acid and N-{3-
[1-(3-aminopropyl)-4-piperidinyl]phenyl}-2-
methylpropanamide: ESMS m/e: 553.0 (M + H)⁺.

10

Example 797**N-(3-{1-[4-(4-METHOXYPHENYL)BUTYL]-4-**

PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure O and Scheme W using 4-(4-methoxyphenyl)-1-
15 butanol and 2-methyl-N-[3-(4-
piperidinyl)phenyl]propanamide: ESMS m/e: 409 (M + H)⁺.

Example 798**N-(4-{1-[3-(1,2-DIPHENYL-1H-INDOL-3-YL)PROPYL]-4-**

20 **PIPERIDINYL}PHENYL)PROPANAMIDE:** Prepared by Procedure O
and Scheme W using 3-(1,2-diphenyl-1H-indol-3-yl)-1-
propanol and N-[4-(4-piperidinyl)phenyl]propanamide:
ESMS m/e: 542.0 (M + H)⁺.

25 **Example 799**

N-{4-[1-(3,3-DIPHENYLPROPYL)-4-

PIPERIDINYL}PHENYL)PROPANAMIDE: Prepared by Procedure O
and Scheme W using 3,3-diphenyl-1-propanol and
N-[4-(4-piperidinyl)phenyl]propanamide: ESMS m/e: 427.0
30 (M + H)⁺.

Example 800

450

2-METHYL-N-(3-{1-[4-(4-NITROPHENYL) BUTYL]-4-
PIPERIDINYL}PHENYL): Prepared by Procedure O and Scheme
W using 4-(4-nitrophenyl)-1-butanol and 2-methyl-N-[3-
(4-piperidinyl)phenyl]propanamide: ESMS m/e: 424.2 (M +
5 H)⁺.

Example 801

2-METHYL-N-(3-{1-[2-(1-NAPHTHYL) ETHYL]-4-
PIPERIDINYL}PHENYL) PROPANAMIDE Prepared by Procedure O
10 and Scheme W using 2-(1-naphthyl)ethanol and 2-methyl-N-
[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e: 401.2 (M
+ H)⁺.

Example 802

15 N-{3-[1-(3,3-DIPHENYLPROPYL)-4-PIPERIDINYL]PHENYL}-2-
METHYLPROPANAMIDE: Prepared by Procedure O and Scheme W
using 3,3-diphenyl-1-propanol and 2-methyl-N-[3-(4-
piperidinyl)phenyl]propanamide: ESMS m/e: 441.2 (M + H)⁺.

Example 803

20 N-(3-{1-[3-(3,4-DIMETHOXYPHENYL) PROPYL]-4-
PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure O and Scheme W using 3-(3,4-dimethoxyphenyl)-
1-propanol and 2-methyl-N-[3-(4-
25 piperidinyl)phenyl]propanamide: ESMS m/e: 425.2 (M + H)⁺.

Example 804

2-METHYL-N-{3-[1-(3-PHENYLPROPYL)-4-
PIPERIDINYL]PHENYL}PROPANAMIDE: Prepared by Procedure O
30 and Scheme W using 3-phenyl-1-propanol and
2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS
m/e: 365.2 (M + H)⁺.

451

Example 805**2-METHYL-N-(3-{1-[3-(4-PYRIDINYL) PROPYL]-4-****PIPERIDINYL}PHENYL)PROPANAMIDE:** Prepared by Procedure O and Scheme W using 3-(4-pyridinyl)-1-propanol and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e: 366.2 (M + H)⁺.**Example 806****N-{3-[1-(4-TERT-BUTYLBENZYL)-4-PIPERIDINYL]PHENYL}-2-****METHYLPROPANAMIDE:** Prepared by Procedure AJ and Scheme AV using 1-bromomethyl-4-tert-butylbenzene and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e: 393.0 (M + H)⁺.**Example 807****N-{3-[1-(4-BENZOYLBENZYL)-4-PIPERIDINYL]PHENYL}-2-****METHYLPROPANAMIDE:** Prepared by Procedure AJ and Scheme AV using [4-(bromomethyl)phenyl](phenyl)methanone and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e: 441.0 (M + H)⁺.**1,2-DICHLORO-4-{[(1S)-3-CHLORO-1-****PHENYLPROPYL]OXY}BENZENE:** Prepared by Procedure A using 3,4-dichlorophenol and (1R)-3-chloro-1-phenyl-1-propanol.**Example 808****N-(3-{1-[(3S)-3-(3,4-DICHLOROPHENOXY)-3-PHENYLPROPYL]-4-****PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:** Prepared by Procedure A using 1,2-dichloro-4-{[(1S)-3-chloro-1-phenylpropyl]oxy}benzene and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e: 525.3 (M + H)⁺.

Example 809

N-(3-{1-[6-(2-FLUOROPHENYL)-6-HYDROXYHEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
5 Procedure L and Scheme AN using *N*-(3-{1-[6-(2-fluorophenyl)-6-oxohexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS *m/e*: 441.3 (*M* + *H*)⁺.

Example 810

10 *N*-[3-(1-{5-HYDROXY-5-[4-(TRIFLUOROMETHYL)PHENYL]PENTYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by
Procedure L and Scheme AN using 2-methyl-*N*-[3-(1-{5-oxo-5-[4-(trifluoromethyl)phenyl]pentyl}-4-piperidinyl)phenyl]propanamide: ESMS *m/e*: 477.2 (*M* + *H*)⁺.

Example 811

15 *N*-(3-{1-[5-(4-FLUOROPHENYL)-5-HYDROXYPENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure L and Scheme AN using *N*-(3-{1-[5-(4-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS *m/e*: 427.2 (*M* + *H*)⁺.

Example 812

25 *N*-(3-{1-[7-(2-FLUOROPHENYL)-7-HYDROXYHEPTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure L and Scheme AN using *N*-(3-{1-[7-(2-fluorophenyl)-7-oxoheptyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS *m/e*: 455.2 (*M* + *H*)⁺.

Example 813

30 *N*-(3-{1-[6-(3-FLUOROPHENYL)-6-HYDROXYHEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure L and Scheme AN using *N*-(3-{1-[6-(3-

453

fluorophenyl)-6-oxohexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e : 441.2 (M + H)⁺.

Example 814

5 **N-(3-{1-[5-(2-FLUOROPHENYL)-5-HYDROXPENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:** Prepared by Procedure L and Scheme AN using N-(3-{1-[5-(2-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e : 427.2 (M + H)⁺.

10

Example 815

N-(3-{1-[5-(3-FLUOROPHENYL)-5-HYDROXPENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN using N-(3-{1-[5-(3-fluorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e : 427.2 (M + H)⁺.

15

Example 816

N-(3-{1-[5-(3-CHLOROPHENYL)-5-HYDROXPENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN using N-(3-{1-[5-(3-chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e : 443.1 (M + H)⁺.

20

Example 817

25 **N-(3-{1-[6-(4-FLUOROPHENYL)-6-HYDROXYHEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:** Prepared by Procedure L and Scheme AN using N-(3-{1-[6-(4-fluorophenyl)-6-oxohexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e : 441.2 (M + H)⁺.

30

Example 818

N-(3-{1-[6-(4-CHLOROPHENYL)-6-HYDROXYHEXYL]-4-

PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure L and Scheme AN using N-(3-{1-[6-(4-
5 chlorophenyl)-6-oxohexyl]-4-piperidinyl}phenyl)-2-
methylpropanamide: ESMS m/e: 456.9 (M + H)⁺.

Example 819

N-(3-{1-[5-(4-CHLOROPHENYL)-5-HYDROXPENTYL]-4-

10 **PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:** Prepared by
Procedure L and Scheme AN using N-(3-{1-[5-(4-
chlorophenyl)-5-oxopentyl]-4-piperidinyl}phenyl)-2-
methylpropanamide: ESMS m/e: 443.0 (M + H)⁺.

15 **Example 820**

N-(4-{1-[(9-ETHYL-9H-CARBAZOL-3-YL)METHYL]-4-

PIPERIDINYL}PHENYL)BUTANAMIDE: Prepared by Procedure F
and Scheme R, without HOAc, using 9-ethyl-9H-carbazole-
3-carbaldehyde and N-[4-(4-
20 piperidinyl)phenyl]butanamide: ESMS m/e: 454.2 (M + H)⁺.

Example 821

N-(3-{1-[(9-ETHYL-9H-CARBAZOL-3-YL)METHYL]-4-

PIPERIDINYL}PHENYL)PROPANAMIDE: Prepared by Procedure F
25 and Scheme R, without HOAc, using 9-ethyl-9H-carbazole-
3-carbaldehyde and N-[3-(4-
piperidinyl)phenyl]propanamide: ESMS m/e: 440.5 (M + H)⁺.

Example 822

30 **N-(3-{1-[(1,9-DIMETHYL-9H-CARBAZOL-3-YL)METHYL]-4-**

PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure F and Scheme R, without HOAc, using 1,9-
dimethyl-9H-carbazole-3-carbaldehyde and 2-methyl-N-[3-

(4-

5 piperidinyl)phenyl]propanamide: ^1H NMR (400 MHz, CDCl_3) δ 8.05-6.77 (m, 10H), 5.20-5.12 (m, 1H), 4.04 (s, 3H), 3.93 (s, 2H), 3.34-3.24 (m, 2H), 2.79 (s, 3H), 2.56-2.38 (m, 2H), 2.38-2.26 (m, 2H), 2.08-1.88 (m, 2H), 1.82-1.70 (m, 2H), 1.16 (d, 6H, $J = 6.8$ Hz); ESMS m/e : 454.2 ($M + H$) $^+$.

Example 823

10 **N-(3-{1-[(9-ETHYL-9H-CARBAZOL-3-YL)METHYL]-4-PIPERIDINYL}PHENYL)CYCLOPROPANECARBOXAMIDE:** Prepared by Procedure F and Scheme R, without HOAc, using 9-ethyl-9H-carbazole-3-carbaldehyde and N-[3-(4-piperidinyl)phenyl]cyclopropanecarboxamide: ESMS m/e :
15 452.6 ($M + H$) $^+$.

Example 824

1- (3-{1-[(9-ETHYL-9H-CARBAZOL-3-YL)METHYL]-4-PIPERIDINYL}PHENYL)-2-PYRROLIDINONE: Prepared by Scheme
20 R and Procedure F. A solution of 1-(9-ethyl-9H-carbazol-3-yl)ethanone (22.3 mg, 0.100 mmol) and 1-[3-(4-piperidinyl)phenyl]-2-pyrrolidinone (27.2 mg, 0.100 mmol) in 1,2-dichloroethane (1.00 mL) was treated with sodium triacetoxyborohydride (63.6 mg, 0.300 mmol) and
25 HOAc (5.70 μL , 0.100 mmol). The mixture was stirred overnight at room temperature. The reaction mixture was treated with a saturated aqueous NaHCO_3 solution (10 mL). The aqueous layer was extracted with CH_2Cl_2 (3 X 10 mL) and the combined organic layers were washed with brine
30 (10 mL), dried over MgSO_4 and concentrated in vacuo. The residue was purified by preparative TLC using 5% of NH_3 (2.0 M in methanol) in CH_2Cl_2 to give the desired product 1-(3-{1-[(9-ethyl-9H-carbazol-3-yl)methyl]-4-

456
piperidinyl}phenyl)-2-pyrrolidinone (4.60 mg,
9.43 %): ^1H NMR (400 MHz, CDCl_3) δ 8.04 (d, 1H, J = 7.4
Hz), 7.99 (s, 1H), 7.43-7.28 (m, 5H), 6.96 (d, 1H, J =
7.4 Hz), 4.31 (q, 2H, J = 6.8 Hz), 3.77 (t, 2H, J = 7.3
5 Hz), 3.70 (s, 2H), 3.06 (d, 2H, J = 10.6 Hz), 2.56-2.42
(m, 3H), 2.07 (m, 4H), 1.77 (m, 4H), 1.36 (m, 3H);
ESMS m/e : 452.5 ($M + H$) $^+$.

***N*-{3-[1-(1*H*-INDOL-5-YLMETHYL)-4-PIPERIDINYL]PHENYL}-2-METHYLPROPANAMIDE:** Prepared by Procedure F and Scheme
10 R, without HOAc, using 1*H*-indole-5-carbaldehyde and 2-methyl-*N*-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e :
376.2 ($M + H$) $^+$.

15 **1-(4-CHLOROBUTYL)-1*H*-INDOLE:** Prepared by Procedure AH,
and Scheme P using 1*H*-indole and 1-bromo-4-chlorobutane:
 ^1H NMR (400 MHz, CDCl_3) δ 7.72-7.02 (m, 5H), 6.49 (d, 1H, J
= 2.8 Hz), 4.13 (t, 2H, J = 6.8 Hz), 3.48 (t, 2H, J =
6.8 Hz), 2.06-1.92 (m, 2H), 1.80-1.70 (m, 2H).

20 **1-(3-CHLOROPROPYL)-1*H*-INDOLE:** Prepared by Procedure AH,
and Scheme P using 1*H*-indole and 1-bromo-3-chloropropane:
 ^1H NMR (400 MHz, CDCl_3) δ 7.70-7.04 (m, 5H), 6.50 (d, 1H, J = 2.8 Hz), 4.31 (t, 2H, J = 6.8 Hz),
25 3.42 (t, 2H, J = 6.4 Hz), 2.28-2.20 (m, 2H).

Example 825

***N*-(4-{1-[5-(1*H*-INDOL-1-YL)PENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:** Prepared by Procedure AH and
30 Scheme P using 1-(5-chloropentyl)-1*H*-indole and 2-methyl-*N*-[4-(4-piperidinyl)phenyl]propanamide: ESMS m/e :
432.3 ($M + H$) $^+$.

Example 826

***N*-(4-{1-[5-(1*H*-INDOL-1-YL)PENTYL]-4-**

5 **PIPERIDINYL}PHENYL)BUTANAMIDE:** Prepared by Procedure AH and Scheme P using 1-(5-chloropentyl)-1*H*-indole and *N*-[4-(4-piperidinyl)phenyl]butanamide: ESMS *m/e*: 432.3 (*M* + *H*)⁺.

Example 827

***N*-(4-{1-[5-(1*H*-INDOL-1-YL)PENTYL]-4-**

10 **PIPERIDINYL}PHENYL)PROPANAMIDE:** Prepared by Procedure AH and Scheme P using 1-(5-chloropentyl)-1*H*-indole and *N*-[4-(4-piperidinyl)phenyl]propanamide: ESMS *m/e*: 418.2 (*M* + *H*)⁺.

Example 828

***N*-(4-{1-[6-(1*H*-INDOL-1-YL)HEXYL]-4-**

15 **PIPERIDINYL}PHENYL)PROPANAMIDE:** Prepared by Procedure AH and Scheme P using 1-(6-chlorohexyl)-1*H*-indole and *N*-[4-(4-piperidinyl)phenyl]propanamide: ESMS *m/e*: 432.3 (*M* + *H*)⁺.

Example 829

2-METHYL-*N*-(3-{1-[(1-METHYL-1*H*-INDOL-2-YL)METHYL]-4-

25 **PIPERIDINYL}PHENYL)PROPANAMIDE:** Prepared by Procedure F and Scheme R, without HOAc, using 1-methyl-1*H*-indole-2-carbaldehyde and 2-methyl-*N*-[3-(4-piperidinyl)phenyl]propanamide: ESMS *m/e*: 390.3 (*M* + *H*)⁺.

Example 830

30 ***N*-(3-[1-(1*H*-INDOL-4-YLMETHYL)-4-PIPERIDINYL]PHENYL)-2-**

METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R, without HOAc, using 1*H*-indole-4-carbaldehyde and 2-

methyl-*N*-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e : 376.2 ($M + H$)⁺.

Example 831

5 *N*-[4-{1-[6-(1*H*-INDOL-1-YL)HEXYL]-4-PIPERIDINYL}PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure AH and Scheme P using 1-(6-chlorohexyl)-1*H*-indole and 2-methyl-*N*-[4-(4-piperidinyl)phenyl]propanamide: ESMS m/e : 446.3 ($M + H$)⁺.

10

Example 832

N-{3-[1-(1*H*-INDOL-7-YLMETHYL)-4-PIPERIDINYL]PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R, without HOAc, using 1*H*-indole-7-carbaldehyde and 2-methyl-*N*-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e : 376.2 ($M + H$)⁺.

15

Example 833

N-[3-(1-{[1-(4-METHOXYPHENYL)-1*H*-INDOL-5-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1-iodo-4-methoxybenzene and *N*-{3-[1-(1*H*-indol-5-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e : 482.0 ($M + H$)⁺.

20

Example 834

METHYL 4-[4-({4-[3-(ISOBUTYRYLAMINO)PHENYL]-1-PIPERIDINYL}METHYL)-1*H*-INDOL-1-YL]BENZOATE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using methyl 4-iodobenzoate and *N*-{3-[1-(1*H*-indol-4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e : 510.3 ($M + H$)⁺.

30

Example 835

2-METHYL-N-[3-(1-{[1-(3-METHYLPHENYL)-1H-INDOL-5-YL]METHYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1-iodo-3-methylbenzene and N-{3-[1-(1H-indol-5-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 466.3 (M + H)⁺.

Example 836

10 N-[3-(1-{[1-(4-FLUOROPHENYL)-1H-INDOL-4-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1-fluoro-4-iodobenzene and N-{3-[1-(1H-indol-4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ¹H
15 NMR (400 MHz, CDCl₃) δ 7.66-6.92 (m, 12H), 6.65 (d, 1H, J = 3.2 Hz), 3.69 (s, 2H), 3.15-3.02 (m, 2H), 2.58-2.40 (m, 2H), 2.20-2.04 (m, 2H), 1.94-1.76 (m, 4H), 1.25 (d, 6H, J = 6.8 Hz); ESMS m/e: 470.6 (M + H)⁺.

Example 837

20 N-(3-{1-[4-(1H-INDOL-1-YL)BUTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure AH and Scheme P using 1-(4-chlorobutyl)-1H-indole and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e: 418.3
25 (M + H)⁺.

Example 838

30 N-[3-(1-{[1-(4-CHLOROPHENYL)-1H-INDOL-5-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1-chloro-4-iodobenzene and N-{3-[1-(1H-indol-5-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 486.2 (M + H)⁺.

Example 839

N-[3-(1-{[1-(3-METHOXYPHENYL)-1*H*-INDOL-5-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by
5 Procedure C and Scheme Q1, with CuBr in place of Cu,
using 1-iodo-3-methoxybenzene and *N*-{3-[1-(1*H*-indol-5-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide:
ESMS *m/e*: 482.2 (*M* + *H*)⁺.

Example 840

10 *N*-(4-{1-[4-(1*H*-INDOL-1-YL)BUTYL]-4-PIPERIDINYL}PHENYL)BUTANAMIDE: Prepared by Procedure AH
and Scheme P using 1-(4-chlorobutyl)-1*H*-indole and *N*-[4-(4-piperidinyl)phenyl]butanamide: ESMS *m/e*: 418.2 (*M* +
15 *H*)⁺.

Example 841

N-[3-(1-{[1-(2-METHOXYPHENYL)-1*H*-INDOL-5-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by
20 Procedure C and Scheme Q1, with CuBr in place of Cu,
using 1-iodo-2-methoxybenzene and *N*-{3-[1-(1*H*-indol-5-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide:
ESMS *m/e*: 482.2 (*M* + *H*)⁺.

Example 842

25 *N*-[3-(1-{[1-(3-CHLOROPHENYL)-1*H*-INDOL-5-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by
Procedure C and Scheme Q1, with CuBr in place of Cu,
using 1-chloro-3-iodobenzene and *N*-{3-[1-(1*H*-indol-5-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide:
30 ESMS *m/e*: 486.2 (*M* + *H*)⁺.

Example 843

METHYL 2-[5-({4-[3-(ISOBUTYRYLAMINO)PHENYL]-1-PIPERIDINYL}METHYL)-1H-INDOL-1-YL]BENZOATE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using methyl 2-iodobenzoate and N-{3-[1-(1H-indol-5-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 510.2 (M + H)⁺.

Example 844

N-(3-{1-[3-(1H-INDOL-1-YL)PROPYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure AH and Scheme P using 1-(3-chloropropyl)-1H-indole and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e: 404.2 (M + H)⁺.

Example 845

2-METHYL-N-{3-[1-({1-[4-(TRIFLUOROMETHYL)PHENYL]-1H-INDOL-5-YL}METHYL)-4-PIPERIDINYL]PHENYL}PROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1-iodo-4-(trifluoromethyl)benzene and N-{3-[1-(1H-indol-5-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 520.2 (M + H)⁺.

Example 846

N-(3-{1-[(1-[1,1'-BIPHENYL]-2-YL-1H-INDOL-5-YL)METHYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 2-iodo-1,1'-biphenyl and N-{3-[1-(1H-indol-5-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 528.3 (M + H)⁺.

Example 847

2-METHYL-N-[3-(1-{[1-(2-METHYLPHENYL)-1H-INDOL-5-YL]METHYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1-iodo-2-methylbenzene and N-{3-[1-(1H-indol-5-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 466.2 (M + H)⁺.

Example 848

10 2-METHYL-N-[3-(1-{[1-(4-METHYLPHENYL)-1H-INDOL-5-YL]METHYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1-iodo-4-methylbenzene and N-{3-[1-(1H-indol-5-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 466.3 (M + H)⁺.

Example 849

N-[3-(1-{[1-(2-CHLOROPHENYL)-1H-INDOL-5-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1-chloro-2-iodobenzene and N-{3-[1-(1H-indol-5-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 486.2 (M + H)⁺.

Example 850

25 2-METHYL-N-{3-[1-({1-[3-(TRIFLUOROMETHYL)PHENYL]-1H-INDOL-5-YL]METHYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1-iodo-3-(trifluoromethyl)benzene and N-{3-[1-(1H-indol-5-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ¹H NMR (400 MHz, CDCl₃) δ 7.80-6.94 (m, 12H), 6.69 (d, 1H, J = 3.6 Hz), 3.36 (s, 2H), 3.10-3.00 (m, 2H), 2.58-2.42 (m, 2H), 2.16-2.02 (m, 2H),

1.85-1.75 (m, 4H), 1.25⁴⁶³ (d, 6H, J = 7.2 Hz); ESMS
m/e: 520.2 (M + H)⁺.

Example 851

5 2-METHYL-N-[3-(1-{[1-(2-NITROPHENYL)-1H-INDOL-5-
YL]METHYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE: Prepared
by Procedure C and Scheme Q1, with CuBr in place of Cu,
using 1-iodo-2-nitrobenzene and N-{3-[1-(1H-indol-5-
ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide:
10 ESMS m/e: 497.2 (M + H)⁺.

Example 852

N-[3-(1-{[1-(2-FLUOROPHENYL)-1H-INDOL-5-YL]METHYL}-4-
PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by
15 Procedure C and Scheme Q1, with CuBr in place of Cu,
using 1-fluoro-2-iodobenzene and N-{3-[1-(1H-indol-5-
ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide:
ESMS m/e: 470.2 (M + H)⁺.

Example 853

20 2-METHYL-N-[3-(1-{[1-(1-NAPHTHYL)-1H-INDOL-5-YL]METHYL}-
4-PIPERIDINYL)PHENYL]PROPANAMIDE: Prepared by Procedure
C and Scheme Q1, with CuBr in place of Cu, using 1-
iodonaphthalene and N-{3-[1-(1H-indol-5-ylmethyl)-4-
25 piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 502.2
(M + H)⁺.

Example 854

N-[3-(1-{[1-(2,3-DICHLOROPHENYL)-1H-INDOL-5-YL]METHYL}-
30 4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by
Procedure C and Scheme Q1, with CuBr in place of Cu,
using 1,2-dichloro-3-iodobenzene and N-{3-[1-(1H-indol-
5-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ¹H

464

NMR (400 MHz, CDCl₃) δ 7.68-6.94 (m, 12H), 6.68 (d, 1H, J = 2.8 Hz), 3.69 (s, 2H), 3.15-3.02 (m, 2H), 2.54-2.42 (m, 2H), 2.18-2.02 (m, 2H), 1.88-1.76 (m, 4H), 1.25 (d, 6H, J = 6.8 Hz); ESMS m/e: 520.1 (M + H)⁺.

5

Example 855

N-[3-(1-{[1-(2,3-DICHLOROPHENYL)-1H-INDOL-7-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1,2-dichloro-3-iodobenzene and N-{3-[1-(1H-indol-7-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 520.2 (M + H)⁺.

10

Example 856

N-[3-(1-{[1-(3-METHOXYPHENYL)-1H-INDOL-4-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1-iodo-3-methoxybenzene and N-{3-[1-(1H-indol-4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 482.3 (M + H)⁺.

15

20

Example 857

N-[3-(1-{[1-(2,3-DICHLOROPHENYL)-1H-INDOL-4-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1,2-dichloro-3-iodobenzene and N-{3-[1-(1H-indol-4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 520.2 (M + H)⁺.

25

30

Example 858

N-[3-(1-{[1-(3-CHLOROPHENYL)-1H-INDOL-4-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu,

using ⁴⁶⁵ 1-chloro-3-iodobenzene and N-{3-[1-(1H-indol-4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 486.2 (M + H)⁺.

5 **Example 859**

2-METHYL-N-[3-(1-{[1-(3-METHYLPHENYL)-1H-INDOL-4-YL]METHYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1-iodo-3-methylbenzene and N-{3-[1-(1H-indol-4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide:
10 ESMS m/e: 466.3 (M + H)⁺.

Example 860

N-[3-(1-{[1-(3-METHOXYPHENYL)-1H-INDOL-7-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by
15 Procedure C and Scheme Q1, with CuBr in place of Cu, using 1-iodo-3-methoxybenzene and N-{3-[1-(1H-indol-7-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide:
ESMS m/e: 482.3 (M + H)⁺.

20

Example 861

2-METHYL-N-{3-[1-({1-[3-(TRIFLUOROMETHYL)PHENYL]-1H-INDOL-4-YL}METHYL)-4-PIPERIDINYL]PHENYL}PROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in
25 place of Cu, using 1-iodo-3-(trifluoromethyl)benzene and N-{3-[1-(1H-indol-4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 520.2 (M + H)⁺.

Example 862

30 N-[3-(1-{[1-(3,4-DIMETHYLPHENYL)-1H-INDOL-4-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using
N-{3-[1-(1H-indol-4-ylmethyl)-4-

466

piperidinyl]phenyl}-2-⁴⁶⁶ methylpropanamide and 4-iodo-1,2-dimethylbenzene: ESMS m/e : 480.0 (M + H)⁺.

Example 863

5 N-[3-(1-{[1-(3,4-DIFLUOROPHENYL)-1H-INDOL-4-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1,3-dichloro-5-iodobenzene and N-{3-[1-(1H-indol-4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide:
10 ESMS m/e : 520.0 (M + H)⁺.

Example 864

N-[3-(1-{[1-(3,4-DICHLOROPHENYL)-1H-INDOL-4-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by
15 Procedure C and Scheme Q1, with CuBr in place of Cu, using 1,2-dichloro-4-iodobenzene and N-{3-[1-(1H-indol-4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide:
ESMS m/e : 520.0 (M + H)⁺.

Example 865

20 N-[3-(1-{[1-(2-CHLORO-4-FLUOROPHENYL)-1H-INDOL-4-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 2-chloro-4-fluoro-1-iodobenzene and
25 N-{3-[1-(1H-indol-4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e : 504.0 (M + H)⁺.

Example 866

30 N-[3-(1-{[1-(2,4-DIFLUOROPHENYL)-1H-INDOL-4-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 2,4-difluoro-1-iodobenzene and N-{3-[1-(1H-indol-

467

4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e : 488.0 (M + H)⁺.

Example 867

5 2-METHYL-N-[3-(1-{[1-(3-PYRIDINYL)-1H-INDOL-7-YL]METHYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 3-iodopyridine and N-{3-[1-(1H-indol-7-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e :
10 453.1 (M + H)⁺.

Example 868

N-{3-[1-(1H-INDOL-6-YLMETHYL)-4-PIPERIDINYL]PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R
15 using 1H-indole-6-carbaldehyde and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e : 376.2 (M + H)⁺.

Example 869

20 2-METHYL-N-[3-(1-{[1-(4-PYRIDINYL)-1H-INDOL-4-YL]METHYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 4-iodopyridine and N-{3-[1-(1H-indol-4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e :
25 453.2 (M + H)⁺.

Example 870

30 2-METHYL-N-[3-(1-{[1-(2-PYRIDINYL)-1H-INDOL-4-YL]METHYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 2-iodopyridine and N-{3-[1-(1H-indol-4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e :
453.2 (M + H)⁺.

Example 871

***N*-[3-(1-{[1-(2-FLUOROPHENYL)-1*H*-INDOL-4-YL]METHYL}-4-**

PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by

Procedure C and Scheme Q1, with CuBr in place of Cu,

5 using 1-fluoro-2-iodobenzene and *N*-{3-[1-(1*H*-indol-4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide:

ESMS *m/e*: 470.1 (*M* + *H*)⁺.

Example 872

10 ***N*-[3-(1-{[1-(4-CHLOROPHENYL)-1*H*-INDOL-4-YL]METHYL}-4-**

PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by

Procedure C and Scheme Q1, with CuBr in place of Cu,

using 1-chloro-4-iodobenzene and *N*-{3-[1-(1*H*-indol-4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide:

15 ESMS *m/e*: 486.1 (*M* + *H*)⁺.

Example 873

2-METHYL-*N*-[3-(1-{[1-(3-PYRIDINYL)-1*H*-INDOL-4-

YL]METHYL}-4-PIPERIDINYL)PHENYL]PROPANAMIDE: Prepared

20 by Procedure C and Scheme Q1, with CuBr in place of Cu,

using 3-iodopyridine and *N*-{3-[1-(1*H*-indol-4-ylmethyl)-

4-piperidinyl]phenyl}-2-methylpropanamide: ESMS *m/e*:

453.2 (*M* + *H*)⁺.

25 **Example 874**

***N*-[3-(1-{[1-(2,3-DIMETHYLPHENYL)-1*H*-INDOL-4-YL]METHYL}-**

4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by

Procedure C and Scheme Q1, with CuBr in place of Cu,

using 1-iodo-2,3-dimethylbenzene and *N*-{3-[1-(1*H*-indol-

30 4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide:

ESMS *m/e*: 480.1 (*M* + *H*)⁺.

Example 875

N-[3-(1-{[1-(3-FLUOROPHENYL)-1H-INDOL-4-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1-fluoro-3-iodobenzene and N-{3-[1-(1H-indol-4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 470.1 (M + H)⁺.

Example 876

2-METHYL-N-{3-[1-({1-[2-(TRIFLUOROMETHYL)PHENYL]-1H-INDOL-4-YL}METHYL)-4-PIPERIDINYL]PHENYL}PROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1-iodo-2-(trifluoromethyl)benzene and N-{3-[1-(1H-indol-4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 520.1 (M + H)⁺.

Example 877

N-[3-(1-{[1-(2-CHLOROPHENYL)-1H-INDOL-4-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1-chloro-2-iodobenzene and N-{3-[1-(1H-indol-4-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 486.1 (M + H)⁺.

Example 878

N-[3-(1-{[1-(2,3-DIMETHYLPHENYL)-1H-INDOL-7-YL]METHYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Q1, with CuBr in place of Cu, using 1-iodo-2,3-dimethylbenzene and N-{3-[1-(1H-indol-7-ylmethyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e: 480.0 (M + H)⁺.

470

2-METHYL-N-[3-(1-{5-**OXO**-5-
(TRIFLUOROMETHYL) PHENYL] PENTYL}-4-

PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure K
and Scheme E using 5-chloro-1-[4-
5 (trifluoromethyl)phenyl]-1-pentanone and 2-methyl-N-[3-
(4-piperidinyl)phenyl]propanamide: ESMS m/e : 475.1 ($M + H$)⁺.

N-(3-{1-[5-(4-**FLUOROPHENYL**)-5-**OXOPENTYL**]-4-

10 PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure K and Scheme E using 5-chloro-1-(4-
fluorophenyl)-1-pentanone and 2-methyl-N-[3-(4-
piperidinyl)phenyl]propanamide: ESMS m/e : 425.2 ($M + H$)⁺.

15 N-(3-{1-[5-(3-**FLUOROPHENYL**)-5-**OXOPENTYL**]-4-

PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure K and Scheme E using 5-chloro-1-(3-
fluorophenyl)-1-pentanone and 2-methyl-N-[3-(4-
piperidinyl)phenyl]propanamide: ESMS m/e : 425.2 ($M + H$)⁺.

20 N-(3-{1-[5-(3-**CHLOROPHENYL**)-5-**OXOPENTYL**]-4-

PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure K and Scheme E using 5-chloro-1-(3-
chlorophenyl)-1-pentanone and 2-methyl-N-[3-(4-
25 piperidinyl)phenyl]propanamide: ESMS m/e : 441.1 ($M + H$)⁺.

N-(3-{1-[5-(4-**CHLOROPHENYL**)-5-**OXOPENTYL**]-4-

PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure K and Scheme E using 5-chloro-1-(4-
30 chlorophenyl)-1-pentanone and 2-methyl-N-[3-(4-
piperidinyl)phenyl]propanamide: ESMS m/e : 441.1 ($M + H$)⁺.

Example 879**2-METHYL-N-{3-[1-(3-OXO-3-PHENYLPROPYL)-4-**

5 **PIPERIDINYL}PHENYL}PROPANAMIDE:** Prepared by Procedure K and Scheme E using K_2CO_3 instead of Na_2CO_3 and NaI instead of KI and 3-chloro-1-phenyl-1-propanone and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e : 379.3 ($M + H$)⁺.

Example 880

10 **N-(3-{1-[7-(2-FLUOROPHENYL)-7-OXOHEPTYL]-4-**

PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme E using K_2CO_3 instead of Na_2CO_3 and NaI instead of KI and 7-chloro-1-(2-fluorophenyl)-1-heptanone and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: 1H NMR (400 MHz, $CDCl_3$), δ 8.17 (s, br, 1H), 8.06-6.88 (m, 8H), 3.08-2.94 (m, 4H), 2.62-2.48 (m, 1H), 2.48-2.38 (m, 1H), 2.38-2.15 (m, 2H), 2.02-1.92 (m, 2H), 1.84-1.77 (m, 4H), 1.77-1.66 (m, 2H), 1.62-1.46 (m, 2H), 1.46-1.29 (m, 4H), 1.21 (d, 6H, 20 $J = 6.8$ Hz); ESMS m/e : 453.2 ($M + H$)⁺.

Example 881**N-(3-{1-[5-(2-FLUOROPHENYL)-5-OXOPENTYL]-4-**

25 **PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:** Prepared by Procedure K and Scheme E using K_2CO_3 instead of Na_2CO_3 and NaI instead of KI and 5-chloro-1-(2-fluorophenyl)-1-pentanone and 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide: ESMS m/e : 425.2 ($M + H$)⁺.

30 **Example 882**

N-(3-{1-[6-(3-FLUOROPHENYL)-6-OXOHXYL]-4-

PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme E using K_2CO_3 instead of Na_2CO_3 and

472

NaI instead of KI and 6-chloro-1-(3-fluorophenyl)-
1-hexanone and 2-methyl-N-[3-(4-
piperidinyl)phenyl]propanamide: ESMS m/e : 439.2 (M + H)⁺.

5 **Example 883**

N-(3-{1-[6-(2-FLUOROPHENYL)-6-OXOHXYL]-4-

PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure K and Scheme E using K₂CO₃ instead of Na₂CO₃ and
NaI instead of KI and 6-chloro-1-(2-fluorophenyl)-1-
10 hexanone and 2-methyl-N-[3-(4-
piperidinyl)phenyl]propanamide: ESMS m/e : 439.2 (M + H)⁺.

Example 884

N-(3-{1-[7-(4-FLUOROPHENYL)-7-OXOHEPTYL]-4-

15 PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure K and Scheme E using K₂CO₃ instead of Na₂CO₃ and
NaI instead of KI and 7-chloro-1-(4-fluorophenyl)-1-
heptanone and 2-methyl-N-[3-(4-
piperidinyl)phenyl]propanamide: ESMS m/e : 453.2 (M + H)⁺.

20

Example 885

N-(3-{1-[6-(4-CHLOROPHENYL)-6-OXOHXYL]-4-

PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure K and Scheme E using K₂CO₃ instead of Na₂CO₃ and
25 NaI instead of KI and 6-chloro-1-(4-chlorophenyl)-1-
hexanone and 2-methyl-N-[3-(4-
piperidinyl)phenyl]propanamide: ESMS m/e : 455.1 (M + H)⁺.

Example 886

30 *N*-(3-{1-[7-(4-CHLOROPHENYL)-7-OXOHEPTYL]-4-

PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure K and Scheme E using K₂CO₃ instead of Na₂CO₃ and
NaI instead of KI and 7-chloro-1-(4-chlorophenyl)-1-

473

heptanone and 2-methyl-*N*- [3-(4-piperidinyl)phenyl]propanamide: ESMS *m/e*: 469.1 (*M* + *H*)⁺.

Example 887

5 *N*-(3-{1-[6-(4-FLUOROPHENYL)-6-OXOHEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme E using K₂CO₃ instead of Na₂CO₃ and NaI instead of KI and 6-chloro-1-(4-fluorophenyl)-1-hexanone and 2-methyl-*N*-(3-(4-piperidinyl)phenyl)propanamide: ESMS *m/e*: 439.1 (*M* + *H*)⁺.

10

Example 888

N-(3-{1-[6-(3-ACETYLPHENOXY)-6-(2-FLUOROPHENYL)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 1-(3-hydroxyphenyl)ethanone and *N*-(3-{1-[6-(2-fluorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS *m/e*: 559.5 (*M* + *H*)⁺.

15

20 **Example 889**

N-(3-{1-[6-(2-FLUOROPHENOXY)-6-(2-FLUOROPHENYL)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-fluorophenol and *N*-(3-{1-[6-(2-fluorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS *m/e*: 535.1 (*M* + *H*)⁺.

25

Example 890

N-(3-{1-[6-(4-FLUOROPHENOXY)-6-(2-FLUOROPHENYL)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-fluorophenol and *N*-(3-{1-[6-(2-fluorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ¹H NMR (400 MHz,

30

474

CDCl₃), HCl salt δ 7.72- 6.72 (m, 12H), 5.42-5.34 (m, 1H), 3.68-3.58 (m, br, 2H), 3.02-2.92 (m, 2H), 2.80-2.46 (m, 6H), 2.05-1.78 (m, 6H), 1.68-1.56 (m, 1H), 1.56-1.38 (m, 3H), 1.25 (d, 6H, J = 6.8 Hz); ESMS m/e: 535.1 (M + H)⁺.

Example 891

N-(3-{1-[6-(2-FLUOROPHENYL)-6-(2-METHOXYPHENOXY)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-methoxyphenol and N-(3-{1-[6-(2-fluorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e: 547.0 (M + H)⁺.

Example 892

N-(3-{1-[6-(2-FLUOROPHENYL)-6-(4-METHOXYPHENOXY)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-methoxyphenol and N-(3-{1-[6-(2-fluorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e: 547.1 (M + H)⁺.

Example 893

N-(3-{1-[6-(4-ACETYLPHENOXY)-6-(2-FLUOROPHENYL)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 1-(4-hydroxyphenyl)ethanone and N-(3-{1-[6-(2-fluorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e: 559.2 (M + H)⁺.

Example 894

N-(3-{1-[6-(3,4-DIMETHOXYPHENOXY)-6-(2-FLUOROPHENYL)HEXYL]-4-PIPERIDINYL}PHENYL)-2-

475

METHYLPROPANAMIDE:

Prepared by Procedure A and Scheme AN using 3,4-dimethoxyphenol and *N*-(3-{1-[6-(2-fluorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS *m/e*: 577.6 (M + H)⁺.

5

Example 895

N-(3-{1-[6-(2-ETHOXYPHENOXY)-6-(2-FLUOROPHENYL)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-ethoxyphenol and *N*-(3-{1-[6-(2-fluorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS *m/e*: 561.1 (M + H)⁺.

10

Example 896

N-(3-{1-[6-(4-BROMOPHENOXY)-6-PHENYLHEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-bromophenol and *N*-(3-{1-[6-(4-bromophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS *m/e*: 577.0 (M + H)⁺.

15

20

Example 897

N-(3-{1-[6-(4-FLUOROPHENOXY)-6-(4-FLUOROPHENYL)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-fluorophenol and *N*-(3-{1-[6-(4-fluorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ¹H NMR (400 MHz, CDCl₃), HCl salt δ 8.22 (s, br, 1H), 7.74-6.70 (m, 12H), 5.05-4.94 (m, 1H), 3.66-3.52 (m, br, 2H), 3.02-2.83 (m, br, 2H), 2.81-2.58 (m, br, 4H), 2.58-2.36 (m, br, 2H), 2.02-1.66 (m, br, 6H), 1.66-1.46 (m, br, 1H), 1.46-1.35 (m, br, 3H), 1.26 (d, 6H, J = 6.0 Hz); ESMS *m/e*: 535.1 (M + H)⁺.

25

30

Example 898

N-(3-{1-[6-(4-METHOXYPHENOXY)-6-PHENYLHEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-methoxyphenol and *N*-(3-{1-[6-(4-chlorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS *m/e*: 529.6 (M + H)⁺.

Example 899

N-(3-{1-[6-(4-CHLOROPHENOXY)-6-(4-CHLOROPHENYL)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-chlorophenol and *N*-(3-{1-[6-(4-chlorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS *m/e*: 566.9 (M + H)⁺.

Example 900

N-(3-{1-[6-(4-BROMOPHENOXY)-6-(4-FLUOROPHENYL)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-bromophenol and *N*-(3-{1-[6-(4-fluorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS *m/e*: 595.0 (M + H)⁺.

Example 901

N-(3-{1-[6-(4-CHLOROPHENOXY)-6-(4-FLUOROPHENYL)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-chlorophenol and *N*-(3-{1-[6-(4-fluorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ¹H NMR (400 MHz, CDCl₃), HCl salt δ 7.93 (s, 1H), 7.72-6.68 (m, 12H), 5.06-4.98 (m, 1H), 3.66-3.50 (m, br, 2H), 3.02-2.82 (m, br, 2H), 2.80-2.57 (m, br, 4H), 2.57-2.38 (m, br, 2H), 2.02-1.76 (m, br, 6H), 1.64-1.48 (m, br, 1H), 1.48-1.36

477

(m, br, 3H), 1.25 (d, 6H, $J = 6.8$ Hz); Anal. Calc. for $C_{33}H_{41}Cl_2FN_2O_2 \cdot 0.5EtOAc$: C, 66.55; H, 7.18; N, 4.43; Found: C, 66.35; H, 6.86; N, 4.46. ESMS m/e : 550.8 ($M + H$)⁺.

5

Example 902

***N*-(3-{1-[6-(4-CHLOROPHENYL)-6-(4-FLUOROPHENOXY)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:** Prepared by Procedure A and Scheme AN using 4-fluorophenol and *N*-(3-{1-[6-(4-chlorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ¹H NMR (400 MHz, CDCl₃), HCl salt δ 8.22 (s, br, 1H), 7.74-6.68 (m, 12H), 5.04-4.92 (m, 1H), 3.66-3.50 (m, br, 2H), 3.00-2.82 (br, 2H), 2.80-2.58 (m, br, 4H), 2.58-2.40 (m, br, 2H), 2.00-1.68 (m, br, 6H), 1.66-1.46 (m, br, 1H), 1.46-1.36 (br, 3H), 1.25 (d, 6H, $J = 7.2$ Hz); ESMS m/e : 551.1 ($M + H$)⁺.

10

15

Example 903

***N*-(3-{1-[6-(3-ACETYLPHENOXY)-6-PHENYLHEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:** Prepared by Procedure A and Scheme AN using 1-(3-hydroxyphenyl)ethanone and *N*-(3-{1-[6-hydroxy-6-phenylhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e : 541.2 ($M + H$)⁺.

20

25

Example 904

***N*-(3-{1-[6-(4-CHLOROPHENOXY)-6-PHENYLHEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:** Prepared by Procedure A and Scheme AN using 4-chlorophenol and *N*-(3-{1-[6-hydroxy-6-phenylhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ¹H NMR (400 MHz, CDCl₃), HCl salt δ 8.28 (s, 1H), 7.78-6.70 (m, 13H), 5.08-4.98 (m, 1H), 3.64-3.46 (m, br, 2H), 3.02-2.82 (br, 2H), 2.82-2.56 (m,

30

478

br, 4H), 2.56-2.34 (m, br, 2H), 2.05-1.75 (m, br, 6H), 1.64-1.48 (m, br, 1H), 1.48-1.34 (br, 3H), 1.25 (d, 6H, J = 6.8 Hz); ESMS m/e: 533.1 (M + H)⁺.

5 **Example 905**

N-(3-{1-[6-(4-BROMOPHENOXY)-6-(4-CHLOROPHENYL)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-bromophenol and *N*-(3-{1-[6-(4-chlorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e: 611.0 (M + H)⁺.

10

Example 906

N-(3-{1-[6-(4-CHLOROPHENYL)-6-(4-METHOXYPHENOXY)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-methoxyphenol and *N*-(3-{1-[6-(4-chlorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e: 563.1 (M + H)⁺.

15

20

Example 907

N-(3-{1-[6-(4-FLUOROPHENYL)-6-(4-METHOXYPHENOXY)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-methoxyphenol and *N*-(3-{1-[6-(4-fluorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ¹H NMR (400 MHz, CDCl₃), HCl salt δ 8.11 (s, 1H), 7.65-6.84 (m, 12H), 5.21-5.10 (m, 1H), 3.66-3.56 (m, br, 2H), 3.02-2.82 (br, 2H), 2.82-2.56 (m, br, 4H), 2.54 (s, 3H), 2.53-2.32 (m, br, 2H), 2.02-1.70 (m, br, 6H), 1.64-1.48 (m, br, 1H), 1.48-1.34 (br, 3H), 1.25 (d, 6H, J = 6.8 Hz); ESMS m/e: 547.1 (M + H)⁺.

25

30

Example 908

***N*-(3-{1-[6-(3-ACETYLPHENOXY)-6-(4-FLUOROPHENYL)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:** Prepared by Procedure A and Scheme AN using 1-(3-hydroxyphenyl)ethanone and *N*-(3-{1-[6-(4-fluorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS *m/e*: 559.1 (*M* + *H*)⁺.

Example 909

***N*-(3-{1-[6-(4-FLUOROPHENOXY)-6-PHENYLHEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:** Prepared by Procedure A and Scheme AN using 4-fluorophenol and *N*-(3-{1-[6-hydroxy-6-phenylhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ¹H NMR (400 MHz, CDCl₃), HCl salt δ 8.05 (s, br, 1H), 7.72-6.70 (m, 13H), 5.06-4.96 (m, 1H), 3.66-3.51 (m, 2H), 3.01-2.82 (m, br, 2H), 2.82-2.57 (m, br, 4H), 2.57-2.34 (m, br, 2H), 2.05-1.78 (m, br, 6H), 1.64-1.52 (m, br, 1H), 1.52-1.16 (m, br, 3H), 1.25 (d, 6H, *J* = 7.2 Hz); ESMS *m/e*: 517.0 (*M* + *H*)⁺.

Example 910

***N*-(3-{1-[6-(2-ACETYLPHENOXY)-6-(2-FLUOROPHENYL)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:** Prepared by Procedure A and Scheme AN using 1-(2-hydroxyphenyl)ethanone and *N*-(3-{1-[6-(2-fluorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS *m/e*: 559.0 (*M* + *H*)⁺.

Example 911

***N*-(3-{1-[6-(4-FLUOROPHENYL)-6-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENOXY]HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:** Prepared by Procedure A and Scheme AN using 2-fluoro-5-(trifluoromethyl)phenol and *N*-(3-{1-

480

[6-(4-fluorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ^1H NMR (400 MHz, CDCl_3), HCl salt δ 8.23 (s, br, 1H), 7.74-6.88 (m, 11H), 5.20-5.12 (m, 1H), 3.68-3.52 (m, br, 2H), 3.02-2.82 (m, br, 2H), 2.82-2.60 (m, 4H), 2.58-2.38 (m, br, 2H), 2.12-2.02 (m, br, 1H), 2.02-1.80 (m, br, 5H), 1.68-1.52 (m, br, 1H), 1.52-1.36 (br, 3H), 1.25 (d, 6H, $J = 7.2$ Hz); ESMS m/e : 603.3 ($M + H$) $^+$.

10 Example 912

***N*-(3-{1-[6-(3-ACETYLPHENOXY)-6-(4-CHLOROPHENYL)HEXYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:** Prepared by Procedure A and Scheme AN using 1-(3-hydroxyphenyl)ethanone and *N*-(3-{1-[6-(4-chlorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ^1H NMR (400 MHz, CDCl_3), HCl salt δ 8.41 (s, 1H), 7.72-6.84 (m, 12H), 5.18-5.10 (m, 1H), 3.62-3.50 (m, br, 2H), 3.00-2.92 (m, 2H), 2.90-2.58 (m, 4H), 2.54 (s, 3H), 2.50-2.12 (m, 2H), 2.02-1.70 (m, br, 6H), 1.64-1.50 (m, br, 1H), 1.50-1.14 (m, br, 3H), 1.25 (d, 6H, $J = 6.8$ Hz); ESMS m/e : 575.3 ($M + H$) $^+$.

Example 913

***N*-[3-(1-{6-(2-FLUOROPHENYL)-6-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENOXY]HEXYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE:** Prepared by Procedure A and Scheme AN using 2-fluoro-5-(trifluoromethyl)phenol and *N*-(3-{1-[6-(2-fluorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ^1H NMR (400 MHz, CDCl_3), HCl salt δ 8.35 (s, 1H), 7.68-6.82 (m, 11H), 5.58-5.48 (m, 1H), 3.64-3.50 (m, 2H), 3.01-2.94 (m, br, 2H), 2.92-2.54 (m, 4H), 2.48-2.32 (m, br, 2H), 2.20-2.04 (m, 1H), 2.01-1.80 (m, 5H), 1.70-1.54 (m, 1H), 1.54-1.36

481

(m, 3H), 1.25 (d, 6H, J = 7.2 Hz). Anal. Calc. for $C_{34}H_{40}ClF_5N_2O_2 \cdot 0.6MeOH$: C, 63.12; H, 6.49; N, 4.25; Found: C, 63.38; H, 6.61; N, 3.95. ESMS m/e : 603.3 (M + H)⁺.

5 **Example 914**

N-[3-(1-{6-(4-CHLOROPHENYL)-6-[2-FLUORO-5-(TRIFLUOROMETHYL) PHENOXY] HEXYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-fluoro-5-(trifluoromethyl)phenol and *N*-(3-{1-[6-(4-chlorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e : 619.2 (M + H)⁺.

10

Example 915

15 *N*-[3-(1-{6-(3-FLUOROPHENYL)-6-[2-FLUORO-5-(TRIFLUOROMETHYL) PHENOXY] HEXYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-fluoro-5-(trifluoromethyl)phenol and *N*-(3-{1-[6-(3-fluorophenyl)-6-hydroxyhexyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e : 603.3 (M + H)⁺.

20

Example 916

N-[3-(1-{6-[2-FLUORO-5-(TRIFLUOROMETHYL) PHENOXY]-6-PHENYLHEXYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-fluoro-5-(trifluoromethyl)phenol and *N*-(3-{1-[6-(6-hydroxy-6-phenylhexyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e : 585.3 (M + H)⁺.

25

30 **Example 917**

N-[3-(1-{7-(2-FLUOROPHENYL)-7-[2-FLUORO-5-(TRIFLUOROMETHYL) PHENOXY] HEPTYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme

AN using 2-fluoro-5-⁴⁸² (trifluoromethyl)phenol
and *N*-(3-{1-[7-(2-fluorophenyl)-7-hydroxyheptyl]-4-
piperidinyl}phenyl)-2-methylpropanamide: ESMS *m/e*: 617.3
(*M* + *H*)⁺.

5

Example 918

N-(3-{1-[5-(4-FLUOROPHENYL)-5-(4-METHOXYPHENOXY)PENTYL]-4-
4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure A and Scheme AN using 4-methoxyphenol and *N*-(3-
10 {1-[5-(4-fluorophenyl)-5-hydroxypentyl]-4-
piperidinyl}phenyl)-2-methylpropanamide: ESMS *m/e*: 533.1
(*M* + *H*)⁺.

Example 919

N-(3-{1-[5-(4-BROMOPHENOXY)-5-(4-FLUOROPHENYL)PENTYL]-4-
15 PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure A and Scheme AN using 4-bromophenol and *N*-(3-
{1-[5-(4-fluorophenyl)-5-hydroxypentyl]-4-
piperidinyl}phenyl)-2-methylpropanamide: ¹H NMR (400 MHz,
CDCl₃), HCl salt δ 7.94 (s, br, 1H), 7.68-6.64 (m, 12H),
20 5.12-5.04 (m, 1H), 3.68-3.52 (m, br, 2H), 3.01-2.82 (br,
2H), 2.78-2.58 (m, br, 4H), 2.57-2.38 (m, br, 2H), 2.05-
1.80 (m, br, 6H), 1.64-1.38 (m, br, 2H), 1.25 (d, 6H, *J*
= 7.2 Hz); ESMS *m/e*: 581.0 (*M* + *H*)⁺.

25

Example 920

N-(3-{1-[5-(4-CHLOROPHENOXY)-5-(4-CHLOROPHENYL)PENTYL]-4-
4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure A and Scheme AN using 4-chlorophenol and *N*-(3-
{1-[5-(4-chlorophenyl)-5-hydroxypentyl]-4-
30 piperidinyl}phenyl)-2-methylpropanamide: ¹H NMR (400 MHz,
CDCl₃), HCl salt δ 7.86 (s, br, 1H), 7.62-6.72 (m, 12H),
5.12-5.02 (m, 1H), 3.68-3.52 (m, br, 2H), 3.02-2.82 (br,
2H), 2.82-2.56 (m, br, 4H), 2.56-2.40 (m, br, 2H), 2.06-

483

1.80 (m, br, 6H), 1.64-1.40 (m, br, 2H), 1.25 (d, 6H, $J = 6.8$ Hz). Anal. Calc. for $C_{32}H_{39}Cl_3N_2O_2 \cdot 1.3MeOH$: C, 63.25; H, 7.07; N, 4.42; Found: C, 63.41; H, 6.99; N, 4.17. ESMS m/e : 553.0 ($M + H$)⁺.

5

Example 921

***N*-(3-{1-[5-(4-CHLOROPHENOXY)-5-PHENYLPENTYL]-4-**

PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-chlorophenol and *N*-(3-[1-(5-hydroxy-5-phenylpentyl)-4-piperidinyl]phenyl)-2-

10 methylpropanamide: ¹H NMR (400 MHz, CDCl₃), HCl salt δ 7.72-6.72 (m, 13H), 5.12-5.04 (m, 1H), 3.66-3.52 (m, br, 2H), 3.01-2.83 (br, 2H), 2.68-2.62 (m, br, 2H), 2.62-2.48 (m, br, 4H), 2.04-1.82 (m, br, 6H), 1.62-1.40 (m, br, 2H), 1.25 (d, 6H, $J = 7.2$ Hz); ESMS m/e : 519.1 ($M +$
15 H)⁺.

Example 922

***N*-(3-{1-[5-(3-ACETYLPHENOXY)-5-(4-FLUOROPHENYL)PENTYL]-**

4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by

20 Procedure A and Scheme AN using 1-(3-hydroxyphenyl)ethanone and *N*-(3-{1-[5-(4-fluorophenyl)-5-hydroxypentyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e : 545.1 ($M + H$)⁺.

25

Example 923

***N*-(3-{1-[5-(4-CHLOROPHENYL)-5-(4-FLUOROPHENOXY)PENTYL]-**

4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-fluorophenol and *N*-(3-{1-[5-(4-chlorophenyl)-5-hydroxypentyl]-4-

30 piperidinyl}phenyl)-2-methylpropanamide: ¹H NMR (400 MHz, CDCl₃), HCl salt δ 8.05 (s, br, 1H), 7.74-6.68 (m, 12H), 5.08-4.99 (m, 1H), 3.67-3.56 (m, br, 2H), 3.02-2.82 (br, 2H), 2.80-2.57 (m, br, 4H), 2.57-2.38 (m, br, 2H), 2.05-

484

1.80 (m, br, 6H), 1.64- 1.40 (m, br, 2H), 1.25 (d, 6H, $J = 7.2$ Hz). Anal. Calc. for $C_{32}H_{39}Cl_2FN_2O_2 \cdot 1.3EtOAc$: C, 64.93; H, 7.24; N, 4.07. Found: C, 65.01; H, 6.97; N, 3.85. ESMS m/e : 537.1 ($M + H$)⁺.

5

Example 924

***N*-(3-{1-[5-(4-BROMOPHENOXY)-5-PHENYLPENTYL]-4-**

PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-bromophenol and *N*-(3-
 10 [1-(5-hydroxy-5-phenylpentyl)-4-piperidinyl]phenyl)-2-methylpropanamide: ¹H NMR (400 MHz, CDCl₃), HCl salt δ 7.74-6.66 (m, 13H), 5.13-5.02 (m, 1H), 3.73-3.51 (m, br, 2H), 3.05-2.83 (br, 2H), 2.83-2.62 (br, 4H), 2.62-2.42 (m, br, 2H), 2.10-1.80 (m, br, 6H), 1.65-1.37 (m, br, 2H),
 15 2H), 1.25 (d, 6H, $J = 6.8$ Hz); ESMS m/e : 562.9 ($M + H$)⁺.

Example 925

***N*-(3-{1-[5-(4-CHLOROPHENYL)-5-(4-METHOXYPHENOXY)PENTYL]-4-**
4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
 20 Procedure A and Scheme AN using 4-methoxyphenol and *N*-(3-{1-[5-(4-chlorophenyl)-5-hydroxypentyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ¹H NMR (400 MHz, CDCl₃), HCl salt δ 8.13 (s, br, 1H), 7.72-6.70 (m, 12H), 5.08-4.97 (m, 1H), 3.72 (s, 3H), 3.66-3.50 (m, br, 2H),
 25 3.03-2.82 (br, 2H), 2.80-2.54 (m, br, 4H), 2.53-2.17 (m, br, 2H), 2.08-1.78 (m, br, 6H), 1.65-1.38 (m, br, 2H), 1.25 (d, 6H, $J = 6.8$ Hz). Anal. Calc. for $C_{33}H_{42}Cl_2N_2O_3 \cdot 0.54CH_2Cl_2$: C, 63.80; H, 6.88; N, 4.44. Found: C, 63.84; H, 7.18; N, 4.00. ESMS m/e : 549.1 ($M + H$)⁺.
 30

Example 926

N-(3-{1-[5-(4-FLUOROPHENOXY)-5-(4-FLUOROPHENYL)PENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-fluorophenol and N-(3-
5 {1-[5-(4-fluorophenyl)-5-hydroxypentyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ^1H NMR (400 MHz, CDCl_3), HCl salt δ 7.62-6.70 (m, 12H), 5.10-5.00 (m, 1H), 3.71-3.56 (m, br, 2H), 3.04-2.82 (br, 2H), 2.78-2.64 (m, br, 3H), 2.64-2.48 (m, br, 3H), 2.05-1.82 (m, br, 6H),
10 1.62-1.42 (m, br, 2H), 1.25 (d, 6H, $J = 6.0$ Hz); ESMS m/e : 521.2 (M + H) $^+$.

Example 927

N-(3-{1-[5-(3-ACETYLPHENOXY)-5-PHENYLPENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
15 Procedure A and Scheme AN using 1-(3-hydroxyphenyl)ethanone and N-{3-[1-(5-hydroxy-5-phenylpentyl)-4-piperidinyl]phenyl}-2-methylpropanamide:
ESMS m/e : 526.9 (M + H) $^+$.

20

Example 928

N-(3-{1-[5-(4-METHOXYPHENOXY)-5-PHENYLPENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by
Procedure A and Scheme AN using 4-methoxyphenol and N-
25 {3-[1-(5-hydroxy-5-phenylpentyl)-4-piperidinyl]phenyl}-2-methylpropanamide: ESMS m/e : 515.6 (M + H) $^+$.

Example 929

N-[3-(1-{5-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENOXY]-5-[4-(TRIFLUOROMETHYL)PHENYL]PENTYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme
30 AN using 2-fluoro-5-(trifluoromethyl)phenol and N-[3-(1-{5-hydroxy-5-[4-(trifluoromethyl)phenyl]pentyl}-4-

486

piperidinyl}phenyl]-2-methylpropanamide: ESMS
m/e: 639.2 (M + H)⁺.

Example 930

5 N-[3-(1-{5-(3-CHLOROPHENYL)-5-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENOXY]PENTYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-fluoro-5-(trifluoromethyl)phenol and N-(3-{1-[5-(3-chlorophenyl)-5-hydroxypentyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ¹H NMR (400 MHz, CDCl₃), HCl salt δ 8.17 (s, br, 1H), 7.75-6.88 (m, 11H), 5.26-5.14 (m, 1H), 3.68-3.56 (m, br, 2H), 3.05-2.90 (br, 2H), 2.90-2.60 (m, br, 4H), 2.56-2.36 (m, br, 2H), 2.18-1.84 (m, br, 6H), 1.70-1.44 (m, br, 2H), 1.25 (d, 6H, J = 7.2 Hz). Anal. Calc. for C₃₃H₃₈Cl₂F₄N₂O₂·0.9EtOAc: C, 60.98; H, 6.32; N, 3.89; Found: C, 60.99; H, 6.17; N, 3.81. ESMS m/e: 605.2 (M + H)⁺.

10

15

Example 931

20 N-[3-(1-{5-(2-FLUOROPHENYL)-5-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENOXY]PENTYL}-4-PIPERIDINYL)PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-fluoro-5-(trifluoromethyl)phenol and N-(3-{1-[5-(2-fluorophenyl)-5-hydroxypentyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ¹H NMR (400 MHz, CDCl₃), HCl salt δ 7.89 (s, br, 1H), 7.72-6.88 (m, 11H), 5.59-5.48 (m, 1H), 3.70-3.48 (br, 2H), 3.05-2.84 (br, 2H), 2.82-2.58 (m, br, 4H), 2.58-2.40 (m, br, 2H), 2.22-1.82 (m, br, 6H), 1.71-1.42 (m, br, 2H), 1.25 (d, 6H, J = 6.4 Hz); ESMS m/e: 589.3 (M + H)⁺.

25

30

Example 932

N-[3-(1-{5-(3-FLUOROPHENYL)-5-[2-FLUORO-5-(TRIFLUOROMETHYL) PHENOXY] PENTYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-fluoro-5-(trifluoromethyl)phenol and N-(3-{1-[5-(3-fluorophenyl)-5-hydroxypentyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ^1H NMR (400 MHz, CDCl_3), HCl salt δ 7.79 (s, br, 1H), 7.63-6.82 (m, 11H), 5.24-5.15 (m, 1H), 3.70-3.56 (br, 2H), 3.04-2.84 (br, 2H), 2.82-2.60 (m, br, 4H), 2.60-2.42 (m, br, 2H), 2.20-1.83 (m, br, 6H), 1.70-1.44 (m, br, 2H), 1.25 (d, 6H, $J = 6.4$ Hz); ESMS m/e : 589.3 ($M + H$) $^+$.

Example 933

N-(3-{1-[5-(3-ACETYLPHENOXY)-5-(4-CHLOROPHENYL) PENTYL]-4-PIPERIDINYL} PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 1-(3-hydroxyphenyl)ethanone and N-(3-{1-[5-(4-chlorophenyl)-5-hydroxypentyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ^1H NMR (400 MHz, CDCl_3), HCl salt δ 8.05 (s, br, 1H), 7.74-6.88 (m, 12H), 5.27-5.16 (m, 1H), 3.69-3.52 (m, br, 2H), 3.10-2.81 (br, 2H), 2.81-2.57 (m, br, 4H), 2.54 (s, 3H), 2.52-2.40 (m, br, 2H), 2.05-1.80 (m, br, 6H), 1.66-1.42 (m, br, 2H), 1.25 (d, 6H, $J = 6.8$ Hz); Anal. Calc. for $\text{C}_{34}\text{H}_{42}\text{Cl}_2\text{N}_2\text{O}_3 \cdot 0.5\text{CH}_2\text{Cl}_2 \cdot 1.0\text{H}_2\text{O}$: C, 63.46; H, 6.91; N, 4.30. Found: C, 63.46; H, 7.09; N, 4.00. ESMS m/e : 561.1 ($M + H$) $^+$.

Example 934

N-[3-(1-{5-(4-CHLOROPHENYL)-5-[2-FLUORO-5-(TRIFLUOROMETHYL) PHENOXY] PENTYL}-4-PIPERIDINYL) PHENYL]-2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-fluoro-5-(trifluoromethyl)phenol and N-(3-{1-

488

[5-(4-chlorophenyl)-5-hydroxypentyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ^1H NMR (400 MHz, CDCl_3), HCl salt δ 7.61-6.92 (m, 11H), 5.24-5.16 (m, 1H), 3.70-3.58 (m, 2H), 3.02-2.91 (br, 2H), 2.80-2.64 (m, br, 3H), 2.64-2.50 (m, 3H), 2.18-1.94 (m, br, 6H), 1.62-1.44 (m, br, 2H), 1.25 (d, 6H, $J = 7.2$ Hz); ESMS m/e : 605.3 ($M + H$) $^+$.

Example 935

10 ***N*-(3-(1-{5-(4-FLUOROPHENYL)-5-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENOXY]PENTYL}-4-PIPERIDINYL)PHENYL)-2-METHYLPROPANAMIDE:** Prepared by Procedure A and Scheme AN using 2-fluoro-5-(trifluoromethyl)phenol *N*-(3-{1-[5-(4-fluorophenyl)-5-hydroxypentyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e : 589.3 ($M + H$) $^+$.

Example 936

20 ***N*-(3-(1-[5-(4-BROMOPHENOXY)-5-(4-CHLOROPHENYL)PENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:** Prepared by Procedure A and Scheme AN using 4-bromophenol and *N*-(3-{1-[5-(4-chlorophenyl)-5-hydroxypentyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e : 597.2 ($M + H$) $^+$.

Example 937

25 ***N*-(3-(1-[5-(4-CHLOROPHENOXY)-5-(4-FLUOROPHENYL)PENTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:** Prepared by Procedure A and Scheme AN using 4-chlorophenol and *N*-(3-{1-[5-(4-fluorophenyl)-5-hydroxypentyl]-4-piperidinyl}phenyl)-2-methylpropanamide: ESMS m/e : 537.3 ($M + H$) $^+$.

Example 938

N-(3-{1-[5-(2-ACETYLPHENOXY)-5-PHENYLPENTYL]-4-

PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by

Procedure A and Scheme AN using 1-(2-

5 hydroxyphenyl)ethanone and *N*-(3-[1-(5-hydroxy-5-phenylpentyl)-4-piperidinyl]phenyl)-2-methylpropanamide:

ESMS *m/e*: 527.0 (*M* + *H*)⁺.

Example 939

10 *N*-(3-{1-[5-(2-ETHOXYPHENOXY)-5-PHENYLPENTYL]-4-

PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by

Procedure A and Scheme AN using 2-ethoxyphenol and *N*-(3-

[1-(5-hydroxy-5-phenylpentyl)-4-piperidinyl]phenyl)-2-

methylpropanamide: ESMS *m/e*: 529.2 (*M* + *H*)⁺.

15

Example 940

N-(3-{1-[5-(4-FLUOROPHENOXY)-5-PHENYLPENTYL]-4-

PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by

Procedure A and Scheme AN using 4-fluorophenol and *N*-(3-

20 [1-(5-hydroxy-5-phenylpentyl)-4-piperidinyl]phenyl)-2-

methylpropanamide: ESMS *m/e*: 503.2 (*M* + *H*)⁺.

Example 941

N-(3-{1-[4-(4-FLUOROPHENYL)-4-OXOBUTYL]-4-

25 PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by

Procedure K (KI) and Scheme E (K₂CO₃) using 2-methyl-*N*-

[3-(4-piperidinyl)phenyl]propanamide and 4-chloro-1-(4-

fluorophenyl)-1-butanone: ESMS *m/e*: 411.2 (*M* + *H*)⁺.

30 **Example 942**

2-METHYL-*N*-(3-{1-[3-(1*H*-PYRROL-3-YL)PROPYL]-4-

PIPERIDINYL}PHENYL)PROPANAMIDE: Prepared by Procedure K

(KI) and Scheme E (K₂CO₃) using 2-methyl-*N*-(3-(4-

piperidinyl)phenyl]propanamide and 3-(3-bromopropyl)-1H-pyrrole: ESMS m/e : 354.2 (M + H)⁺.

Example 943

5 **N-(3-{1-[4-(4-ISOPROPYLPHENYL)-4-OXOBUTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE:** Prepared by Procedure K (KI) and Scheme E (K₂CO₃) using 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide and 4-chloro-1-(4-isopropylphenyl)-1-butanone: ESMS m/e : 435.2 (M + H)⁺.

10

Example 944

N-(3-{1-[4-(4-METHOXYPHENYL)-4-OXOBUTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure K (KI) and Scheme E (K₂CO₃) using 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide and 4-chloro-1-(4-methoxyphenyl)-1-butanone: ESMS m/e : 423.2 (M + H)⁺.

15

Example 945

2-METHYL-N-(3-{1-[4-(4-METHYLPHENYL)-4-OXOBUTYL]-4-PIPERIDINYL}PHENYL)PROPANAMIDE: Prepared by Procedure K (KI) and Scheme E (K₂CO₃) using 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide and 4-chloro-1-(4-methylphenyl)-1-butanone: ESMS m/e : 407.2 (M + H)⁺.

20

25 **Example 946**

N-(3-{1-[4-(4-TERT-BUTYLPHENYL)-4-OXOBUTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure K (KI) and Scheme E (K₂CO₃) using 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide and 1-(4-tert-butylphenyl)-4-chloro-1-butanone: ESMS m/e : 449.2 (M + H)⁺.

30

Example 947

491

N-(3-{1-[4-(4-BROMOPHENYL)-4-OXOBUTYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE: Prepared by Procedure K (KI) and Scheme E (K₂CO₃) using 2-methyl-*N*-[3-(4-piperidinyl)phenyl]propanamide and 1-(4-bromophenyl)-4-chloro-1-butanone: ESMS *m/e*: 471.3 (M + H)⁺.

Example 948

2-METHYL-*N*-(3-{1-[4-OXO-4-(2-THIENYL)BUTYL]-4-PIPERIDINYL}PHENYL)PROPANAMIDE: Prepared by Procedure K (KI) and Scheme E (K₂CO₃) using 2-methyl-*N*-[3-(4-piperidinyl)phenyl]propanamide and 4-chloro-1-(2-thienyl)-1-butanone: ESMS *m/e*: 399.1 (M + H)⁺.

II. Synthetic Methods for General Structures

The examples described in Section I are merely illustrative of the methods used to synthesize MCH1 antagonists. Further derivatives may be obtained
5 utilizing generalized methods based on the synthetic methods used to synthesize the examples.

It may be necessary to incorporate protection and deprotection strategies for substituents such as amino,
10 amido, carboxylic acid, and hydroxyl groups in the generalized synthetic methods to form further derivatives. Methods for protection and deprotection of such groups are well-known in the art, and may be found, for example in Green, T.W. and Wuts, P.G.M. (1991)
15 Protection Groups in Organic Synthesis, 2nd Edition John Wiley & Sons, New York.

III. Oral Compositions

As a specific embodiment of an oral composition of a
20 compound of this invention, 100 mg of one of the compounds described herein is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size O hard gel capsule.

25 IV. Pharmacological Evaluation of Compounds at Cloned rat MCH1 Receptor

The pharmacological properties of the compounds of the present invention were evaluated at the cloned rat MCH1 receptor using protocols described below.

30

Host Cells

493

A broad variety of host cells can be used to study heterologously expressed proteins. These cells include but are not restricted to assorted mammalian lines such as: Cos-7, CHO, LM(tk-), HEK293, Peak rapid 293, etc.;
5 insect cell lines such as: Sf9, Sf21, etc.; amphibian cells such as xenopus oocytes; and others.

COS 7 cells are grown on 150 mm plates in DMEM with supplements (Dulbecco's Modified Eagle Medium with 10%
10 bovine calf serum, 4 mM glutamine, 100 units/ml penicillin/100 Fg/ml streptomycin) at 37°C, 5% CO₂. Stock plates of COS-7 cells are trypsinized and split 1:6 every 3-4 days.

15 Human embryonic kidney 293 cells are grown on 150 mm plates in DMEM with supplements (10% bovine calf serum, 4 mM glutamine, 100 units/ml penicillin/100 Fg/ml streptomycin) at 37°C, 5% CO₂. Stock plates of 293 cells are trypsinized and split 1:6 every 3-4 days.

20 Human embryonic kidney Peak rapid 293 (Peakr293) cells are grown on 150 mm plates in DMEM with supplements (10% fetal bovine serum, 10% L-glutamine, 50 Fg/ml gentamycin) at 37°C, 5% CO₂. Stock plates of Peak rapid
25 293 cells are trypsinized and split 1:12 every 3-4 days.

Mouse fibroblast LM(tk-) cells are grown on 150 mm plates in DMEM with supplements (Dulbecco's Modified Eagle Medium with 10% bovine calf serum, 4 mM glutamine,
30 100 units/ml penicillin/100 Fg/ml streptomycin) at 37°C, 5% CO₂. Stock plates of LM(tk-) cells are trypsinized and split 1:10 every 3-4 days.

494

Chinese hamster ovary (CHO) cells were grown on 150 mm plates in HAM=s F-12 medium with supplements (10% bovine calf serum, 4 mM L-glutamine and 100 units/ml penicillin/ 100 Fg/ml streptomycin) at 37°C, 5% CO₂.
5 Stock plates of CHO cells are trypsinized and split 1:8 every 3-4 days.

Mouse embryonic fibroblast NIH-3T3 cells are grown on 150 mm plates in Dulbecco=s Modified Eagle Medium (DMEM)
10 with supplements (10% bovine calf serum, 4 mM glutamine, 100 units/ml penicillin/100 Fg/ml streptomycin) at 37°C, 5% CO₂. Stock plates of NIH-3T3 cells are trypsinized and split 1:15 every 3-4 days.

15 Sf9 and Sf21 cells are grown in monolayers on 150 mm tissue culture dishes in TMN-FH media supplemented with 10% fetal calf serum, at 27°C, no CO₂. High Five insect cells are grown on 150 mm tissue culture dishes in Ex-Cell 400™ medium supplemented with L-Glutamine, also at
20 27°C, no CO₂.

In some cases, cell lines that grow as adherent monolayers can be converted to suspension culture to increase cell yield and provide large batches of uniform
25 assay material for routine receptor screening projects.

Transient expression

DNA encoding proteins to be studied can be transiently expressed in a variety of mammalian, insect, amphibian
30 and other cell lines by several methods including but not restricted to; calcium phosphate-mediated, DEAE-dextran mediated, Liposomal-mediated, viral-mediated, electroporation-mediated and microinjection delivery.

495

Each of these methods may require optimization of assorted experimental parameters depending on the DNA, cell line, and the type of assay to be subsequently employed.

5

A typical protocol for the calcium phosphate method as applied to Peak rapid 293 cells is described as follows:

Adherent cells are harvested approximately twenty-four hours before transfection and replated at a density of 3.5×10^6 cells/dish in a 150 mm tissue culture dish and allowed to incubate over night at 37°C at 5% CO₂. 250 Fl of a mixture of CaCl₂ and DNA (15 Fg DNA in 250 mM CaCl₂) is added to a 5 ml plastic tube and 500 Fl of 2X HBS (280 mM NaCl, 10 mM KCl, 1.5 mM Na₂HPO₄, 12 mM dextrose, 50 mM HEPES) is slowly added with gentle mixing. The mixture is allowed to incubate for 20 minutes at room temperature to allow a DNA precipitate to form. The DNA precipitate mixture is then added to the culture medium in each plate and incubated for 5 hours at 37°C, 5% CO₂. After the incubation, 5ml of culture medium (DMEM, 10% FBS, 10% L-glut and 50 µg/ml gentamycin) is added to each plate. The cells are then incubated for 24 to 48 hours at 37°C, 5% CO₂.

25

A typical protocol for the DEAE-dextran method as applied to Cos-7 cells is described as follows; Cells to be used for transfection are split 24 hours prior to the transfection to provide flasks which are 70-80% confluent at the time of transfection. Briefly, 8 Fg of receptor DNA plus 8 Fg of any additional DNA needed (e.g. G_α protein expression vector, reporter construct, antibiotic resistance marker, mock vector, etc.) are

30

496

added to 9 ml of complete DMEM plus DEAE-dextran mixture (10 mg/ml in PBS). Cos-7 cells plated into a T225 flask (sub-confluent) are washed once with PBS and the DNA mixture is added to each flask. The cells are
5 allowed to incubate for 30 minutes at 37°C, 5% CO₂. Following the incubation, 36 ml of complete DMEM with 80 FM chloroquine is added to each flask and allowed to incubate an additional 3 hours. The medium is then aspirated and 24 ml of complete medium containing 10%
10 DMSO for exactly 2 minutes and then aspirated. The cells are then washed 2 times with PBS and 30 ml of complete DMEM added to each flask. The cells are then allowed to incubate over night. The next day the cells are harvested by trypsinization and reseeded as needed
15 depending upon the type of assay to be performed.

A typical protocol for liposomal-mediated transfection as applied to CHO cells is described as follows; Cells to be used for transfection are split 24 hours prior to
20 the transfection to provide flasks which are 70-80% confluent at the time of transfection. A total of 10Fg of DNA which may include varying ratios of receptor DNA plus any additional DNA needed (e.g. G_α protein expression vector, reporter construct, antibiotic
25 resistance marker, mock vector, etc.) is used to transfect each 75 cm² flask of cells. Liposomal mediated transfection is carried out according to the manufacturer=s recommendations (LipofectAMINE, GibcoBRL, Bethesda, MD). Transfected cells are harvested 24 hours
30 post transfection and used or reseeded according the requirements of the assay to be employed.

497

A typical protocol for the electroporation method as applied to Cos-7 cells is described as follows; Cells to be used for transfection are split 24 hours prior to the transfection to provide flasks which are subconfluent at the time of transfection. The cells are harvested by trypsinization resuspended in their growth media and counted. 4×10^6 cells are suspended in 300 Fl of DMEM and placed into an electroporation cuvette. 8 Fg of receptor DNA plus 8 Fg of any additional DNA needed (e.g. G_α protein expression vector, reporter construct, antibiotic resistance marker, mock vector, etc.) is added to the cell suspension, the cuvette is placed into a BioRad Gene Pulser and subjected to an electrical pulse (Gene Pulser settings: 0.25 kV voltage, 950 FF capacitance). Following the pulse, 800 Fl of complete DMEM is added to each cuvette and the suspension transferred to a sterile tube. Complete medium is added to each tube to bring the final cell concentration to 1×10^5 cells/100 Fl. The cells are then plated as needed depending upon the type of assay to be performed.

A typical protocol for viral mediated expression of heterologous proteins is described as follows for baculovirus infection of insect Sf9 cells. The coding region of DNA encoding the receptor disclosed herein may be subcloned into pBlueBacIII into existing restriction sites or sites engineered into sequences 5' and 3' to the coding region of the polypeptides.. To generate baculovirus, 0.5 Fg of viral DNA (BaculoGold) and 3 Fg of DNA construct encoding a polypeptide may be co-transfected into 2×10^6 *Spodoptera frugiperda* insect Sf9 cells by the calcium phosphate co-precipitation method, as outlined in by Pharmingen (in "Baculovirus Expression

498

Vector System: Procedures and Methods Manual"). The cells then are incubated for 5 days at 27°C. The supernatant of the co-transfection plate may be collected by centrifugation and the recombinant virus plaque purified. The procedure to infect cells with virus, to prepare stocks of virus and to titer the virus stocks are as described in Pharmingen's manual. Similar principals would in general apply to mammalian cell expression via retro-viruses, Simliki forest virus and double stranded DNA viruses such as adeno-, herpes-, and vacinia-viruses, and the like.

Stable expression

Heterologous DNA can be stably incorporated into host cells, causing the cell to perpetually express a foreign protein. Methods for the delivery of the DNA into the cell are similar to those described above for transient expression but require the co-transfection of an ancillary gene to confer drug resistance on the targeted host cell. The ensuing drug resistance can be exploited to select and maintain cells that have taken up the heterologous DNA. An assortment of resistance genes are available including but not restricted to Neomycin, Kanamycin, and Hygromycin. For the purposes of receptor studies, stable expression of a heterologous receptor protein is carried out in, but not necessarily restricted to, mammalian cells including, CHO, HEK293, LM(tk-), etc.

Cell membrane preparation

For binding assays, pellets of transfected cells are suspended in ice-cold buffer (20 mM Tris.HCl, 5 mM EDTA, pH 7.4) and homogenized by sonication for 7 sec. The

499

cell lysates are centrifuged at 200 x g for 5 min at 4°C. The supernatants are then centrifuged at 40,000 x g for 20 min at 4°C. The resulting pellets are washed once in the homogenization buffer and suspended in binding buffer (see methods for radioligand binding). Protein concentrations are determined by the method of Bradford (1976) using bovine serum albumin as the standard. Binding assays are usually performed immediately, however it is possible to prepare membranes in batch and store frozen in liquid nitrogen for future use.

Radioligand binding assays

Radioligand binding assays for the rat MCH1 receptor were carried out using plasmid pcDNA3.1-rMCH1-f (ATCC Patent Deposit Designation No. PTA-3505). Plasmid pcDNA3.1-rMCH1-f comprises the regulatory elements necessary for expression of DNA in a mammalian cell operatively linked to DNA encoding the rat MCH1 receptor so as to permit expression thereof. Plasmid pcDNA3.1-rMCH1-f was deposited on July 05, 2001, with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and was accorded ATCC Patent Deposit Designation No. PTA-3505.

Binding assays can also be performed as described hereinafter using plasmid pEXJ.HR-TL231 (ATCC Accession No. 203197) Plasmid pEXJ.HR-TL231 encodes the human MCH1 receptor and was deposited on September 17, 1998, with the American Type Culture Collection (ATCC), 12301

500

Parklawn Drive, Rockville, Maryland 20852, U.S.A.
under the provisions of the Budapest Treaty for the
International Recognition of the Deposit of
Microorganisms for the Purposes of Patent Procedure and
5 was accorded ATCC Accession No. 203197.

Human embryonic kidney Peak rapid 293 cells (Peakr293
cells) were transiently transfected with DNA encoding the
MCH1 receptor utilizing the calcium phosphate method and
10 cell membranes were prepared as described above. Binding
experiments with membranes from Peakr293 cells
transfected with the rat MCH1 receptor were performed
with 0.08 nM [³H]Compound A (the synthesis of Compound A
is described in detail below) using an incubation buffer
15 consisting of 50 mM Tris pH 7.4, 10 mM MgCl₂, 0.16 mM
PMSF, 1 mM 1,10 phenantroline and 0.2% BSA. Binding was
performed at 25°C for 90 minutes. Incubations were
terminated by rapid vacuum filtration over GF/C glass
fiber filters, presoaked in 5% PEI using 50 mM Tris pH
20 7.4 as wash buffer. In all experiments, nonspecific
binding is defined using 10 pM Compound A.

Functional assays

25 Cells may be screened for the presence of endogenous
mammalian receptor using functional assays. Cells with
no or a low level of endogenous receptor present may be
transfected with the exogenous receptor for use in
functional assays.

30

A wide spectrum of assays can be employed to screen for
receptor activation. These range from traditional
measurements of phosphatidyl inositol, cAMP, Ca⁺⁺, and

501

K⁺, for example; to systems measuring these same second messengers but which have been modified or adapted to be higher throughput, more generic, and more sensitive; to cell based platforms reporting more general cellular events resulting from receptor activation such as metabolic changes, differentiation, and cell division/proliferation, for example; to high level organism assays which monitor complex physiological or behavioral changes thought to be involved with receptor activation including cardiovascular, analgesic, orexigenic, anxiolytic, and sedation effects, for example.

Radioligand Binding Assay Results









The compounds described above were assayed using cloned rat MCH1. The binding affinities of the compounds are shown in Table I.

20










25

30

502


EXAMPLE No.	STRUCTURE	Ki (nM) rMCH1
1		90
2		3.9
3		768
4		357
5		14.2
6		274
7		1000
8		627

503

9		69
10		2.8
11		197
12		84
13		11.9
14		167
15		720
16		272
17		342


504

18




29.5

19




506

20




21

21




630

22




.52

23




1036

24




67

25












463

26




192

505

27		91
28		511
29		654
30		382
31		362
32		160
33		615
34		651
35		11.5


506

36




62

37




29.1

38




18.2

39




11.8

40




.50

41




946

42




118

43



12


44



11.5


507

45




1.6

46




187

47




52

48




6.7

49




7.1

50




3.9

51




3.1

52



3.8


53



7.1


508

54




4.9

55




5

56




22.3

57




16.6

58




2.01

59




12.9

60




0.923

61



13.6


62



12.8


509

63




22.4

64




14.8

65




17

66




3.3

67




5.9

68




9.3

69












32.5

70




50

510

71		6.6
72		31.4
73		22.3
74		48.6
75		11.8
76		44.6
77		25.7
78		22.2
79		19.4


511

80




14.3

81




377

82




11.2

83




48.1

84








721

85









3.2







EXAMPLE	STRUCTURE	Ki (nM) rMCH1
---------	-----------	------------------

86	<p style="text-align: center;">512</p> 	20.6
87		14.9
88		16.0
89		3.0 -
90		3.0







513






91		2.3
92		8.0
93		4.2
94		2.3
95		5.4
96		15.9




514

97		27.3
98		37.9
99		1.7
100		27.5 -
101		7.8
102		38.4


515

103		21.3
104		11.2
105		4.6
106		7.1 -
107		1.7
108		5.2

516		
109		20.9
110		1.8
111		ND
112		6.1
113		ND

114	<div>517</div> 	3.6
115		ND
116		3.8

117




19.0

518


118

43.6




119

75.7




120





31.1



121

183.7






520


126

13.8




127

168.5




128

328.8



129


38.8



521


130

6.0




131

11.9




132

41.7



133


14.1



522


134

36.6




135

10.9




136

15.9



137


25.2



523


138

9.3




139

38.7




140

27.4



141


61.0



524


142

18.3




143

8.7




144

13.4



145


196.8



525


146

19.2




147

8.7




148

24.7



149


148.9



526


150

8.0




151

14.2




152

13.3



153


8.1



527


154

9.3




155

7.4




156

8.8



157


15.4



528


158

7.8




159

4.5




160

6.2



161


7.9



529


162

7.2




163

58.3




164

16.3



165


6.2



530


166

7.7




167

80.4




168

7.0



169


7.7



531


170

3.0




171

3.7




172

3.0



173


112.3



532


174

17.0




175

16.2




176

11.8




177


6.8




178 533 119.2




179 82.3



180 9.7




181 91.9



534


182

101.3




183

4.0




184

105.2



185


20.6



535

186


4.9



187

Chiral

15.6




Example

Structure

rMCH1
Ki (nM)


188

531.5



189


438.3



190


536

435.6




191

648.7




192





80.5








193





5.2



194	537	1.8
		
195		106.0
		
196		35.2
		
197		63.1
		

198	 <chem>CC(C)C(=O)Nc1ccc(cc1)C2CCN(CC2)Cc3ccc(Oc4ccc(Cl)c(Cl)c4)cc3</chem>	538	6.1
199	 <chem>CC(C)C(=O)Nc1ccc(cc1)C2CCN(CC2)Cc3ccc(N(c4ccccc4)c5ccccc5)cc3</chem>		3.6
200	 <chem>CC(C)C(=O)Nc1ccc(cc1)C2CCN(CC2)Cc3c(C)c(C)n(c3C4=CC=C(C(F)(F)F)C4)c5ccccc5</chem>		20.9
201	 <chem>CC(C)C(=O)Nc1ccc(cc1)C2CCN(CC2)Cc3cc4c(s3)nc(C)c4c5ccccc5</chem>		996.1




206	<div>540</div> 	17.7
207		136.8
208		30.8
209		64.8

541


210

23.3




211

111.3




212





43.0




213

519.1




214	 <chem>CC(C)C(=O)Nc1ccc(cc1)C2CCN(CC2)Cc3ccc(cc3)N4CCCCC4[N+](=O)[O-]</chem>	542	56.3
215	 <chem>CC(C)C(=O)Nc1ccc(cc1)C2CCN(CC2)Cc3ccc4c(c3)sc5cc(C)c(C)sc45</chem>		283.1
216	 <chem>CC(C)C(=O)Nc1ccc(cc1)C2CCN(CC2)Cc3cc4c(c3)nnc4C(F)(F)F</chem>		817.9
217	 <chem>CC(C)C(=O)Nc1ccc(cc1)C2CCN(CC2)Cc3ccc4c(c3)nnc4</chem>		300.1



544


222

152.4




223

318.2




224

48.0








225

213.6




226	545	238.8	
227		261.6	
228		841.1	
229		884.5	







238 548 65.9




239




240




241






550


246




247



248




249




551


250




251







252









253



361.6











Example

Structure

rMCH-1
Ki (nM)




270




3.4

271



40.1


272



Chiral





15.6





273







Chiral

196.4

274	 <chem>CCN(CC)c1ccc2ccccc2c1CN3CCCCC3c4ccccc4C(=O)C(C)C</chem>	557 843.5
275	 <chem>CC(C)C(=O)Nc1ccc(cc1CN2CCCCC2C3C(=CC=C(C=C3)F)C4C(=CC=C(C=C4)F)C5=CC=CC=C5</chem>	3.1
276	 <chem>CC(C)C(=O)Nc1ccccc1CN2CCCCC2C3C(=CC=C(C=C3)F)C4C(=CC=C(C=C4)F)C5=CC=CC=C5</chem>	734.4
277	 <chem>CC(C)C(=O)Nc1ccc(cc1CN2CCCCC2C3C(=CC=C(C=C3)F)C4C(=CC=C(C=C4)F)C5=CC=CC=C5OC(F)(F)F</chem>	117.8
Example	Structure	rMCH-1 Ki (nM)


278		558 Chiral	85.8
279			74.5
280			27.6
281			7.9



560


286

67.8




287

34.3




288


30.2



289

31.8






562


294

15.8




295

8.7




296

20.0



297


11.9



563


298

40.1




299

37.5




300


7.6



301




302 564 Chiral 20.5




Example Structure rMCH-1
Ki (nM)


303 9.5











304 Chiral 4.0







305 Chiral 177.2







306		565 Chiral	167.9
307		Chiral	97.4
308		Chiral	401.6
309		Chiral	310.1





310		566 Chiral	152.2
311		Chiral	43.0
312		Chiral	61.5
313		Chiral	249.3

314		567 Chiral	7.6
315		Chiral	11.4
316		Chiral	8.3
317		Chiral	110.2

318	 <chem>CC(C)C(=O)Nc1ccc(cc1CN2CCCCC2CC[C@@H](c3ccccc3)NC(=O)c4cc5c(cc4)oc6cc(Cl)cc(Cl)c6n5)C(=O)N2</chem>	568 Chiral	251.2
319	 <chem>CC(C)C(=O)Nc1ccc(cc1CN2CCCCC2CC[C@@H](c3ccccc3)NC(=O)c4ccncc4)C(=O)N2</chem>	Chiral	89.8
320	 <chem>CC(C)C(=O)Nc1ccc(cc1CN2CCCCC2CC[C@@H](c3ccccc3)NC(=O)c4cc(F)c(F)cc4)C(=O)N2</chem>	Chiral	10.6
321	 <chem>CC(C)C(=O)Nc1ccc(cc1CN2CCCCC2CC[C@@H](c3ccccc3)NC(=O)c4c5c(ccc4n5)N(c6ccccc6)CC7=CN(C7)CC</chem>	Chiral	50.9

322	 <chem>CN(C)c1ccc(cc1)C(=O)N[C@H](c2ccccc2)CCCN3CCCCC3CC[C@H](c4ccccc4)N(C(=O)CC)C5=CC=CC=C5</chem>	569 Chiral	99.9
323	 <chem>CC(=O)N[C@H](c1ccccc1)CCCN2CCCCC2CC[C@H](c3ccccc3)N(C(=O)CC)C4=CC=CC=C4C5=CC=CSC5</chem>	Chiral	37.0
324	 <chem>[O-][N+](=O)c1cc2oc(cc2o1)C(=O)N[C@H](c3ccccc3)CCCN4CCCCC4CC[C@H](c5ccccc5)N(C(=O)CC)C6=CC=CC=C6</chem>	Chiral	76.8
325	 <chem>CC(=O)N[C@H](c1ccccc1)CCCN2CCCCC2CC[C@H](c3ccccc3)N(C(=O)CC)C4=CC=CC=C4C5=CC=CSC5</chem>		29.8

326		570 Chiral	19.2
327		Chiral	7.7
328			47.6
329			2.9




572

334

Chiral


602.8



335

Chiral


887.7



336

Chiral


693.0



337

Chiral

907.4




573

338

Chiral


843.9



339

Chiral


889.9



340


Chiral

15.6



341


255.6



574


342

183.0




343

194.7




344

44.6



345


15.4



575


346

106.9




347

54.8




348





84.0











349





20.4

























374	 <chem>CC1(C)COC(CCCN2CCCCC2c3ccc(cc3)N4C(=O)C(C)N4)OC1</chem> 582	96.8
375	 <chem>CC(C)C(=O)Nc1ccc(cc1)C2NCCCC2OCCCOc3ccc(cc3)C(=O)C</chem> 375	185.6
376	 <chem>COc1ccc(cc1)OCCCN2CCCCC2c3ccc(cc3)N4C(=O)C(C)N4</chem> 376	887.6
377	 <chem>COc1ccc(cc1)OCCCN2CCCCC2c3ccc(cc3)N4C(=O)C(C)N4</chem> 377	711.9




[illegible]

386


585

26.3




387

19.7




388





20.7








389

2.2




390	 586	1.0
391		21.9
392		18.1
393		9.5






402

589




403


11.7




404




405




406 590 12.3




407 16.6











408 21.6



409 96.7




410		591	262.7
411			82.3
412			27.0
413			76.8

414	 <chem>CN1C=CC2=CC=CC=C2C1CCCCN3CCCCC3C4=CC=CC=C4NC(=O)C(C)C</chem>	2.9
415	 <chem>CN1C=CC2=CC=CC=C2C1CCCCN3CCCCC3C4=CC=CC=C4NC(=O)C(C)C</chem>	8.1
416	 <chem>CN1C=CC2=CC=CC=C2C1CCCCN3CCCCC3C4=CC=CC=C4NC(=O)C(C)C</chem>	12.6
417	 <chem>CN1C=CC2=CC=CC=C2C1CCCCN3CCCCC3C4=CC=CC=C4NC(=O)C(C)C</chem>	20.5

418


593

51.6




419

83.9




420




421

1.8




422




173.0

423




405.2

424



114.2

425




599.3

426


595

556.1




427

248.3




428

132.4



429


121.4



430


596

647.4




431

967.7




432

198.2



433


30.4



434


597

214.2




435

215.4




436


434.3







437

552.1






442		7.8
443		23.4
444		544.7
445		486.3

446


600

17.9




447

9.8




448

61.0



449


623.4



450


601

7.1




451

18.7




452


12.7











453

194.8







458	 <chem>CC(C)C(=O)Nc1ccc(cc1)C2CCN(CC2Cc3c[nH]c4ccccc34)c5ccc(Cl)cc5</chem>	15.3
459	 <chem>CC(C)C(=O)Nc1ccc(cc1)C2CCN(CC2Cc3c[nH]c4ccccc34)c5cccc(Cl)c5</chem>	10.4
460	 <chem>CC(C)C(=O)Nc1ccc(cc1)C2CCN(CC2Cc3c[nH]c4ccccc34)c5ccccc5Cl</chem>	9.1
461	 <chem>CC(=O)Nc1ccc(cc1)C2CCN(CC2Cc3c[nH]c4ccccc34)c5ccccc5Cl</chem>	35.6

462		604	12.4
463			17.2
464			84.1
465			10.7


466




467



468




469



470


606

654.1




471

4.3




472

12.2




473

11.3




474




13.3

475




12.4

476



12.7

477




14.9

478


608

11.7




479

8.1




480

9.0




481

664.0




609


482




483







484




485






611


490




491



492




493




494

612




495

95.1




496

288.0



497


97.7



498


613

52.2




499

11.9




500

29.4



501


22.1



502


614

4.6




503

6.0




504


22.5



505

6.5






510


616

304.9




511

6.0




512

42.7




513


178.7




514 617 151.4




515 296.2





516 90.9



517 286.9








526


620

410.6




527

226.5




528

115.1




529

42.4




621

530




531

105.3




532


8.7



533

10.6






538


623

36.3




539

268.4




540

172.3



541


318.6



542


624

31.3




543

27.6




544

16.2



545


52.0



546


625

87.9




547

75.5




548





125.6



549

39.7






627


554

70.9




555

50.3




556





35.6





557

25.6











570



136.3

571




88.3

Example

Structure

rMCH1
Ki (nM)


572



Chiral

181.5

573



Chiral


114.3

632

574

Chiral


87.1



575

Chiral


192.6



576

Chiral


74.3



577


Chiral

64.7



633

578




Chiral 98.8

Example

Structure


rMCH1
Ki (nM)

579




131.1

580



54.0

581




86.4

634


582

58.3




583

55.5




584


51.8




585

37.2






590 636 157.1



591 137.5



Example


Structure

mMCH1
Ki (nM)

592

Chiral


185.6



593

Chiral

7.6




637

594

Chiral


67.0



595

Chiral


36.3



596

Chiral


596.7







597


Chiral

222.7




598		638 Chiral	25.3
599		Chiral	50.0
600		Chiral	41.3
601		Chiral	144.2

602

639
Chiral

44.6

603




286.8

Example

MOLSTRUCTURE

rMCH1
Ki (nM)


604



Chiral





36.8_





605








Chiral

94.5

606	 <chem>CC(C)C(=O)Nc1ccc(cc1)CN2CCCN(C2Cc3ccccc3N(Cc4ccccc4)N5C(=S)N(C5C6C(C)C)C6)c7ccccc7</chem>	640 Chiral	40.4
607	 <chem>CC(C)C(=O)Nc1ccc(cc1)CN2CCCN(C2Cc3ccccc3N(Cc4ccccc4)N5C(=O)N(C5C6C(C)C)C6)c7ccccc7F</chem>	Chiral	142.1
608	 <chem>CC(C)C(=O)Nc1ccc(cc1)CN2CCCN(C2Cc3ccccc3N(Cc4ccccc4)N5C(=S)N(C5C6C(C)C)C6)c7ccccc7C</chem>	Chiral	34.9
609	 <chem>CC(C)C(=O)Nc1ccc(cc1)CN2CCCN(C2Cc3ccccc3N(Cc4ccccc4)N5C(=O)N(C5C6C(C)C)C6)c7ccccc7CN(C8C(=O)N(C8C9C(C)C)C9)c10ccccc10</chem>	Chiral	35.4

610		641 Chiral	529.8
611		Chiral	65.1
612		Chiral	121.0
613			34.9




Example	Structure	rMCH1 Ki (nM)
618		399.5
619		177.5
620		223.3
621		204.6

644


622

162.4




623

23.1




624


47.8




625

29.5







630 646 201.8




631 258.8



632 76.6




633 107.9



647


634

116.1




635

73.6




636

40.8




637

105.6




638




29.8

639




36.3

640







11.2

641




14.2



646


650

235.7




647

81.6




648

13.4



649


1.7



650


651

21.1




651

16.7




652

7.1




653


48.8




654 652 43.6




655 31.1








656 49.7



657 77.9






654


663

73.4




664





21.9











665

38.4












678 658 14.7




679 97.9




680 28.1




681 23.9




682 659 7.1




683 54.2



684 5.4




685 82.4



660


686

33.9




687

20.6




688

41.0



689


11.3



662


694

6.4




695

2.1




696

48.3



697


3.0



663


698

3.0




699

5.4




700


2.0



701

2.5






665


706

4.2




707

19.6




708

3.8



709


1.3



666


710

6.9




711

90.5




712


8.6



713

7.7






668


718

3.4




719

14.9




720

12.5



721


75.3



722


669

6.4




723

9.2




724

5.0



725


151.6



670


726

5.0




727

3.4




728

16.3




729


1.7




730 671 0.9




731 9.9



732 5.8




733 10.0



672


734

28.6




735

1.1




736


5.7



737

1.0






674


742

1.4




743

4.1




744


47.1




745

15.8







750 676 2.6




751 12.4



752 21.7




753 16.6



677


754

49.2




755

23.8




756


4.2




757

6.9








680


766

7.6




767

34.8




768

17.5



769


12.4



681


770

12.7




771

189.0




772

14.9



773


23.8



682


774

7.9




775

4.9




776

18.2



777


8.5



683


778

26.5




779

7.6




780

64.3



781


7.6



684


782

18.1




783

18.0




784

121.2



785


22.7



685


786

19.7




787

21.6




788

11.1



789


36.4



686


790

4.4




791

12.7




792





122.0




793

16.3







798 688 474.7




799 370.6



800 9.9




801 311.1



689


802

36.7




803

298.6




804




89.2




805

903.9







Example	Structure	rMCH1 KI (nM)
---------	-----------	------------------




810 691 191.2




811 190.8



812 244.8




813 57.3



814


692

159.5




815

126.9




816



89.6



817

34.9






5

Example

Structure


rMCH1
Ki (nM)

820








108.6

821



12.1


822		1.0
823		2.7
824		36.5

Example	Structure	rMCH1 Ki (nM)
825		600.7
826		785.6

695


827

215.4




828

515.9



829


228.0



830


696

468.6




831

569.8




832

614.3



833


27.5



834


697

38.3




835

21.3




836





7.8





837





35.9











850	 <chem>CC1=C(C(=O)N1c2ccc(cc2)CN3CCCCC3Cc4ccc5c(c4)c[nH]5)C(F)(F)F</chem>	9.5
851	 <chem>CC1=C(C(=O)N1c2ccc(cc2)CN3CCCCC3Cc4ccc5c(c4)c[nH]5)C(=O)[N+](=O)[O-]</chem>	27.4
852	 <chem>CC1=C(C(=O)N1c2ccc(cc2)CN3CCCCC3Cc4ccc5c(c4)c[nH]5)F</chem>	14.5
853	 <chem>CC1=C(C(=O)N1c2ccc(cc2)CN3CCCCC3Cc4ccc5c(c4)c[nH]5)c6ccccc67</chem>	48.0




858




44.9

859




320.7

860











40.5

861




94.1

862	704	437.6
		
863	#NAME?	269.0
		
864		292.0
		
865		94.6
		




870




166.7

871




251.7

872




306.3

873




345.0

874




247.1

875




130.1

876




758.2

877



245.1




Example	Structure	mMCH1 Ki (nM)
888		19.8
889		8.6
890		11.1

709


891

6.5




892

17.3




893

23.0



894


41.7



710


895

6.4




896

30.3




897

6.4



898


33.7



711


899

18.0




900

11.2




901

8.2



902


11.0



712


903

12.2




904

14.2




905

5.9



906


5.7



713


907

3.1




908

3.7




909

10.0



910


10.1



714


911

7.6




912

5.7




913

12.9



914


17.3



715


915

22.6




916

20.2




917

78.0



918

29.3




919	<div>716</div> <chem>CC(C)C(=O)Nc1ccc(cc1)C2CCN(CC2)CCCCC[C@H](c3ccc(F)cc3)Oc4ccc(Br)cc4</chem>	14.0
920	<chem>CC(C)C(=O)Nc1ccc(cc1)C2CCN(CC2)CCCCC[C@H](c3ccc(Cl)cc3)Oc4ccc(Cl)cc4</chem>	6.9
921	<chem>CC(C)C(=O)Nc1ccc(cc1)C2CCN(CC2)CCCCC[C@H](c3ccccc3)Oc4ccc(Cl)cc4</chem>	6.8
922	<chem>CC(C)C(=O)Nc1ccc(cc1)C2CCN(CC2)CCCCC[C@H](c3ccc(F)cc3)Oc4ccc(cc4)C(=O)C</chem>	25.0

923


717

1.3




924

13.1




925

13.4




926

1.4




927




60.7

928




14.9

929



29.9

930




14.6

719


931

9.6




932

9.4




933

10.9



934


12.3



935


720

19.7




936

11.6




937



28.4



938



608.6





Example


Structure

rMCH1
Ki (nM)

722


943

101.7




944

38.8




945

31.2



946


336.6



947

723

4.3



948

21.2




Table 2: Binding affinities (K_i) at the rat MCH1, human Dopamine D2, human Histamine H1 and human Alpha-1a Adrenergic receptors.

Compound	rMCH1 K_i (nM)	hD2 K_i (nM)	hH1 K_i (nM)	hAlpha-1a K_i (nM)
1	90	6092	823	49
2	3.9	2839	700	32.1
3	768	ND	ND	ND
4	357	ND	ND	ND
5	14.2	1139	1618	9.1
6	274	ND	ND	ND
7	1000	ND	ND	ND
8	627	ND	ND	ND
9	69	1430	1733	26.4
10	2.8	862	461	19.4
11	197	ND	ND	ND
12	84	771	571	57
13	11.9	561	ND	61
14	167	ND	ND	ND
15	720	ND	ND	ND
16	272	ND	ND	ND
17	342	ND	ND	ND
18	29.5	782	ND	115
19	506	ND	ND	ND
20	21	470	ND	41.3
21	630	ND	ND	ND

Table 2: Binding affinities (K_i) at the rat MCH1, human Dopamine D2, human Histamine H1 and human Alpha-1a Adrenergic receptors.

22	52	5181	2277	284
23	1036	ND	ND	ND
24	67	1252	ND	127
25	463	ND	ND	ND
26	192	1977	ND	516
27	91	503	ND	130
28	511	ND	ND	ND
29	654	ND	ND	ND
30	382	ND	ND	ND
31	362	ND	ND	ND
32	160	ND	ND	ND
33	615	ND	ND	ND
34	651	ND	ND	ND
35	11.5	9654	2000	533
36	62	12,026	2454	1489
37	29.1	34,993	16,734	1087
38	18.2	>50000	6595	1592
39	11.8	>50000	6401	2937
40	50	7451	273	12.3
41	946	ND	ND	ND
42	118	ND	ND	ND
43	12	10,428	2560	434
44	11.5	8673	11,092	704

Table 2: Binding affinities (K_i) at the rat MCH1, human Dopamine D₂, human Histamine H₁ and human Alpha-1a Adrenergic receptors.

45	1.6	42.2	3.4	18
46	187	ND	ND	ND
47	52	>5000	36,907	>5000
48	6.7	735	6390	452
49	7.1	471	39.1	140
50	3.9	1077	304	161
51	3.1	152	130	33.5
52	3.8	244	264	13.2
53	7.1	191	1320	221
54	4.9	83	283	187
55	5	162	1100	125
56	22.3	435	32.5	55
57	16.6	41,994	48,658	3206
58	20.1	390	590	233
59	12.9	262	46.9	49.1
60	0.923	52	546	22.3
61	13.6	281	969	310
62	12.8	319	25,320	719
63	22.4	766	25,307	1058
64	14.8	313	6994	1142
65	17	331	9390	1720
66	3.3	132	3473	944
67	5.9	133	2146	511

Table 2: Binding affinities (K_i) at the rat MCH1, human Dopamine D2, human Histamine H1 and human Alp

68	9.3	66	329	204
69	32.5	46.6	>50000	232
70	50	1050	7998	1521
71	6.6	119	1710	226
72	31.4	41,454	33,096	645
73	22.3	41,454	6522	381
74	48.6	39,511	1862	333
75	11.8	19,041	2844	2469
76	44.6	41,454	39,710	10,965
77	25.7	447	4178	167
78	22.2	37.6	>50000	1313
79	19.4	244	507	722
80	14.3	833	9789	620
81	377	ND	ND	ND
82	11.2	ND	ND	ND
83	48.1	ND	ND	ND
84	121	ND	ND	ND
85	3.2	2449	3816	3021

V. Synthesis of Compound A

Described below is the synthesis of Compound A.
5 Compound A is the radiolabeled compound that was used in the radioligand binding assays described above.

***N*-[3-(1,2,3,6-TETRAHYDRO-4-PYRIDINYL)PHENYL]ACETAMIDE:**

The reaction of saturated of aqueous Na₂CO₃ solution (25
10 mL), *tert*-butyl 4-[[trifluoromethyl)sulfonyl]oxy]-1,2,3,6-tetrahydro-1-pyridine-carboxylate (20 mmol), 3-acetamidophenylboronic acid (30 mmol) and tetrakis-triphenylphosphine palladium (0) (1.15 g) in dimethoxyethane (40 mL) at reflux temperature overnight
15 gave *tert*-butyl 4-[3-(acetylamino)phenyl]-3,6-dihydro-1(2*H*)-pyridinecarboxylate. Deprotection of the BOC group using HCl in dioxane followed by basification (pH 11-12) gave the desired product.

20 ***TERT*-BUTYL *N*-(3-BROMOPROPYL)CARBAMATE:** was prepared from 3-bromopropylamine hydrobromide and BOC₂O in the presence of base in dichloromethane.

***N*-{3-[1-(3-AMINOPROPYL)-1,2,3,6-TETRAHYDRO-4-PYRIDINYL]PHENYL}ACETAMIDE:** The reaction of *tert*-butyl
25 *N*-(3-bromopropyl)carbamate and *N*-[3-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]acetamide in refluxing dioxane with catalytic Bu₄NI and base as described in Scheme A gave *tert*-butyl 3-(4-[3-(acetylamino)phenyl]-3,6-dihydro-
30 1(2*H*)-pyridinyl)propylcarbamate. Deprotection of the BOC group using HCl in dioxane followed by basification (pH 11-12) gave the desired product.

729

METHYL (4S)-3-({[3-(4-[3-(ACETYLAMINO)PHENYL]-3,6-DIHYDRO-1(2H)-PYRIDINYL]PROPYL)AMINO]CARBONYL)-4-(3,4-DIFLUOROPHENYL)-6-(METHOXYMETHYL)-2-OXO-1,2,3,4-

5 TETRAHYDRO-5-PYRIMIDINECARBOXYLATE: Prepared from the reaction of 5-methyl 1-(4-nitrophenyl) (6S)-6-(3,4-difluorophenyl)-4-(methoxymethyl)-2-oxo-3,6-dihydro-1,5(2H)-pyrimidinedicarboxylate (describe in PCT Publication No. WO 00/37026, published June 29, 2000) and N-{3-[1-(3-aminopropyl)-1,2,3,6-tetrahydro-4-pyridinyl]phenyl}acetamide: ¹H NMR δ 8.90 (t, 1 H, J=3.6 Hz), 7.75 (s, 1 H), 7.50-7.00 (m, 8 H), 6.68 (s, 1 H), 6.03 (br s, 1 H), 4.67 (s, 2 H), 3.71 (s, 3 H), 3.47 (s, 3 H), 3.38 (ABm, 2 H), 3.16 (m, 2 H), 2.71 (t, 2 H, J=5.4 Hz), 2.56 (m, 4 H), 2.35-1.90 (br, 2 H), 2.17 (s, 3 H), 1.82 (p, 2 H, J=7.2 Hz); ESMS, 612.25 (M+H)⁺.

TRITIATED METHYL (4S)-3-{{[3-(4-[3-(ACETYLAMINO)PHENYL]-1-PIPERIDINYL]PROPYL)AMINO]CARBONYL}-4-(3,4-DIFLUOROPHENYL)-6-(METHOXYMETHYL)-2-OXO-1,2,3,4-

20 TETRAHYDRO-5-PYRIMIDINECARBOXYLATE ([³H] COMPOUND A): This radiochemical synthesis was carried out by Amersham Pharmacia Biotech, Cardiff, Wales. A methanolic solution of methyl (4S)-3-({[3-(4-[3-(acetylamino)phenyl]-3,6-dihydro-1(2H)-pyridinyl]propyl)amino]carbonyl)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate was exposed to tritium gas at 1 atmosphere pressure in the presence of 5% palladium on carbon with stirring overnight to give the tritiated methyl (4S)-3-{{[3-(4-[3-(acetylamino)phenyl]-1-piperidinyl]propyl)amino]carbonyl}-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate ((+)-isomer) After

730

purification by reverse phase HPLC (Hypersil ODS, 4.6 x 100 mm, methanol:H₂O:Et₃N 10:90:1 to 100:0:1 in 15 min at 1.0 mL/min, with radiochemical and UV detection), this product was used as a radioligand in the MCH1 binding assays. The same procedure was carried out with H₂ gas in place of ³H₂ to afford the non-radioactive version of Compound A.

VI. In-Vivo Methods

10

The following *in vivo* methods were performed to predict the efficacy of MCH1 antagonists for the treatment of obesity (3-day body weight and sweetened condensed milk), depression (forced swim test), anxiety (social interaction test), and urinary disorders (DIRC and CSTI).

15

Effects of MCH1 Antagonists on Body Weight (3 Day)

Male Long Evans rats (Charles River) weighing 180-200 grams were housed in groups of four on a 12-hour light/dark cycle with free access to food and water. Test compounds were administered twice daily via i.p. injection, 1 hour before the dark cycle and 2 hours after lights on, for three days. All rats were weighed daily after each morning injection. Overall results were expressed as body weight (grams) gained per day (mean \pm SEM) and were analyzed by two-way ANOVA. Data for each time point were analyzed by one-way ANOVA followed by post hoc Newman-Keuls test. The data were analyzed using the GraphPad Prism (v2.01) (GraphPad Software, Inc., San Diego, CA). All data were presented as means \pm S.E.M.

20
25
30

731

Effects of MCH1 Antagonists on Consumption
of Sweetened Condensed Milk

Male C57BL/6 mice (Charles River) weighing 17-19 grams
5 at the start of experiments were housed in groups of
four or five on a 12 hour light/dark cycle with free
access to food and water. For 7 days, mice were weighed,
placed in individual cages and allowed to drink
sweetened condensed milk (Nestle, diluted 1:3 with
10 water) for 1 hour, 2-4 hours into the light cycle. The
amount of milk consumed was determined by weighing the
milk bottle before and after each drinking bout. On the
test day, mice received i.p. injections of Test Compound
(3, 10 or 30 mg/kg in 0.01 % lactic acid), vehicle (0.01
15 % lactic acid) of d-fenfluramine (10 mg/kg in 0.01 %
lactic acid) 30 min. prior to exposure to milk. The
amount of milk consumed on the test day (in mls milk/ kg
body weight) was compared to the baseline consumption
for each mouse determined on the previous 2 days. Data
20 for each time point were analyzed by one-way ANOVA.

Forced Swim Test (FST) in the Rat

Animals

25 Male Sprague-Dawley rats (Taconic Farms, NY) were used
in all experiments. Rats were housed 5 per cage and
maintained on a 12:12-h light-dark cycle. Rats were
handled for 1 minutes each day for 4 days prior to
behavioral testing.

30

Drug Administration

Animals were randomly assigned to receive a single i.p. administration of vehicle (2.5% EtOH / 2.5% Tween-80), imipramine (positive control; 60 mg/kg), or Test
5 Compound 60 minutes before the start of the 5 minute test period. All injections were given using 1 cc tuberculin syringe with 26 3/8 gauge needles (Becton-Dickinson, VWR Scientific, Bridgeport, NJ). The volume of injection was 1 ml/kg.

10

Experimental Design

The procedure used in this study was similar to that previously described (Porsolt, et al., 1978), except the water depth was 31 cm in this procedure. The greater
15 depth in this test prevents the rats from supporting themselves by touching the bottom of the cylinder with their feet. Swim sessions were conducted by placing rats in individual plexiglass cylinders (46 cm tall x 20 cm in diameter) containing 23-25°C water 31 cm deep. Swim
20 tests were conducted always between 900 and 1700 hours and consisted of an initial 15-min conditioning test followed 24h later by a 5-minute test. Drug treatments were administered 60 minutes before the 5-minute test period. Following all swim sessions, rats were removed
25 from the cylinders, dried with paper towels and placed in a heated cage for 15 minutes and returned to their home cages. All test sessions were videotaped using a color video camera and recorded for scoring later.

Behavioral Scoring

The rat's behavior was rated at 5-second intervals during the 5-minute test by a single individual, who was blind to the treatment condition. Scored behaviors were:

1. Immobility- rat remains floating in the water without struggling and was only making those movements necessary to keep its head above water;
- 10 2. Climbing - rat was making active movements with its forepaws in and out of the water, usually directed against the walls;
3. Swimming - rat was making active swimming motions, more than necessary to merely maintain its head above water, e.g. moving around in the cylinder; and
- 15 4. Diving - entire body of the rat was submerged.

Data Analysis

- 20 The forced swim test data (immobility, swimming, climbing, diving) were subjected to a randomized, one-way ANOVA and post hoc tests conducted using the Newman-Keuls test. The data were analyzed using the GraphPad Prism (v2.01) (GraphPad Software, Inc., San Diego, CA).
- 25 All data were presented as means \pm S.E.M. All data were presented as means \pm S.E.M.

Forced Swim Test (FST) in the MouseAnimals

- 30 DBA/2 mice (Taconic Farms, NY) were used in all experiments. Animals were housed 5 per cage in a controlled environment under a 12:12 hour light:dark cycle. Animals were handled 1 min each day for 4 days

734

prior to the experiment. This procedure included a mock gavage with a 1.5 inch feeding tube.

Drug Administration

5 Animals were randomly assigned to receive a single administration of vehicle (5% EtOH/5% Tween-80), Test Compound, or imipramine (60 mg/kg) by oral gavage 1 hour before the swim test.

10 Experimental Design

The procedure for the forced swim test in the mouse was similar to that described above for the rat, with some modifications. The cylinder used for the test was a 1-liter beaker (10.5cm diameter X 15 cm height) fill to 15 800ml (10cm depth) of 23-25°C water. Only one 5-minute swim test was conducted for each mouse, between 1300 and 1700 hours. Drug treatments were administered 30-60 minutes before the 5-minute test period. Following all swim sessions, mice were removed from the cylinders, 20 dried with paper towels and placed in a heated cage for 15 minutes. All test sessions were videotaped using a Sony color video camera and recorder for scoring later.

Behavioral Scoring

25 The behavior during minutes 2-5 of the test was played back on a TV monitor and scored by the investigator. The total time spent immobile (animal floating with only minimal movements to remain afloat) and mobile (swimming and movements beyond those required to remain afloat) 30 were recorded.

Data Analysis

The forced swim test data (time exhibiting immobility, mobility; seconds) were subjected to a randomized, one-way ANOVA and post hoc tests conducted using the Newman-Keuls test. The data were analyzed using the GraphPad Prism (v2.01) (GraphPad Software, Inc., San Diego, CA). All data were presented as means \pm S.E.M.

Social Interaction Test (SIT)

Rats are allowed to acclimate to the animal care facility for 5 days and are housed singly for 5 days prior to testing. Animals are handled for 5 minutes per day. The design and procedure for the Social Interaction Test is carried out as previously described by Kennett, et al. (1997). On the test day, weight matched pairs of rats (\pm 5%); unfamiliar to each other, are given identical treatments and returned to their-home cages. Animals are randomly divided into 5 treatment groups, with 5 pairs per group, and are given one of the following i.p. treatments: Test Compound (10, 30 or 100 mg/kg), vehicle (1 ml/kg) or chlordiazepoxide (5 mg/kg). Dosing is 1 hour prior to testing. Rats are subsequently placed in a white perspex test box or arena (54 x 37 x 26 cm), whose floor is divided up into 24 equal squares, for 15 minutes. An air conditioner is used to generate background noise and to keep the room at approximately 74°F. All sessions are videotaped using a JVC camcorder (model GR-SZ1, Elmwood Park, NJ) with either TDK (HG ultimate brand) or Sony 30 minute videocassettes. All sessions are conducted between 1300 - 1630 hours. Active social interaction, defined as grooming, sniffing, biting, boxing, wrestling, following and crawling over or under, is scored using a stopwatch

736

(Sportsline model no. 226, 1/100 sec.
discriminability). The number of episodes of rearing
(animal completely raises up its body on its hind
limbs), grooming (licking, biting, scratching of body),
5 and face washing (i.e. hands are moved repeatedly over
face), and number of squares crossed are scored. Passive
social interaction (animals are lying beside or on top
of each other) is not scored. All behaviors are assessed
later by an observer who is blind as to the treatment of
10 each pair. At the end of each test, the box is
thoroughly wiped with moistened paper towels.

Animals

Male albino Sprague-Dawley rats (Taconic Farms, NY) are
15 housed in pairs under a 12 hr light dark cycle (lights
on at 0700 hrs.) with free access to food and water.

Drug Administration

Test Compound is dissolved in either 100% DMSO or 5%
20 lactic acid, v/v (Sigma Chemical Co., St. Louis, MO).
Chlordiazepoxide (Sigma Chemical Co., St. Louis, MO) is
dissolved in double distilled water. The vehicle
consists of 50% DMSO (v/v) or 100% dimethylacetamide
(DMA). All drug solutions are made up 10 minutes prior
25 to injection and the solutions are discarded at the end
of the test day. The volume of drug solution
administered is 1 ml/kg.

Data Analysis

30 The social interaction data (time interacting, rearing
and squares crossed) are subjected to a randomized, one-
way ANOVA and post hoc tests conducted using the

737

Student-Newman-Keuls test. The data are subjected to a test of normality (Shapiro-Wilk test). The data are analyzed using the GBSTAT program, version 6.5 (Dynamics Microsystems, Inc., Silver Spring, MD, 1997).

5

In Vivo Models of the Micturition Reflex

The effects of compounds on the micturition reflex were assessed in the "distension-induced rhythmic contraction" (DIRC), as described in previous
10 publications (e.g. Maggi et al, 1987; Morikawa et al, 1992), and Continuous Slow Transvesicular Infusion (CSTI) models in rats.

15 DIRC Model

Female Sprague Dawley rats weighing approximately 300 g were anesthetized with subcutaneous urethane (1.2 g/kg). The trachea was cannulated with PE240 tubing to provide
20 a clear airway throughout the experiment. A midline abdominal incision was made and the left and right ureters were isolated. The ureters were ligated distally (to prevent escape of fluids from the bladder) and cannulated proximally with PE10 tubing. The incision
25 was closed using 4-0 silk sutures, leaving the PE10 lines routed to the exterior for the elimination of urine. The bladder was canulated via the transurethral route using PE50 tubing inserted 2.5 cm beyond the urethral opening. This cannula was secured to the tail
30 using tape and connected to a pressure transducer. To prevent leakage from the bladder, the cannula was tied tightly to the exterior urethral opening using 4-0 silk.

738

To initiate the micturition reflex, the bladder was first emptied by applying pressure to the lower abdomen, and then filled with normal saline in 100 increments (maximum = 2 ml) until spontaneous bladder
5 contractions occurred (typically 20-40 mmHg at a rate of one contraction every 2 to 3 minutes. Once a regular rhythm was established, vehicle (saline) or Test Compounds were administered i.v. or i.p. to explore their effects on bladder activity. The 5-HT_{1A} antagonist
10 WAY-100635 was given as a positive control. Data were expressed as contraction interval (in seconds) before drug application (basal), or after the application of vehicle or test article.

15 **Continuous Slow Transvesicular Infusion (CSTI) rat Model**

Male Sprague Dawley rats weighing approximately 300 g were used for the study. Rats were anaesthetized with pentobarbitone sodium (50 mg/kg, i.p). Through a median
20 abdominal incision, bladder was exposed and a polyethylene cannula (PE 50) was introduced into the bladder through a small cut on the dome of the bladder and the cannula was secured with a purse string suture. The other end of the cannula was exteriorized
25 subcutaneously at the dorsal neck area. Similarly, another cannula (PE 50) was introduced into the stomach through a paramedian abdominal incision with the free end exteriorized subcutaneously to the neck region. The surgical wounds were closed with silk 4-0 suture and the
30 animal was allowed to recover with appropriate post surgical care. On the following day, the animal was placed in a rat restrainer. The open end of the bladder-cannula was connected to a pressure transducer as well

739

as infusion pump through a three-way stopcock. The bladder voiding cycles were initiated by continuous infusion of normal saline at the rate of 100 μ l/min. The repetitive voiding contractions were recorded on a Power
5 Lab on-line data acquisition software. After recording the basal voiding pattern for an hour, the test drug or vehicle was administered directly into stomach through the intragastric catheter and the voiding cycles were monitored for 5 hours. Micturition pressure and
10 frequency were calculated before and after the treatment (at every 30 min interval) for each animal. Bladder capacity was calculated from the micturition frequency, based on the constant infusion of 100ul/min. The effect of the test drug was expressed as a percentage of basal,
15 pre-drug bladder capacity. WAY 100635 was used as positive control for comparison.

In Vivo Results

Table 2

5 Effect of MCH1 antagonist (Example No.) in the following
 in vivo models: 3-day Body Weight (3D BW), mouse
 Sweetened Condensed Milk (mSwCM), mouse Forced Swim Test
 (mFST), rat Forced Swim Test (rFST), DIRC model, or CSTI
 model.

10

Example No.	3D BW	mSwCM	mFST	rFST	DIRC	CSTI
2	A	B	C	D	E	F
10	Not Done	Not Done	C	Not Done	E	F
39	A	B	Not Done	D	Not Done	Not Done
43	Not Done	B	C	Not Done	Not Done	Not Done
44	Not Done	Not Done	No effect	Not Done	Not Done	Not Done
89	Not Done	B	No effect	Not Done	Not Done	Not Done
90	Not Done	No effect	No effect	Not Done	Not Done	Not Done
91	Not Done	Not Done	C	Not Done	E	F
93	Not Done	Not Done	No effect	Not Done	Not Done	Not Done
95	Not Done	B	No effect	Not Done	Not Done	Not Done
99	A	Not Done	C	Not Done	E	F
105	Not Done	B	C	Not Done	Not Done	Not Done
106	Not Done	B	C	Not Done	E	F
112	Not Done	Not Done	No effect	Not Done	Not Done	Not Done
116	A	Not Done	C	Not Done	E	F

15

A = Produced a significant reduction in weight gain relative to vehicle-treated controls

741

- 5 B = Produced a significant decrease in
consumption of milk relative to vehicle-
treated controls
- C = Produced a significant decrease in immobility
relative to vehicle-treated animals when
administered orally.
- D = Produced a significant decrease in immobility
or a significant increase in swimming activity
relative to vehicle-treated animals
- 10 E = Produced a significant increase in contraction
interval relative to pre-drug interval
- F = Produced an increase in bladder capacity in
rats relative to baseline capacity.

15

References:

- American Psychiatric Association (1994a), Diagnostic and Statistical Manual of Mental Disorders. 4th ed.
5 Washington, DC: American Psychiatric Association.
- American Psychiatric Association (1994b), American DSM-IV Sourcebook. Washington, DC: American Psychiatric Association.
- Auburger, G., et al., (1992) Assignment of the second
10 (cuban) locus of autosomal dominant cerebellar ataxia to chromosome 12q23-24.1, between flanking markers D12S58 and PLA2. *Cytogenet. Cell. Genet.* 61:252-256.
- Bahjaoui-Bouhaddi, M., et al., (1994) Insulin treatment
15 stimulates the rat melanin-concentrating hormone-producing neurons. *Neuropeptides* 24:251-258.
- Baker, B.I. (1991) Melanin-concentrating hormone: a general vertebrate neuropeptide. *Int. Rev. Cytol.* 126:1-
20 47.
- Baker, B.I. (1994) Melanin-concentrating hormone update: functional consideration. *TEM* 5:120-126.
- 25 Bassett, A.S., et al., (1988) Partial trisomy chromosome 5 cosegregating with schizophrenia. *Lancet* 1:799-801.
- Bednarek, M.A., et al. "Synthesis and biological evaluation in vitro of a selective, high potency peptide
30 agonist of human melanin-concentrating hormone action at

743

human melanin-concentrating hormone
receptor 1" *J Biol Chem* 277(16): 13821-13826 (2002).

5 Bittencourt, J.C., et al., (1992) The melanin-
concentrating hormone system of the rat brain: An
immuno- and hybridization histochemical characterization
. *J. Comp. Neurol.* 319:218-245.

Bobes, J. (1998) *J Clin Psychiatry*; 59[suppl 17]:12-16.

Borowsky, B., et al., *Nature Medicine* (in press).

10

Bradford, M.M. (1976) A rapid and sensitive method for
the quantitation of microgram quantities of protein
utilizing the principle of protein-dye binding. *Anal.*
Biochem. 72: 248-254.

15

Burgaud, J.L., et al., (1997) Melanin-concentrating
hormone binding sites in human SVK14 keratinocytes.
Biochem.Biophys.Res.Comm. 241(3):622-629.

20

Chambers, J., et al., "Melanin-concentrating hormone is
the cognate ligand for the orphan G-protein-coupled
receptor SLC-1" *Nature* 400(6741): 261-6 (1999).

25

Chen, Y., et al, "Targeted disruption of the melanin-
concentrating hormone receptor-1 results in hyperphagia
and resistance to diet-induced obesity" *Endocrinology*
143(7): 2469-2477(2002).

30

Craddock, N., et al., (1993) The gene for Darier's
disease maps to chromosome 12q23-q24.1. *Hum. Mol. Genet.*
2:1941-1943.

744

Dondoni, A., et al., (1995) *T. Synthesis*, 181.

5 Drozdz, R. and Eberle, A.N. (1995) Binding sites for melanin-concentrating hormone (MCH) in brain synaptosomes and membranes from peripheral tissues identified with highly tritiated MCH. *J. Recept. Signal. Transduct. Res.* 15(1-4):487-502.

10 Drozdz, R., et al., (1995) Melanin-concentrating hormone binding to mouse melanoma cells in vitro. *FEBS* 359:199-202.

15 Drozdz, R., et al., (1998) Characterization of the receptor for melanin-concentrating hormone on melanoma cells by photocrosslinking. *Ann. NY Acad. Sci.* 839(1):210-213.

Gale Group (2001) *Gale Encyclopedia of Psychology*, 2nd ed. Gale Group.

20 Gilliam, T.C., et al., (1989) Deletion mapping of DNA markers to a region of chromosome 5 that cosegregates with schizophrenia. *Genomics* 5:940-944.

Goodman WK, Price LH, Rasmussen SA et al. (1989), The Yale-Brown Obsessive Compulsive Scale. *Arch Gen Psychiatry* 46:1006-1011.

25

Gonzalez, M.I., et al., (1997) Stimulatory effect of melanin-concentrating hormone on luteinizing hormone release. *Neuroendocrinology* 66(4):254-262.

30

Gonzalez, M.I., et al., (1996) Behavioral effects of α -melanocyte-stimulating hormone (α -MSH) and melanin-

745

concentrating hormone (MCH) after central
administration in female rats. *Peptides* 17:171-177.

5 Grillon, S., et al., (1997) Exploring the expression of
the melanin-concentrating hormone messenger RNA in the
rat lateral hypothalamus after goldthiogluco-
se injection. *Neuropeptides* 31(2):131-136.

10 Herve, C. and Fellmann, D. (1997) Changes in rat
melanin-concentrating hormone and dynorphin messenger
ribonucleic acids induced by food deprivation.
Neuropeptides 31(3):237-242.

15 Hervieu, G., et al., (1996) Development and stage-
dependent expression of melanin-concentrating hormone in
mammalian germ cells. *Biology of Reproduction* 54:1161-
1172.

20 Kawachi, H., et al., (1983) Characterization of
melanin-concentrating hormone in chum salmon
pituitaries. *Nature* 305:321-333.

25 Knigge, K.M., et al., (1996) Melanotropic peptides in
the mammalian brain: The melanin-concentrating hormone.
Peptides 17:1063-1073.

30 Knigge, K.M. and Wagner, J.E. (1997) Melanin-
concentrating hormone (MCH) involvement in
pentylenetetrazole (PTZ)-induced seizure in rat and
guinea pig. *Peptides* 18(7):1095-1097.

Lakaye, B., et al., "Cloning of the rat brain cDNA
encoding for the SLC-1 G protein-coupled receptor

746

reveals the presence of an intron in the gene"
Biochem Biophys Acta 1401(2): 216-220 (1998).

5 Ludwig, D.S., et al., (1998) Melanin-concentrating
hormone: a functional melanocortin antagonist in the
hypothalamus. *Am. J. Physiol. Endocrinol. Metab.*
274(4):E627-E633.

10 MacKenzie, F.J., et al., (1984) Evidence that the
dopaminergic incerto-hypothalamic tract has a
stimulatory effect on ovulation and gonadotropin
release. *Neuroendocrinology* 39:289-295.

15 Maggi, C.A., et al., "Spinal and supraspinal components
of GABAergic inhibition of the micturition reflex in
rats." *J Pharmacol Exp Ther* 240: 998-1005 (1987).

20 Marsh, D.J., et al, "Melanin-concentrating hormone 1
receptor-deficient mice are lean, hyperactive, and
hyperphagic and have altered metabolism" *Proc Natl Acad*
Sci U S A 99(5): 3240-3245 (2002).

25 Martin, R., et al., (1997) *J. Tetrahedron Letters*, 38,
1633.

McBride, R.B., et al., (1994) The actions of melanin-
concentrating hormone (MCH) on passive avoidance in
rats: A preliminary study. *Peptides* 15:757-759.

30 Medical Economics Company (2002), Physicians' Desk
Reference, 56th ed., Montvale, NJ: Medical Economics
Company, Inc., pp. 1609-1615, 2751-2756, 3495-3504.

747

Melki, J., et al., (1990) Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q. *Nature* (London) 344:767-768.

5 Miller, C.L., et al., (1993) α -MSH and MCH are functional antagonists in a CNS auditory paradigm. *Peptides* 14:1-10.

10 Morikawa, K., et al., "Inhibitory effect of inaperisone hydrochloride (inaperisone), a new centrally acting muscle relaxant, on the micturition reflex." *Eur J Pharmacol* 213: 409-415 (1992).

15 Nahon, J-L. (1994) The melanin-concentrating hormone: from the peptide to the gene. *Critical Rev. in Neurobiol* 221:221-262.

20 Parkes, D.G. (1996) Diuretic and natriuretic actions of melanin concentrating hormone in conscious sheep. *J. Neuroendocrinol.* 8:57-63.

25 Pedoutour, F., et al., (1994) Assignment of the human pro-melanin-concentrating hormone gene (PMCH) to chromosome 12q23-24 and two variant genes (PMCHL1 and PMCHL2) to chromosome 5p14 and 5q12-q13. *Genomics* 19:31-37.

30 Porsolt, R.D., et al., "Behavioural despair in rats: a new model sensitive to antidepressant treatments" *Eur J Pharmacol* 47(4): 379-391 (1978).

Presse, F., et al. (1992) Rat melanin-concentrating hormone messenger ribonucleic acid expression: marked

changes during development and after stress and glucocorticoid stimuli. *Endocrinology* 131:1241-1250.

5 Qu, D., et al. (1996) A role for melanin-concentrating hormone in the central regulation of feeding behaviour. *Nature* 380:243-247.

10 Rossi, M., et al., (1997) Melanin-concentrating hormone acutely stimulates feeding, but chronic administration has no effect on body weight. *Endocrinology* 138:351-355.

15 Sahu, A. (1998) Evidence suggesting that galanin (GAL), melanin-concentrating hormone (MCH), neurotensin (NT), proopiomelanocortin (POMC) and neuropeptide Y (NPY) are targets of leptin signaling in the hypothalamus. *Endocrinology* 139(2):795-798.

20 Sakurai, T., et al., (1998) Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 92:573-585.

25 Sanchez, M., et al., (1997) Melanin-concentrating hormone (MCH) antagonizes the effects of α -MSH and neuropeptide E-I on grooming and locomotor activities in the rat. *Peptides* 18:393-396.

30 Saito, Y., et al., "Molecular characterization of the melanin-concentrating-hormone receptor" *Nature* 400(6741): 265-269 (1999).


Schneier FR, Heckelman LR, Garfinkel R, et al. (1994) *J Clin Psychiatry* 55:322-331.

- Sherrington, R., et al., (1988) Localization of a susceptibility locus for schizophrenia on chromosome 5. *Nature (London)* 336:164-167.
- 5 Srebnik, M., et al., (1988) *J. Org. Chem.*, 53, 2916-2920.
- Takekawa, S., et al., "T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist" *Eur J Pharmacol* 438(3): 129-35 (2002)
- 10
- Twells, R., et al., (1992) Chromosomal assignment of the locus causing olivo-ponto-cerebellar atrophy (SCA2) in a cuban founder population. *Cytogenet. Cell. Genet.*
- 15 61:262-265.
- Westbrook, C.A., et al., (1992) Report of the second international workshop on human chromosome 5 mapping. *Cytogenet. Cell. Genet.* 61:225-231.

750

What is claimed is:

1. A compound having the structure:



5

wherein R_1 is hydrogen, straight chained or branched C_1 - C_7 alkyl, monofluoroalkyl or polyfluoroalkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -
10 NO_2 , -CH₃, -CF₃, -COCH₃, -CO₂R₂, phenyl, phenoxy or straight chained or branched C_1 - C_7 alkyl;

15

wherein R_2 is straight-chained or branched C_3 - C_4 alkyl or cyclopropyl;

20

wherein R_3 is aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -CN, - NO_2 , straight chained or branched C_1 - C_7 alkyl;

25

wherein A is -H, -F, -Cl, -Br, -CN, - NO_2 , -COR₃, -CO₂R₃, straight chained or branched C_1 - C_7 alkyl, monofluoroalkyl or polyfluoroalkyl;

wherein X is O or NH; and

wherein n is an integer from 0 to 5 inclusive.

751

2. The compound of claim 1, wherein R_1 is aryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -NO₂, -COCH₃, -CO₂R₂, straight chained or branched C₁-C₇ alkyl;

5

wherein R_3 is phenyl;

wherein A is H; and


10

wherein X is O.


3. The compound of claim 2, wherein R_2 is isopropyl.

15

4. The compound of claim 3, wherein the compound has the structure:



5. The compound of claim 3, wherein the compound has the structure:



20

6. The compound of claim 1, wherein R_1 is hydrogen, straight chained or branched C₁-C₇ alkyl; and wherein R_3


752

is aryl.

7. The compound of claim 6, wherein R_2 is isopropyl; and A is hydrogen.


5

8. The compound of claim 7, wherein the compound has the structure:




9. The compound of claim 7, wherein the compound has the structure:

10



10. A compound having the structure:

15



wherein R_1 is aryl or heteroaryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -NO₂, -OCH₃, phenoxy, fused cyclopentanyl, straight chained or

20

753

branched C₁-C₇ alkyl, monofluoroalkyl or
polyfluoroalkyl;

5 wherein R₂ is straight-chained or branched C₁-C₄ alkyl or
cyclopropyl;

wherein A is -H, -F, -Cl, -Br, -CN, -NO₂, straight
chained or branched C₁-C₇ alkyl, monofluoroalkyl or
polyfluoroalkyl; and

10

wherein n is an integer from 1 to 5 inclusive.


11. The compound of claim 10, wherein R₁ is aryl
optionally substituted with one or more -F, -Cl, -Br, -I
15 or straight chained or branched C₁-C₄ alkyl; and

wherein A is H.

12. The compound of claim 11, wherein R₂ is isopropyl;
20 and

wherein n is 2.


13. The compound of claim 12, wherein the compound has
25 the structure:




14. The compound of claim 12, wherein the compound has
the structure:

30

754




15. The compound of claim 12, wherein the compound has
5 the structure:




16. The compound of claim 10, wherein R_1 is thienyl; and
10 wherein A is H.
17. The compound of claim 16, wherein R_2 is isopropyl.

18. The compound of claim 17, wherein the compound has
the structure:




- 15
19. A compound having the structure:




wherein W is

20

755



or



wherein each R_1 is independently hydrogen, methyl or ethyl;

5

wherein R_2 is straight-chained or branched C_3 - C_4 alkyl or cyclopropyl;

wherein R_3 is hydrogen, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -H, -F, -Cl, -Br, -I, -CN, -NO₂, straight chained or branched C_1 - C_7 alkyl.


wherein each A is independently -H, -F, -Cl, -Br, -CN, -NO₂, -COR₃, -CO₂R₃, straight chained or branched C_1 - C_7 alkyl, monofluoroalkyl or polyfluoroalkyl;

wherein X is O, NR₃, CO or may be absent; and

wherein Y is hydrogen, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -NO₂, straight chained or branched C_1 - C_7 alkyl.

20. The compound of claim 19, wherein W is

756




and wherein X is O or may be absent.


21. The compound of claim 20, wherein R₂ is isopropyl.

5

22. The compound of claim 21, wherein the compound has the structure:




10 23. The compound of claim 21, wherein the compound has the structure:



15

24. The compound of claim 19, wherein W is




757

25. The compound of claim 24, wherein A is -H, -F, -Cl, -Br.


26. The compound of claim 25, wherein R₂ is isopropyl;
5 and A is hydrogen.

27. The compound of claim 26, wherein the compound has the structure:


10




28. A compound having the structure:



15 wherein W is



or



20 wherein R₁ is hydrogen, straight chained or branched C₁-C₇ alkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -CN, -NO₂, -OCH₃, -CO₂CH₃, -CF₃, phenyl, straight chained or branched C₁-C₇ alkyl;


758

wherein R_2 is straight-chained or branched C_3 - C_4 alkyl or cyclopropyl;

wherein A is -H, -F, -Cl, -Br, -CN, -NO₂, -COR₁, -CO₂R₁,
5 straight chained or branched C_1 - C_7 alkyl, monofluoroalkyl
or polyfluoroalkyl or phenyl.

wherein each B is independently -H, -F, -Cl, -Br, -I, -
CN, -NO₂, -COR₁, -CO₂R₁, -OCH₃, -OCF₃, -CF₃, straight
10 chained or branched C_1 - C_7 alkyl, monofluoroalkyl or
polyfluoroalkyl or aryl, phenoxy or benzyloxy, wherein
the aryl, phenoxy or benzyloxy is optionally substituted
with one or more -F, -Cl, -Br, -CN, -NO₂, -COR₁, -CO₂R₁,
-OCH₃, -OCF₃, -CF₃ or straight chained or branched C_1 - C_7
15 alkyl.

29. The compound of claim 28, wherein W is




20 30. The compound of claim 29, wherein R_1 is hydrogen or
phenyl optionally substituted with one or more -F, -Cl,
-Br, -CN, -NO₂, straight chained or branched C_1 - C_7 alkyl.

31. The compound of claim 30, wherein R_2 is isopropyl.


25

32. The compound of claim 31, wherein the compound has
the structure:

759




33. The compound of claim 31, wherein the compound has the structure:



5

34. A compound having the structure:



10 wherein R_1 is hydrogen, straight chained or branched C_1 - C_7 alkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -CN, -NO₂, -CF₃, -OCH₃, straight chained or branched C_1 - C_3 alkyl;

15

wherein R_2 is straight-chained or branched C_3 - C_4 alkyl or cyclopropyl;

wherein R_3 is -H, -F, -Cl, -Br, -I, -CN, -NO₂, -CF₃, -

760

OCH₃, or straight chained or branched C₁-C₃ alkyl, monofluoroalkyl or polyfluoroalkyl, or a phenyl ring fused to C₆ and C₇ of the indole moiety;

5 wherein R₄ is hydrogen or aryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -NO₂, -CF₃, straight chained or branched C₁-C₃ alkyl;

10 wherein A is -H, -F, -Cl, -Br, -CN, -NO₂, straight chained or branched C₁-C₇ alkyl, monofluoroalkyl or polyfluoroalkyl; and

wherein n is an integer from 2 to 4 inclusive.

15 35. The compound of claim 34, wherein R₃ is -H, -F, -Cl, -Br, -I, -CN, -NO₂, -OCF₃ or -OCH₃; and

wherein R₄ is hydrogen or phenyl optionally substituted with one or more -F, -Cl or -CF₃.

20


36. The compound of claim 35, wherein R₁ is hydrogen or phenyl optionally substituted with one or more -F, -Cl, -Br, -CN, -NO₂, -CF₃, -OCH₃ or straight chained or branched C₁-C₃ alkyl;

25


37. The compound of claim 36, wherein R₂ is isopropyl.

38. The compound of claim 37, wherein the compound has the structure:

761




39. The compound of claim 37, wherein the compound has the structure:




5

10 40. The compound of claim 37, wherein the compound has the structure:



15 41. A compound having the structure:



wherein each R_1 is independently hydrogen or CH_3 ;

5 wherein R_2 is straight-chained or branched C_1 - C_4 alkyl or cyclopropyl;

10 wherein R_3 is benzyl or phenyl, wherein the benzyl or phenyl is optionally substituted with a methylenedioxy group or one or more $-F$ or $-Cl$;

wherein A is $-H$, $-F$, $-Cl$, $-Br$, $-CN$, $-NO_2$, straight chained or branched C_1 - C_7 alkyl, monofluoroalkyl or polyfluoroalkyl;

15 wherein X is $(CH_2)_2$, $COCH_2$ or $CONH$;

42. The compound of claim 41, wherein R_3 is phenyl optionally substituted with one or more $-F$; and


20 wherein A is hydrogen.

43. The compound of claim 42, wherein X is $CONH$.


25 44. The compound of claim 43, wherein R_2 is methyl.

45. The compound of claim 44, wherein the compound has the structure:

763



46. The compound of claim 44, wherein the compound has the structure:




5

wherein each Y is independently hydrogen or -F.

47. The compound of claim 46, wherein the compound has the structure:


10



15

764

48. The compound of claim 46, wherein the compound has the structure:




5

49. The compound of claim 41, wherein R_3 is benzyl optionally substituted with a methylenedioxy group or one or more -F or -Cl.

10

50. The compound of claim 49, wherein the compound has the structure:




15

wherein each Y is independently hydrogen or -F.

51. The compound of claim 50, wherein the compound has the structure:

20

765



52. A compound of claims 1 to 51, wherein the
5 compound is enantiomerically pure.

53. A compound of claims 1 to 51, wherein the compound
is diastereomerically pure.

10 54. The compound of claims 52 and 53, wherein the
compound is enantiomerically and diastereomerically
pure.

55. A pharmaceutical composition comprising a
15 therapeutically amount of a compound of any of claims 1
to 51 and a pharmaceutically acceptable carrier.

56. The pharmaceutical composition of claim 55, wherein
the amount of the compound is from about 0.01mg to about
20 500mg.

57. The pharmaceutical composition of claim 56, wherein
the amount of the compound is from about 0.1mg to about
60mg.

25 58. The pharmaceutical composition of claim 57,
wherein the amount of the compound is from about 1mg to
about 20mg.

59. The pharmaceutical composition of claim 55, wherein the carrier is a liquid and the composition is a solution.

5

60. The pharmaceutical composition of claim 55, wherein the carrier is a solid and the composition is a tablet.

61. The pharmaceutical composition of claim 55, wherein the carrier is a gel and the composition is a suppository.

62. A process for making a pharmaceutical composition comprising admixing a therapeutically effective amount of the compound of any of claims 1 to 51 and a pharmaceutically acceptable carrier.

63. A method of treating a subject suffering from a disorder selected from the group consisting of depression, anxiety, urge incontinence, or obesity comprising administering to the subject a therapeutically effective amount of the compound of any of claims 1 to 51.

64. The method of claim 63, wherein the therapeutically effective amount is between about 0.03 and about 1000 mg per day.

65. The method of claim 64, wherein the therapeutically effective amount is between about 0.30 and about 300 mg per day.

767

66. The method of claim 65, wherein the therapeutically effective amount is between about 1.0 and about 100 mg per day.

5 67. The method of claim 63, wherein the disorder is depression.

68. The method of claim 63, wherein the disorder is anxiety.

10

69. The method of claim 63, wherein the disorder is obesity.

15

70. The method of claim 63, wherein the disorder is urge incontinence.

20

71. A method of reducing the body mass of a subject, which comprises administering to the subject an amount of a compound of any of claims 1 to 51 effective to reduce the body mass of the subject.

25

72. A method of treating a subject suffering from depression, which comprises administering to the subject an amount of a compound of any of claims 1 to 51 effective to treat the subject's depression.

30

73. A method of treating a subject suffering from anxiety, which comprises administering to the subject an amount of a compound of any of claims 1 to 51 effective to treat the subject's anxiety.

74. A method of alleviating urge urinary incontinence in a subject suffering from an overactive bladder, which

768

comprises administering to the subject an amount of the compound of any of claims 1 to 51 effective to alleviate the subject's urge urinary incontinence.

5 74. A method of managing obesity in a subject in need of weight loss, which comprises administering to the subject an amount of a compound of any of claims 1 to 51 effective to induce weight loss in the subject.

10 75. A method of managing obesity in a subject who has experienced weight loss, which comprises administering to the subject an amount of a compound of any of claims 1 to 51 effective to maintain such weight loss in the subject.

15 76. A method of treating overactive bladder in a subject, which comprises administering to the subject an amount of a compound of any of claims 1 to 51 effective to treat the subject's overactive bladder.

20 78. A method of treating a disorder in a subject, wherein the symptoms of the subject can be alleviated by treatment with an MCH1 antagonist, wherein the MCH1 antagonist is the compound of any of claims 1 to 51.

25 79. A method of alleviating the symptoms of a disorder in a subject, which comprises administering to the subject an amount of an MCH1 antagonist effective to alleviate the symptoms, wherein the MCH1 antagonist is
30 the compound of any of claims 1 to 51.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US02/21063

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : Please See Extra Sheet.

US CL : 514/323, 326; 546/200, 201, 209, 212

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/323, 326; 546/200, 201, 209, 212

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS—structure

EAST/WEST—subclass image

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, E	US 6,441,000 B1 (GIBSON et al) 27 August 2002, see entire document, especially columns 30-40 preparations 1-27.	1-2, 10-11, 19-20
Y	WO 99/59971 A1 (PFIZER INC.) 25 November 1999, see entire document, especially examples 46, 61, 69 and pages 2-3 formula I.	1-2, 10-11, 19-20, 51-61
X,P — Y,P	WO 02/02744 A2 (SYNAPTIC PHARMACEUTICAL) CORP.] 10 January 2002, see entire document, especially pages 349-358, compounds and abstract.	1-2, 10-11, 19-20, 41-42, 52-79 ----- 1-23, 41-79



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

11 SEPTEMBER 2002

Date of mailing of the international search report

26 SEP 2002

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CELIA CHANG

Telephone No. (703) 808-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US02/21063

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

IPC7 A61K 31/445; C07D 211/30, 211/94, 401/06, 401/12, 403/06, 403/12